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ABSTRACT 
Recent epidemiological data have implicated prenatal events in the development of 
cardiovascular disorders. Thus low birth weight strongly predicts the later 
occurrence of hypertension, type II diabetes mellitus, syndrome X and deaths from 
ischaemic heart disease. The mechanism linking prenatal events and later disease 
is not clear, although maternal malnutrition has been advocated. We have 
advanced the hypothesis that glucocorticoids might be important as they retard 
foetal growth and programme offspring hypertension in rats. The foetus has been 
thought to be protected from the 2-10 times higher maternal glucocorticoid levels 
by the placental enzyme 11B-hydroxysteroid dehydrogenase (11B-HSD), which is 
present in many tissues and in humans catalyses the conversion of the active 
glucocorticoid cortisol to inert cortisone (corticosterone to 11-
dehydrocorticosterone in rats). The precise role of 11B-HSD as a barrier to 
maternal glucocorticoids during prenatal life has not been fully characterised. The 
role of 11B-HSD in controlling prenatal glucocorticoid exposure in humans and 
animals has thus been examined. Two isoforms of 11B-HSD exist, type 1, a 
widespread NADP dependent reversible enzyme and type 2, a high affinity NAD 
dependent dehydrogenase found mainly in placenta and kidney. 
11B-HSD was found in abundance in the ovary and placenta. The main site of 
immunohistochemical staining and expression of mRNA (11B-HSD-1) in the rat 
ovary was in the oocyte. 11B-HSD was oxidative, inactivating corticosterone. In 
both rat placenta in-vitro (11B-HSD-2), and human placenta in-vitro and ex-vivo 
(11B-HSD-2) the bioactivity was also predominantly oxidative. The lowest 
placental enzyme activity at term (and hence the greatest foetal glucocorticoid 
exposure) was found in the smallest rats with the largest placentas, i.e. those in 
human studies who would be predicted to develop the highest adult blood pressures 
(birth weight vs. placental 11B-HSD activity: n = 56; r = 0.46; p < 0.0005). 
A method to examine 11B-HSD function in fresh intact human placentas was 
developed (ex-vivo dual circuit cotyledon perfusion) which allows close 
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approximation to the in-vivo situation. The majority of cortisol, from low to high 
nanomolar concentrations, infused through the maternal circulation was 
metabolised to inert cortisone by the time it reached the foetal circulation, although 
considerable individual variation was observed. 118-HSD was the only significant 
contributor to placental cortisol metabolism at physiological maternal 
concentrations and inhibition of 118-HSD with either the liquorice constituent 
glycyrrhetinic acid or its hemi-succinate, carbenoxolone, resulted in abolition of 
the glucocorticoid barrier, allowing maternally administered cortisol to pass 
unmetabolised through the placenta. In a prospective study, on 16 normal 
primiparous women whose placentas were studied with this technique, a positive 
and significant correlation was found between the effectiveness of 118-HSD and 
offspring birth weight (r = 0. 67; p < 0. 005). 
The relationship between placental 118-HSD effectiveness in-vivo and term cord 
blood osteocalcin (a sensitive marker of glucocorticoid exposure) was prospectively 
examined in 19 women. Cord blood levels of the bone specific protein osteocalcin 
were determined with radioimmunoassay. The lowest cord blood osteocalcin 
levels were found in the foetuses whose placental 118-HSD barrier function was 
poorest (r = 0.58; p < 0.02), (and had presumably had the greatest glucocorticoid 
exposure), suggesting that term cord blood osteocalcin levels might be a useful 
predictor of hypertension, ischaemic heart disease and possibly metabolic bone 
disease. 
The findings presented in this thesis represent direct evidence that 118-HSD is the 
barrier to maternal glucocorticoids, its effectiveness correlating with foetal growth 
in rats (in-vitro), in humans (ex-vivo), and in-vivo with human cord blood 
osteocalcin levels ( osteocalcin may be a marker of glucocorticoid exposure). In the 
light of studies on pregnant rats in which administration of exogenous 
glucocorticoids or 118-HSD inhibitors reduces birth weight and programmes 
hypertension in the offspring, it is reasonable to propose that increased foetal 
glucocorticoid exposure consequent upon attenuated placental 118-HSD function 
may play a role in intrauterine programming of later hypertension. 
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Introduction: Early Development and Disease 
1 . INTRODUCTION 
1 . 1 . EARLY DEVELOPMENT AND DISEASE 
"Lengi byr ao fyrstu gero". This Icelandic proverb is of obscure origin, but was 
probably first recorded and published in a collection of Icelandic sayings by 
Guomundur J6nsson in 1830 [J6nsson 1830]. Its meaning is that early events give 
a lasting impression. Thus for a long time, the general public appears to have been 
aware of the importance of early development. This is not unique to Iceland, 
although an exactly equivalent saying may not exist, and several examples of the 
same general theme can be found in other cultures' literature. It is only in recent 
years however, that this has attracted the attention of scientists, who have 
generated solid data to support this concept. This thesis strives to support this 
notion, by suggesting a mechanism to explain the phenomenon of prenatal 
programming of cardiovascular diseases, specifically hypertension. 
1.1.1. Epidemiology 
In recent years there has been a dramatic shift in our appraisal of the origins of 
common adult diseases, most notably ischaemic heart disease. These observations 
have shifted the emphasis from adult "life-style!' risk factors (like smoking, 
exercise and diet) to indicate the importance of early life events. This started when 
epidemiologists noticed the striking geographical differences in death rates for 
chronic bronchitis, stroke and ischaemic heart disease. Most of these studies have 
been conducted in this country by Professor Barker at the MRC Epidemiology Unit 
in Southampton [Barker 1992a], but similar data has also been gathered in other 














Introduction: Early Development and Disease 
The curious paradox apparent in the British geographical data for ischaemic heart 
disease was that although most common in poorer areas and in lower income 
groups, the steep increase in incidence during this century had taken place in the 
most affluent areas [Barker & Osmond 1986; Barker 1988]. These observations 
suggested that two separate influences were involved; current risk factors and the 
events of the past [Barker 1988]. In search of past determinants, past neonatal 
(birth - 28 days), postneonatal (28 days - 1 year) and maternal mortality rates in 
defined areas of England and Wales were related to current rates of respiratory and 
cardiac diseases in the same areas. 
Using these data it was found that chronic bronchitis could be predicted by past 
postneonatal mortality, but ischaemic heart disease and stroke correlated better 
with past neonatal mortality and past maternal mortality [Barker & Osmond 1987; 
Barker & Osmond 1986], both being indicators of adverse influences at the time of 
conception and during pregnancy. The data have been criticised for not taking into 
account the fact that those areas in Britain which were most deprived 50 years ago 
are also the most deprived areas today [Ben-Shlomo & Smith 1991]. In fact the 
correlations mentioned above are attenuated if one adjusts for current deprivation 
and socio-economic status [Ben-Shlomo & Smith 1991] . The level of attenuation 
partly depends on how one looks at deprivation and socio-economic status, and 
most of Professor Barker's studies show correlations to be independent of social 
class (using their definitions). A further study found that in spite of migration, the 
risk of dying from stroke or ischaemic heart disease could be predicted by the 
place of birth, the lowest risk being confined to the areas with the lowest infant 
mortality rates [Osmond et al., 1990], again supporting the view that there are 
probably two factors to be taken into account, the present and the past. 
These were fascinating results which prompted further exploration, this time 
looking for better and more specific measures of the early life environment and 
their associations with subsequent disease. Longitudinal data (as opposed to cross 
sectional studies on populations at two different times) were then obtained, mainly 
- 17-
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from two areas in England where unusually detailed obstetrical records were still 
(luckily) kept, namely Hertfordshire and Preston. This therefore allowed different 
morbidity parameters currently observed in these populations to be associated with 
specific indices of development in the same individuals over half a century before. 
These data were obtained in sizeable cohorts of over 15000 people. Ischaemic 
heart disease was found to correlate with birth weight (an indicator of foetal 
development), but better with weight at one year [Barker et al., 1989b], which 
itself does not correlate well with birth weight [Tanner et al., 1956]. It therefore 
seemed possible to detach two important early factors, the in-utero environment as 
assessed by birth weight and neonatal influences, estimated by weight at one year. 
Looking at the risk factors for ischaemic heart disease, specific patterns could be 
found. Adult cholesterol metabolism seemed to be partly programmed during 
infancy [Fall et al., 1992], a notion supported by animal studies [Mott 1986]. Low 
weight at one year predicted adult elevated fibrinogen concentrations [Barker et al., 
1992b], elevated apolipoprotein-B concentrations [Fall et al., 1992], impaired 
glucose tolerance [Hales et al., 1991] and increased waist-hip ratio [Law et al., 
1992], all well recognised risk factors for ischaemic heart disease. Birth weight 
was also able to predict raised waist-hip ratios [Law et al., 1992]. 
For blood pressure, a major risk factor for ischaemic heart disease and stroke, the 
more important determinant was birth weight, implying that very early life events 
might "programme" blood pressure levels in-utero [Barker et al., 1990]. Thus 
mean systolic blood pressure rose by 11 mmHg as birth weight fell from > 7.5 lb 
to < 5. 5 lb. A very striking observation was that blood pressure also seemed to 
be linked to placental weight, mean systolic blood pressure rising by 15 mmHg as 
placental weight rose from < 1 lb to > 1.5 lb. The strongest predictor of blood 
pressure 50 years from birth was the combination of the two, those attaining the 
highest adult systolic blood pressures having the lowest birth weight with the 
largest placentas [Barker et al., 1990]. These data have been interpreted as 
- 18 -
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indicating different timing and/ or magnitude of the growth retarding influence 
[Barker et al., 1993a] (see later). 
It even seemed that it was possible to subgroup the babies further on the basis of 
placental weights. In the group with smallest placentas, adult hypertension was 
found in those who at birth had a long thin body and low ponderal index 
(weightflength3) with reduced head circumference. On the other hand, among 
those with large placentas, hypertension developed in those who were short in 
relation to their head size [Barker et al., 1992a]. Grouping them by body 
measurements only, those with small head circumference and low ponderal index 
tend to develop Syndrome X (the combination of insulin resistance, hypertension, 
non-insulin dependent diabetes, and dyslipidaemia) [Barker et al., 1993b] and those 
who are short in relation to their head size tend to develop the combination of 
hypertension and high plasma fibrinogen [Barker et al., 1992b]. 
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Figure 1.1 Imprinting of Hypertension In-Utero and its Self Amplification 
The figure shows mean difference (fall in all but one study) in systolic blood pressure per kg increase 
in birth weight (vertical axis) in groups of people at different current ages (horizontal axis). Adapted 
from Law et al. Brit. Med. J. 1993;306:24-7. 
- 19-
[· 
Introduction: Early Development and Disease 
The data for blood pressure have now been confirmed for various populations all 
over the world, such that we now know that low birth weight predicts elevated 
blood pressure at all ages [Cater & Gill 1984; Law et al., 1991; Barker et al., 
1989a; Seidman et al., 1991; Gennser et al., 1988; Barker et al., 1990]. Important 
notions to grasp are, that this is not only observed at the extremes of birth- and 
placental weight distributions but is continuous throughout the normal range 
[Barker et al., 1990], and the correlations observed occur independently of social 
class [Barker et al., 1990], adult smoking and obesity [Barker et al., 1989a]. 
Four of these studies have recently been summarised (Figure 1.1) by Law et al. 
[Law et al. , 1993], demonstrating that the effect is observed already in infancy. 
Indeed, the well recognised "tracking" of blood pressure from infancy to adulthood 
clearly implicates early events in the determination of blood pressure throughout 
life [Lever & Harrap 1992]. As can be seen from Figure 1.1, the effect of birth 
weight on attained systolic blood pressure becomes greater, the older the 
population studied is. This is could be due to the now well recognised 
phenomenon of persistence of hypertension and its self-amplification upon removal 
of the primary cause [Lever & Harrap 1992]. 
Although the above discussed correlations strongly implicate in-utero development 
in determination of later blood pressure, it is important to appreciate that there are 
also several other important "current life-style" factors which influence each 
individuals blood pressure. Growth and current body weight are examples. Thus 
during teenage years when individuals grow fastest and attain sexual maturation, 
the relationship between birth weight and blood pressure is weakest [Seidman et 
al. , 1991], and the tracking of blood pressure becomes temporarily perturbed 
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1.1.2. Determinants of Birth Weight 
Given the persuasive epidemiological observations the key question has to be: 
What determines birth weight? 
There is a strong genetic influence on offspring growth, manifest in the strong 
correlation of offspring adult height with parental height. Birth weight is not 
strongly correlated with weight at one year, which however correlates closely with 
subsequent weight [Tanner et al., 1956]. This must mean that in-utero, other local 
factors are important in determining growth. This is supported by the observation 
that birth weight is much better predicted by maternal size than paternal size; for 
example in crosses between large horses and small ponies, where the size of the 
offspring is directly proportional to maternal size but not intermediate [Hammond 
1944]. This notion is also supported by human studies showing that birth weight is 
influenced by maternal height [Butler & Alberman 1969]. Studies on chimaeric 
mice [Surani et al., 1990] also support this idea that there are strong local maternal 
factors capable of modulating foetal growth. In this model, the size of the foetus 
depends on the relative proportions of maternally vs. paternally derived cells. 
Thus intrauterine growth is proportionally restrained by up to 50% by the maternal 
cells and by increasing the proportion of paternal cells the size of the conceptus can 
be increased. 
A popular explanation for the observed correlations between size at birth and adult 
disease has been that maternal malnutrition is to blame [Barker et al., 1993a]. In 
support of this, data were produced concerning the Dutch famine during World 
War II [Stein et al., 197 5], where the children were born small and had high risk 
of subsequent obesity [Ravelli et al., 1976]. There are a number of other points 
taken in support of the nutrition hypothesis, recently summarised by Barker 
[Barker et al., 1993a]. A further supportive example in humans was that maternal 
anaemia and iron deficiency results in the same pattern of increased placental and 
reduced birth weights [Godfrey et al., 1991] (as does experimental blood loss in 
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the rat [Alexander 1978]) that predicts higher blood pressure levels. But what is 
the precise mechanism of malnutrition? An advocated basic mechanism has been 
alteration of growth factor levels in the foetus; suppression of insulin-like growth 
factor-1 (IGF-1) is observed in foetal sheep where the mother is subjected to 
malnutrition, an effect which is restored by glucose infusion but not by amino acid 
infusion [Oliver et al., 1993]. 
Could this theory explain why the correlations of birth weight and blood pressure 
are observed within the normal range of birth weights? This possibility is rather 
mitigated against by animal studies showing that there must indeed be very severe 
restriction in maternal nutrition before any effect is noted on birth weight. Thus 
sheep with singleton pregnancies fed restricted diet during the last 60 days of 
pregnancy resulting in only 0.5 kg weight gain (fully fed controls gained 17.7 kg 
during the same period) had lambs of similar birth weights [Hammond 1944]. 
Findings in cattle are similar [Eckles 1919] and in rats, only diet containing $; 6% 
protein (normal laboratory chow is 20 - 22%) has any detrimental effects on birth 
weight [Langley & J ackson 1994]. 
Furthermore, in London during the war of 1939- 1945 (when some of the Preston 
cohort [Barker et al. , 1990] were in-utero) there was no evidence of an effect of 
the wartime diet on birth weight or the frequency of prematurity [Huggett 1944], 
and wartime maternal supplementation with minerals and vitamins did not affect 
birth weight [Anonymous 1942]. Indeed, the Dutch famine of World War II may 
be an extreme exception or may be related to non-dietary stress (see later). 
Another problem is why the correlations hold at each level of social class, 
irrespective of whether it is determined at birth by fathers occupation or at the time 
of blood pressure measurement [Barker et al., 1993 b]. Further, although relatives 
may share the same environment and/or nutritional patterns, why is intrauterine 
growth retardation (IUGR) more common in offspring of relatives of mothers that 
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have given birth to growth retarded children [Morton 1955] and in offspring of 
those mothers who themselves suffered IUGR [Ounsted & Ounsted 1966]? 
The type of growth retardation is also important; symmetrical growth retardation is 
caused by adverse influences early in pregnancy while influences acting only in late 
pregnancy (like placental insufficiency) result in asymmetric body proportions with 
brain sparing [Brar & Rutherford 1988; Kramer et al., 1990; Urrusti et al., 1972; 
Villar & Belizan 1982; Wigglesworth 1989; Chiswick 1985]. One of Barker's 
studies [Law et al., 1991] could identify three different patterns of growth 
abnormalities predicting high blood pressure, each consistent with influences 
operating during different periods of intrauterine life (although these data can be 
criticised for the "post -hoc" determination of associations from subpopulations). 
One tends to think of the mother and foetus as unity, and thus it at first seems 
inconceivable that huznan malnutrition should only be present during specific 
periods of pregnancy although examples of separate involvement are in fact 
available, such as hyperemesis gravidarum and late placental insufficiency. 
However, symmetric growth retardation in animals can only be produced by severe 
protein-calorie malnutrition [Straus et al., 1991], when no brain sparing is 
observed [Brar & Rutherford 1988], in contrast to the observations in the Preston 
study [Barker et al., 1990]. Those suffering from this symmetric type of IUGR 
exhibit poor catch-up growth in infancy [Brar & Rutherford 1988], while humans 
with the highest adult blood pressures are those who have grown fastest during 
childhood [Lever & Harrap 1992]. 
In summary, there are problems with the malnutrition hypothesis and to explain the 
associations between low birth weight and subsequent elevated blood pressure (and 
other diseases), one has therefore to consider the explanation as yet unknown. 
Even if one can get aetiological clues from severe IUGR, there might be different 
factors acting to produce the patterns observed within the normal ranges of birth 
and placental weights. There could even be multiple factors capable of inducing 
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offspring hypertension, each acting through different (or common) mechanisms 
and/ or at different times during pregnancy. Thus there are now three papers from 
separate groups reporting in-utero programming of hypertension using different 
approaches; severe maternal protein-calorie malnutrition [Langley & Jackson 
1994], moderate maternal glucocorticoid excess [Benediktsson et al., 1993], and a 
much older paper where numerous (less well characterised) different 
pharmacological maternal manipulations could induce offspring hypertension 
[Grollman & Grollman 1962]. 
1.1.3. Programming 
What could be the basic mechanism by which the factor(s) responsible for the 
above observations act? Several studies have shown that there is perinatal 
plasticity of hormone receptors and enzymes. Csaba [Csaba 1980] introduced the 
term "hormonal imprinting" (here called programming) to describe the 
phenomenon of lasting changes in receptor-ligand interaction, induced by brief 
perinatal manipulations of the relevant system. In one of his studies he reported 
lasting amplification of insulin receptor responses after a single neonatal insulin 
dose [Csaba et al., 1979]. At three months of age the treated animals however 
only differed in fasting glucose levels (controls higher) and no difference was 
observed in the response of glucose to insulin injection. Similarly he reported 
lasting amplification of vasopressin responses in rat aortic strips following a single 
neonatal injection of vasopressin when compared to controls which received saline 
only [Csaba et al., 1980]. However, the differences were small and proved not to 
be specific as the responses of the aortic strips to noradrenaline were also increased 
[Csaba et al., 1980]. 
The permanent effects of steroid hormones given during the perinatal period are 
better established. Brief neonatal exposure to sex steroids leads to permanent 
organisational changes in neuroanatomy, neuronal chemistry and behaviour, which 
persists throughout adult life [Arai & Gorski 1968]. Furthermore, there is strong 
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evidence that steroids cause irreversible programming at birth of both microsomal 
and soluble rat liver enzymes [Gustafsson & Stenberg 1974b; Gustafsson & 
Stenberg 1974a]; a single neonatal testosterone treatment permanently induces liver 
56-reductase, whereas Sa-reductase is suppressed throughout life. 
The low birth/placental weight ratio predicting hypertension is found in maternal 
anaemia [Godfrey et al., 1991] as stated above, but is also found in people living at 
high altitudes [Kriiger & Arias-Stella 1970], where the foetus similarly is 
chronically hypoxic. The disproportionate placental enlargement has in both cases 
been thought to be compensatory or secondary. Are there any other situations 
where this peculiar pattern of birth and placental weights has been observed? 
Smoking results in a proportional reduction in birthweight and length [Miller & 
Hassanein 1974], consistent with an ·influence acting throughout pregnancy (see 
discussion above in relation to Professor Barker's fmdings). The effect of smoking 
on placental weight is somewhat controversial. One study found no effect of 
maternal smoking [Spira et al. , 197 5], while another found smoking reduced 
placental weight as well as birth weight, but disproportionately, increasing the ratio 
of placental to birth weight [Godfrey et al., 1991]. We do not know whether 
maternal smoking leads to offspring hypertension. The effect on offspring blood 
pressure of alcohol administration to pregnant mothers is similarly not known, but 
chronic alcohol administration to pregnant rats leads to low foetal weight and high 
placental weight [Sanchis et al., 1986]. 
Rats made diabetic with streptozotocin give birth to low weight offspring that also 
have high placental weights [Sybulski & Maughan 1971; Robinson et al., 1988; 
Canavan & Goldspink 1988]. These effects are only partially reversed by insulin 
treatment, and interestingly these animals have markedly raised maternal 
glucocorticoid levels [Helier et al., 1988] and foetal plasma amino acid levels are 
significantly lower than in controls, while maternal amino acid levels are normal 
[Martin et al., 1990]. By contrast, alloxan-induced diabetic rats have normal 
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maternal glucocorticoid levels and do not exhibit reduced birth or increased 
placental weights [Sybulski & Maughan 1971]. 
It is now clear that glucocorticoids retard foetal growth both in humans [Reinisch 
et al. , 197 8; Katz et al. , 1990] and animals [Benediktsson et al. , 1993]. For 
placental weight, glucocorticoids may increase or reduce placental weight 
[Gunberg 1957], probably depending on dose and/or timing of exposure. Of 
course, glucocorticoids directly elevate blood pressure in adults (Cushing's 
syndrome for example) and even in-utero, at least in foetal sheep [Tangalakis et 
al., 1992]. 
There are several mechanisms by which glucocorticoids may affect blood pressure. 
Direct effects on vasculature in-utero could be mediated via enhanced vascular 
responses to vasoactive agents like noradrenaline [Russo et al., 1990] and 
angiotensin-II [Tangalakis et al., 1992] or by regulation of prostacyclin synthesis in 
blood vessels [Danon & Prajgrod 1991] (for a review of direct regulatory 
mechanisms, see Walker & Williams 1992). Indirect effects (programming) 
affecting blood pressure could be the result of glucocorticoids altering in-utero 
brain development [Mayer 1985]. Neonatal stress for example permanently 
programmes patterns of hypothalamic-pituitary-adrenal responses, effects mediated 
largely through altered expression of glucocorticoid receptor genes in the brain 
[LaRocque et al., 1992; Meaney et al. , 1993]. Development of several organs 
other than brain is also altered by prenatal glucocorticoids, for example heart and 
kidney [Slotkin et al., 1992b; Bian et al., 1993], both of which could be implicated 
in blood pressure control. Central noradrenergic activity is also permanently 
altered by brief prenatal glucocorticoid exposure [Slotkin et al., 1992a], as is 
peripheral sympathetic innervation, adrenergic receptor expression and adenylate 
cyclase function [Bian et al., 1992; Bian et al., 1993]. For a review of 
organs/ enzymes affected, see Ballard 1979. 
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Recently, we demonstrated that treatment of pregnant rats with dexamethasone, in 
a modest dose which reduced average birth weight by 14% and did not alter litter 
size or gestation length, caused elevated blood pressures in the adult offspring, 
more than 5 months after exposure to exogenous glucocorticoid [Benediktsson et 
al., 1993]. Although the precise mechanism in this example is not known, with 
reference to the above discussion, several mechanisms can be invoked. 
As mentioned above, there are indications that malnutrition might affect the 
expression of growth factors, providing a basic mechanism by which malnutrition 
might act since there are now strong indications that foetal growth is to a large 
extent controlled by IGF-1 and IGF-2 in harmony with their respective binding 
proteins (IGFBP-1 and IGFBP-2) and at least two different receptors. There is 
now a body of evidence showing that glucocorticoids modulate the expression of 
IGF-2, the type-1 IGF receptor and the binding proteins 1 and 2 [Luo et al., 1990]. 
All are altered in foetal liver following dexamethasone treatment of pregnant rats 
[Price et al., 1992], and direct infusion of cortisol into foetal sheep markedly 
reduces hepatic IGF-2 mRNA expression [Li et al., 1993]. Interestingly, the 
streptozotocin diabetic rat, which as stated before has foetal growth retardation, 
high placental weight and elevated maternal glucocorticoid levels, even has raised 
foetal IGFBP-1 and IGFBP-2 expression [Ooi et al., 1990; Helier et al., 1988]. 
So are glucocorticoid hormones likely candidates in man? Could glucocorticoids 
be the basic mechanism explaining the maternal malnutrition hypothesis? 
Chromosomally normal human foetuses suffering IUGR have elevated cortisol 
levels as well as elevated corticotropin-releasing hormone [Go land et al., 1993] 
and although data from IUGR cases has to be interpreted with care, this can be 
taken as supporting evidence. What precisely are glucocorticoid hormones and 
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Introduction: Hormones 
1. 2. HORMONES 
The term hormone is derived from Greek, meaning "to excite or stir up". 
Hormones are substances produced by a cell/tissue. Following secretion, 
hormones affect their target tissue(s)/cell(s). Hormones affecting the cell which 
secreted the hormone, are termed Autocrine, while if the target is another cell 
locally the hormone is termed Paracrine. Endocrine hormones on the other hand 
are secreted by one tissue and have their effects on another (distant) tissue, 




Figure 1.2 Basic Structure of Steroids. 
The basic four ring structure (cyclopentanoperhydrophenanthrene) of all steroid hormones. The rings 
themselves are named A-D while each carbon atom has a number. On the basis of carbon atoms, 
classes of hormones can be identified. C18: oestrogens, C19: androgens, C21: gestagens, gluco-
and mineralocorticoids. Adapted from [Orth et al., 1992a]. 
Biochemically one can classify endocrine hormones as peptides (e.g. insulin), 
amines (e.g. thyroxine) or steroids (e.g. cortisol). Effects are mediated following 
binding of the hormone to specific molecules (Receptors) on the target cell surface 
or within the cell. This either results in an effect or forms (or sets free) an 
intracellular molecule (Second Messenger) which brings about the effect. Although 
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certain generalisations about hormones' synthesis, secretion and control are 
possible, the subject is becoming more complex. Regulation of action generally 
occurs at several levels: synthesis, secretion, carriage in the circulation, 
distribution, clearance, tissue uptake and/or receptor binding and at post-receptor 
level. 
1. 3. CORTICOSTEROID HORMONES 
Steroid hormones are variably lipid soluble, having a common derivation from the 
cyclical alcohol cholesterol, which itself is synthesised from acetyl coenzyme A 
(acetyl-CoA). Examples of steroid hormones are the male and female sex 
hormones, and the adrenal corticosteroids (mineralo- and glucocorticoids). The 
basic structure of steroid hormones is shown in Figure 1.2. The adrenal cortex, 
ovaries and testes are embryologically related and all have the capacity for 
synthesis of steroid hormones. A limited account of steroidogenesis in the adrenal 
cortex follows below. 
1.3.1. Synthesis 
The human adrenal gland is recognisable by the second month of gestation and is 
functionally active from early in pregnancy [Murphy 1973]. At mid-gestation it is 
bigger than the kidney, being composed of an outer cortex, and inner medulla 
which is formed by invasion of the gland by embryologically unrelated tissue of 
neural crest origin. At term, two zones can be distinguished in the cortex, the bulk 
provided by the inner foetal zone which rapidly degenerates following birth. The 
outer definitive cortical zone by birth has two distinct subdivisions: outer zona 
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glomerulosa and inner zona fasciculata. It is only during the first year of life that 
the innermost zona reticularis develops. 
Microscopically the distinction between these three areas is not very sharp, and 
knowledge about the factors regulating growth of the adrenal cortex is incomplete. 
Functionally however, this zonation makes sense, the foetal zone mainly producing 
dehydroepiandrosterone sulphate, while mineralocorticoid synthesis takes place in 
the glomerulosa and glucocorticoid synthesis in fasciculata/reticularis. The adrenal 
cortex is capable of de-novo cholesterol synthesis, although about 80% of the 
requirements for steroid biosynthesis are provided by the plasma pool of 
cholesterol. The principal members of the three major classes of steroids 
(glucocorticoids, mineralocorticoids and androgens) produced by the adrenal cortex 
in humans, are cortisol, aldosterone and dehydroepiandrosterone respectively. The 
biosynthetic pathways are shown in Figure 1. 3. 
The physiological glucocorticoid in humans is cortisol, a 21 carbon (C21) steroid 
formed in five steps from cholesterol in the zona fasciculata/reticularis. Four of 
the enzymes required are cytochrome P-450 enzymes. The physiological 
glucocorticoid in rats is corticosterone as these animals lack the enzyme 17a-
hydroxylase. As indicated in Figure 1.3, the first step is cleavage of the side chain 
of cholesterol between carbons 20 and 22. This is effected by cholesterol 
desmolase (P-450 SCC), which is regulated by ACTH [Waterman & Simpson 
1989]. This enzyme is mitochondrial and the rate limiting step in the biosynthetic 
pathway. This side chain cleavage of cholesterol produces pregnenolone which 
then enters the cytoplasm where it is converted to progesterone by 3B-
hydroxysteroid dehydrogenase (the only non P-450 enzyme). 17a-hydroxylase can 
convert both pregnenolone and progesterone to their respective 17a-hydroxy 
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varieties. 17a-hydroxylase has 17 ,20-lyase activity which is responsible for 
conversion of 17 -hydroxypregnenolone to the principal adrenal androgen, 
dehydroepiandrosterone. 
To form cortisol, 17-hydroxyprogesterone first undergoes 21-hydroxylation by a P-
450 enzyme in the smooth endoplasmic reticulum thus generating 11-deoxycortisol. 
The last step is then llB-hydroxylation by a fasciculata specific isoform [White et 
al., 1994] of liB-hydroxylase (correct nomenclature is now CYPllBl [Nelson et 
al., 1993]). Going down the left pathway (escaping 17a-hydroxylation) in Figure 
1.3, progesterone is acted upon by 21-hydroxylase giving rise to !!-
deoxycorticosterone. llB-hydroxylation then occurs by CYPllBl thus generating 
small amounts of corticosterone in the zona fasciculata. 
In the zona glomerulosa, which functions to generate mineralocorticoids, mainly 
under the control of angiotensin-II and potassium [Quinn & Williams 1988], 
pregnenolone is converted into progesterone which in turn is 21-hydroxylated 
(Figure 1. 3) to give !!-deoxycorticosterone. Corticosterone is then generated by 
the second isoform of liB-hydroxylase, CYP11B2, which is a product of a gene 
different from the gene for CYPllBl [Momet et al., 1989]. CYP11B2 does not 
stop at 11B-hydroxylation like its counterpart in zona fascicularis, but goes on to 
generate aldosterone in two successive steps, 18-hydroxylation and 18-oxidation, 
the substrate probably never leaving the enzyme [White et al., 1994]. 
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3p - Hydroxysteroid Dehydrogenase 
0 
21 - Hydroxylase 
0 
Figure 1.3 Biosynthesis of Adrenocortical Steroids 
The figure is modified from several sources (see text for discussion). 17a-hydroxylase also has 17,20-
lyase activity. CYP11 81 and CYP11 82 are products of separate genes, both can 11 B-hydroxylase. 
The last three steps of aldosterone synthesis are carried out by a single enzyme (CYP11 82). SCC: 
Side Chain Cleavage effected by cholesterol desmolase; DHEA: Dehydroepiandrosterone; ASD: 
Androstenedione. 
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1.3.2. Regulation 
The discussion will be limited to glucocorticoids. The integration of 
glucocorticoid homeostasis is complex and involves various regions in the brain, 
the pituitary gland, the adrenal cortex and target organs as well as plasma proteins. 
An overview is given in Figure 1.4. The main stimulus to glucocorticoid secretion 
from the adrenal cortex is ACTH [Waterman & Simpson 1989; White et al., 
1994]. Corticotropin (ACTH -AdrenoCorticoTropic Hormone) is a 39 amino acid 
peptide secreted from the anterior pituitary but the first 18 NHrterminal amino 
acids are the biologically active part of the molecule. Its synthesis involves 
translation and processing of a 241 amino acid precursor peptide called 
proopiomelanocortin (POMC) [Eipper & Mains 1980]. 
Acutely, ACTH increases cortisol synthesis (adrenal cortisol storage is minimal) by 
inducing side chain cleavage (cholesterol desmolase), converting cholesterol into 
pregnenolone. ACTH acts through a G protein-coupled receptor [Mountjoy et al., 
1992], which increases cAMP levels, resulting acutely in increased activity of 
cholesterol desmolase but also (chronic effects) affects transcription of genes 
encoding the enzymes in the biosynthetic pathway, thereby increasing adrenal 
weight [John et al., 1986; Gill1972]. 
Multiple hormonal factors affect ACTH secretion [Antoni 1986; Antoni 1993], but 
the most important positive stimulus is a hypothalamic 41 amino acid peptide called 
CRF (Corticotropin Releasing Factor), which acts through adenylate 
cyclase/cAMP. CRF is secreted under multiple influences from other areas in the 
brain, including the limbic system. Its actions on ACTH secretion are potentiated 
by Vasopressin (A VP) which itself stimulates ACTH secretion directly. In 
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addition, catecholamines, angiotensin-!!, serotonin, oxytocin, atrial natriuretic 
factor, and several other factors have been implicated [Antoni 1986; Antoni 1993]. 
Negative feedback is an important feature of this homeostatic system and while 
cortisol itself does not appear to exert negative feedback on its biosynthetic 
pathway in the adrenal it does so on ACTH secretion and POMC transcription 
[Lundbland & Roberts 1988]. At the level of the hypothalamus (CRF and AVP), 
cortisol and perhaps ACTH exert negative feedback. Steroid receptors are found 
in many areas of the brain, for example the hippocampus which is also part of the 
feedback system. 
The plasma levels of both cortisol and ACTH exhibit a diurnal rhythm [Krieger et 
al., 1971; Weitzman et al., 1971; Veldhuis et al., 1990], the mechanism for which 
is not clear. ACTH secretion is pulsatile throughout the 24 h but the pulse 
amplitude increases a few hours after onset of sleep in humans. Cortisol levels 
peak a few hours later, therefore usually in the early morning, declining to a nadir 
at midnight. Although there is probably an endogenous pacemaker in the 
hypothalamus (the suprachiasmatic nucleus) which controls the rhythmicity of the 
above system, environmental stimuli play an important role. The system, which 
collectively is called the Hypothalamic-Pituitary-Adrenal Axis, is affected by 
multiple physical and psychological stresses (feeding, trauma, hypoglycaemia, 
smoking, exercise, etc.). 
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Figure 1.4 A Schematic Outline of the Hypothalamic-Pituitary-Adrenal Axis 
CRF 41 , vasopressin and other factors stimulate ACTH secretion which in turn stimulates cortisol 
synthesis by the adrenal cortex. Plasma levels of free cortisol are balanced mainly by CBG which is 
synthesised mainly in the liver and target tissue metabolism is effected by 11 ~-HSD. Negative 
feedback as indicated; environmental stimuli are important as is neural activity within the CNS. Refer 
to text for fuller description. PIT: pituitary gland. CRF: corticotropin releasing factor. n: multiple 
hormonal stimuli including vasopressin. X: multiple environmental physical and psychological stimuli. 
11 ~-HSD: Target tissue metabolism by 11 ~-hydroxysteroid dehydrogenase. CNS: central nervous 
system. ADR: adrenal gland. ACTH: adrenocorticotropin hormone. CBG: corticosteroid binding 
globulin. 
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1.3.3. Metabolism 
Biological activity of cortisol is believed to relate to the plasma fraction which 
remains free in circulation. This is normally in the low nM range in humans, 
about 3 - 4% of plasma total cortisol or corticosterone. Most of circulating 
glucocorticoid is attached to plasma binding proteins, rendering the steroid 
biologically inactive, but protecting the molecule from degradation. The binding 
proteins are corticosteroid binding globulin (CBG) with which about 90% of 
cortisol (ea. 80% of corticosterone) is associated, albumin and a small proportion 
is associated with testosterone binding globulin (TeBG or Sex Hormone Binding 
Globulin: SHBG) [Dunn et al., 1981]. Albumin has greater capacity than CBG for 
cortisol binding due to higher concentration, although the affinity is much lower. 
During diurnal peaks and at times of stress, albumin will thus dampen fluctuations 
in free cortisol levels as CBG is flooded due to its low capacity (although high 
affinity) [Orth et al., 1992e]. 
Anatomically, the metabolism of cortisol can conveniently be divided into hepatic 
and extrahepatic, the latter mainly effected by llB-hydroxysteroid dehydrogenase 
(see Section 1.4 page 40). The biochemical pathways in the liver involve 
oxidation, reduction, hydroxylation and conjugation [Orth et al., 1992b]. The 
structural features important for high affinity binding to the glucocorticoid receptor 
are: !:!,. 4 configuration, liB- and 21-hydroxy group as well as a 3- and 20-keto 
group [Orth et al., 1992d]; modification at these points is therefore most 
important. Accordingly, A-ring reduction is a major liver pathway, shown as steps 
A1 and A2 in Figure 1.5, involving reduction of both the 3-keto and 1:!,.
4 double 
bond, generating tetrahydrocortisol. Oxidation of liB-hydroxyl group (B) is 
similarly important and is considered in Section 1.4 page 40. Various ways of 
inactivating cortisol by modifying the C17 side chain exist. Step (C) indicates 
complete side chain cleavage while (D) indicates reduction of the 20~keto group. 
6B-hydroxylation (E) is not very important in normal individuals, but in cases of 
glucocorticoid excess (e.g. Cushing's syndrome) disproportionally high urinary 
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excretion of 6B-hydroxycortisol is observed, probably due to saturation of normal 
pathways [Voccia et al., 1979]. Not depicted in Figure 1.5, is conversion of the 
CH20H configuration of carbon 21 to a COOH configuration which cortisol and its 
other metabolites can undergo. Finally, the various metabolites can be conjugated 
to glucuronide to render them more water soluble. 
11 hydroxyandrostenedione 
j cortisone ~  
~HO 
I 5a!J3 tetrahydrocortisol ~ 
~ 
lswp dihydrocortisol I 
Figure 1.5 Metabolism of Cortisol 
j20a1J3 dihydrocortisol ~ 
~ je~ hydroxycortisol • 
The figure shows major pathways of cortisol inactivation. a and r! indicate two possible isomers. See 
text for full discussion. 
1.3.4. Role 
Glucocorticoids have myriad roles. Perhaps it is easiest to get an overall view by 
considering disease states. If present in excess, like as Cushing's Syndrome or 
following long term treatment with exogenous glucocorticoids, morphology 
changes. There is redistribution of fat, becoming centripetal; osteoporosis 
develops and degeneration of muscle and connective tissue is observed; growth is 
impaired. The two latter factors lead to the clinical observations of bruising, 
weakness, wasted muscles and thin skin. The patient has hypertension, sexual 
dysfunction and reduced resistance to infections. Glucose intolerance or diabetes 
may develop and psychological changes like depression are frequently observed. 
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hypoglycaemia, weight loss, fluid and electrolyte disturbances (inability to excrete 
a water load). 
For fuel homeostasis in more detail; glucocorticoids promote gluconeogenesis and 
glycogen deposition in the liver by inducing the activity of several specific 
enzymes (e.g. glucose-6-phosphate, phosphoenol pyruvate carboxykinase) [Exton 
1979] as well as by inhibiting the activity of glycogenolytic enzymes (glycogen 
phosphorylase) [Stalmans & Laloux 1979]. These effects are anabolic, aiming at 
elevating plasma glucose levels. Peripherally the actions are classified as 
catabolic, since glucose transport into cells is inhibited, (again keeping plasma 
glucose high) [Munck 1962], while lipolysis is enhanced (for example sensitivity to 
catecholamines increased) [Exton 1979; Fain 1979], and amino acids are mobilised 
from skeletal muscle (substrate for gluconeogenesis). Biochemically this leads to 
elevated plasma glucose and free fatty acids. 
In addition to the above effects on muscle and connective tissue, osteoporosis 
results from excessive glucocorticoid exposure, due to inhibition of osteoblastic 
activity [Cheng et al., 1994]. Glucocorticoids also inhibit Ca + + absorption from 
the gut [Lukert & Adams 197 6], and by decreasing renal Ca + + reabsorption they 
enhance urinary calcium excretion [Laake 1960]. 
Glucocorticoids affect immunological function profoundly [Orth et al., 1992c], 
which is manifest clinically by immunodeficiency and predisposition to infection. 
Distribution of the cells of the immunological system is modulated and so is their 
behaviour. Not only do they inhibit proliferation/maturation of T- and B-
lymphocytes but also the release of mediators from them. Thus prostaglandin and 
leukotriene homeostasis is modulated. 
Fluid and electrolyte homeostasis is also modulated by glucocorticoids. In the gut, 
ion transport is directly affected by glucocorticoids and glucocorticoids do have 
affinity for mineralocorticoid receptors as discussed in Section 1.4 on page 40. It 
is also well established clinically that glucocorticoid excess (Cushing's) is 
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associated with hypertension. This effect has been reproduced in animals 
chronically infused with dexamethasone [Tonolo et al., 1988] and in foetal sheep, 
cortisol infusion increases blood pressure, possibly via increased angiotensin-II 
sensitivity [Tangalakis et al., 1992]. The mechanism has yet to be fully explained, 
but may relate to increased vascular sensitivity to vasoconstrictors via increased 
adrenergic and/ or angiotensin receptor expression, increased 2"d messenger 
responses (induction of adenylate cyclase) and/or increased substrate production 
(angiotensinogen, tyrosine hydroxylase induction) (for further discussion, see 
Section 1.1.3, page 24, and Walker & Williams 1992). 
As regards the central nervous system (CNS), glucocorticoids have multiple effects 
on behaviour, the clinical literature abounding with accounts of psychosis 
following administrations of synthetic glucocorticoids. In fact over half of patients 
with Cushing's are thought to have psychological disturbances, typically depression 
and cognitive/memory dysfunction [Plotz et al., 1952; Jeffcoate et al., 1979; 
Starkman et al., 1986]. Many of these effects are likely to represent effects via 
mineralocorticoid and glucocorticoid receptors which are present on neurons, 
although some of them occur so rapidly that it is unlikely that they are operating 
via classical steroid receptor-gene interactions [Orth et al., 1992f]. On the other 
hand there is also now clear evidence for glucocorticoids affecting development of 
the CNS, and they are directly toxic to neurons causing cell death, largely by 
increasing neuronal vulnerability to a wide range of other insults by inhibiting 
glucose uptake and by potentiating intracellular Ca + + release [Virgin et al., 1991; 
Ell iot & Sapolsky 1993]. 
For discussion on glucocorticoids and development see Section 1.1.3. 
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1.4. 11 B-HYDROXYSTEROID DEHYDROGENASE 
11B-hydroxysteroid dehydrogenase (llB-HSD) is a widely distributed enzyme 
catalysing the interconversion of B-hydroxy and keto groups in position 11 in a 
number of steroids (Figure 1.6) (for a list of over 30 steroid substrates, see 
Monder & White 1993). llB-HSD activity in the liver is responsible for the 
biological activity of cortisone, being converted to active cortisol, while in the 
kidney its function is the opposite, inactivation of cortisol conferring specificity to 
the mineralocorticoid receptor [Edwards et al., 1988]. It is now clear that at least 
two isoforms of llB-HSD exist, llB-HSD-1 [Krozowski et al., 1992; Tannin et 
al., 1991; Moore et al., 1993] and llB-HSD-2 [Albiston et al., 1994; Krozowski 
1994; Brown et al., 1994; NarayFejesToth et al., 1994b; Stewart et al., 1994b; 
Stewart et al., 1994a]. 
Evidence for the interconversion of steroids with 11-hydroxy and 11-keto groups 
was available already in the early 1950's [Hechter et al., 1951; Mason 1950]. In 
1953 Amelung [Amelung et al., 1953b; Amelung et al., 1953a] described a rat 
liver enzyme capable of catalysing this conversion. The enzyme was called "llB-
hydroxy dehydrogenase" by Hiibener in 1956 [Hiibener et al., 1956] but is now 
termed "118-hydroxysteroid dehydrogenase". In 1960, Osinski [Osinski 1960] 
described the enzyme in the placenta, where it has been thought to protect the 
foetus from the much higher maternal glucocorticoid levels. It was however not 
until Edwards and Stewart [Stewart et al., 1988] described a case of the Syndrome 
of Apparent Mineralocorticoid Excess (AME), that the importance of this enzyme 
was realised. 
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Figure 1.6 116-Hydroxysteroid Dehydrogenase 
The figure shows the reaction catalysed by 11 B-HSD in man. The physiological glucocorticoid in the 
rat is corticosterone, and 11-dehydrocorticosterone is the cortisone equivalent. These substances 
differ from their human counterparts only in the lack of an OH group in position 17a. The groups 
involved are indicated in bold. 
1.4.1. Syndrome of Apparent Mineralocorticoid Excess 
When presented with a patient suffering hypertension in conjunction with 
hypokalaemia, aldosterone excess immediately springs to mind. Over the last two 
decades however, a rare syndrome of hypertension with hypokalaemia and 
intriguingly, suppressed plasma renin activity and aldosterone has emerged. More 
than 20 children with this disorder have now been diagnosed, distinguished from 
Liddle' s syndrome by failure of the latter to respond to spironolactone or 
dexamethasone suppression of the hypothalamic-pituitary-adrenal axis. Other 
disorders like congenital adrenal hyperplasia and primary glucocorticoid resistance, 
in contrast to AME have raised 11-deoxycorticosterone (DOC) (they also have 
abnormal levels of other adrenal steroids). Clinical features in addition to 
hypertension in children with AME are short stature, failure to thrive, polyuria and 
polydipsia. 
Although in retrospect the first case [Werder et al., 1974] was described in 1974, it 
was not until New and colleagues described similar cases [New et al., 1977; Ulick 
et al., 1979] that the term Apparent Mineralocorticoid Excess (AME) was coined 
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for this disorder. The term "apparent" was appropriate, as an intensive search for 
a hitherto unknown mineralocorticoid steroid was fruitless and !!-
deoxycorticosterone (DOC) levels were not raised. The salient abnormality in this 
syndrome is a defect in the peripheral metabolism of the physiological 
glucocorticoid cortisol. Thus urinary liB-hydroxy metabolites of cortisol 
(tetrahydrocortisol: THF and allo-tetrahydrocortisol: allo-THF) were raised in 
comparison to the 11-oxo metabolites (cortisone-metabolites i.e. 
tetrahydrocortisone: THE) indicating impaired conversion of the active 
glucocorticoid cortisol to its inactive counterpart cortisone [Stewart et al., 1988]. 
The half life of cortisol was thus prolonged, estimated by conversion of lla3H-
cortisol to unlabelled cortisone and tritiated water, indicating impaired oxidation of 
the 11-hydroxyl group [Ulick et al., 1979; Stewart et al., 1988]. Cortisol levels in 
peripheral blood were normal however, maintained by reduced adrenal cortisol 
secretion rate via altered hypothalamic/pituitary feedback . 
These children responded to pituitary-adrenal suppression by administration of the 
pure glucocorticoid dexamethasone. Treatment with hydrocortisone aggravated the 
condition leading to the suggestion that cortisol was the mineralocorticoid involved 
[Oberfield et al., 1983]. 
Ulick and New [New et al., 1977; Ulick et al., 1979] had described an abnormality 
of the dehydrogenase component of llB-HSD in the children with AME, but the 
pivotal role of this enzyme in the pathogenesis of the syndrome remained obscure 
until a 20 year old male presented with severe hypertension, hypokalaemia, and 
suppression of the renin-angiotensin-aldosterone axis [Stewart et al., 1988]. The 
diagnosis of AME was made, based on metabolic balance studies and the urinary 
steroid metabolite profile along with a prolonged half-life of lla3H-cortisol 
confirming the impaired inactivation of cortisol. These studies showed that the 
hypertension and biochemical abnormalities responded to pituitary-adrenal 
suppression with dexamethasone and on oral hydrocortisone supplementation (or 
dexamethasone withdrawal) the syndrome could be reproduced with kaliuresis, 
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sodium retention with corresponding changes in the plasma electrolytes, and 
suppression of the renin-angiotensin-aldosterone axis. Concomitantly the patient's 
weight rose and there was an increase in his blood pressure. 
The above description relates to what is now known as Type-1 Apparent 
Mineralocorticoid Excess, being a defect in the liB-dehydrogenase, but not 11-
oxidase. This is supported by finding a normal increase in plasma cortisol 
following oral administration of cortisone in addition to the characteristic urinary 
steroid metabolite profile and a prolonged half life of lla3H-cortisol [Stewart et 
al., 1988]. 
Recently Ulick and colleagues described 4 cases of what has become known as 
Type-2 Apparent Mineralocorticoid Excess [Ulick et al., 1989; Ulick et al., 1990] 
(Recently summarised by Mantero [Mantero et al., 1994]). These patients have an 
identical picture of cortisol dependent low renin hypertension with hypokalaemic 
alkalosis and suppressed aldosterone and DOC. They however have a normal ratio 
of cortisol to cortisone metabolites in urine. Proof of abnormal liB-
dehydrogenation was obtained by finding a prolonged half life of lla3H-cortisol 
[Mantero et al., 1994], thus cortisol will occupy the renal mineralocorticoid 
receptor. In addition these patients have an impaired ability to convert orally 
administered cortisone to cortisol [Mantero et al., 1994], explaining the unchanged 
ratios of cortisol to cortisone in plasma and urine and their metabolites in urine. 
1.4.2. Liquorice and the Kidney 
Key to understanding the pathogenesis of AME, was recognition of the similarities 
between the type of hypertension induced by liquorice and the syndrome. It had 
been known for many years that abuse of liquorice caused classical 
mineralocorticoid hypertension [Salassa et al., 1962]. Suggested explanations 
included binding of glycyrrhetinic acid (the active component of liquorice see 
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Figure 1. 7) to the kidney mineralocorticoid receptor [Armanini et al., 1983] but 













Figure 1. 7 Inhibitors of 11.8-HSD 
Note similarities in structure of 11 B-HSD inhibitors and steroids (Figure 1.2). To the right is the 
common triterpene structure. R is replaced by an OH group in glycyrrhetinic acid (GE - the principal 
active constituent of liquorice). GE is the hydrolytic product of the water soluble glycoside glycyrrhizic 
acid which also is present in liquorice (in Gl, bottom left replaces R). The ulcer healing drug 
carbenoxolone (CBX) is a water soluble hemisuccinate derivative of GE (top left replaces R). 
Firstly the affinity of the mineralocorticoid receptor for glycyrrhetinic acid was far 
lower than that for aldosterone, and secondly some elegant studies in both humans 
[Borst et al., 1953] and animals [Card et al., 1953] had shown that an intact 
adrenal gland was necessary to allow liquorice to exert its action. In fact oral 
cortisone was able to restore the effect of glycyrrhetinic acid in patients with 
Addison's disease [Borst et al., 1953] and dexamethasone produced natriuresis in 
subjects taking glycyrrhetinic acid [Hoefnagels & Kloppenborg 1983]. 
Further studies reproduced an AME like syndrome in subjects taking liquorice, 
confirmed by raised urinary excretion of liB-hydroxy metabolites of cortisol in 
comparison to 11-oxo metabolites (cortisone metabolites), sodium retention, 
kaliuresis, and a prolonged half life of lla3H-cortisol with suppression of the 
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renin-angiotensin-aldosterone axis [Stewart et al., 1987]. It therefore seemed that 
liquorice abuse resulted in an acquired form of AME [Edwards et al., 1993b]. 
Using the active ingredients of liquorice, glycyrrhetinic acid [MacKenzie et al., 
1990] and glycyrrhizic acid [Kageyama et al., 1992], it was shown that the urinary 
steroid profile was identical to Apparent Mineralocorticoid Excess type 1 (as in 
liquorice abuse) but carbenoxolone did not result in a change of this ratio although 
total urinary cortisol metabolite excretion was reduced [Stewart et al., 1990b]. 
Carbenoxolone treatment thus was more like Apparent Mineralocorticoid Excess 
type 2. 
Clinching the site of the defect, Edwards and Stew art [Stewart et al., 1987] looked 
at the effect of glycyrrhetinic acid on binding of glucocorticoids to rat renal 
receptors [Edwards et al., 1988]. It was shown by autoradiography that inhibition 
of 11B-HSD in rat kidney with glycyrrhizic acid allowed 3H-corticosterone to bind 
to aldosterone binding sites, whereas none bound in the absence of the 11B-HSD 
inhibitor. 
In-vitro work with purified Type-1 mineralocorticoid receptor [Krozowski & 
Funder 1983] as well as cloning and expression of the human Type-1 receptor 
[Arriza et al., 1987] has since shown it to have similar affinities for cortisol, 
corticosterone and aldosterone lending plausibility to the hypothesis that in-vivo an 
additional factor was necessary to ensure tissue mineralocorticoid specificity, 
namely 11B-HSD. This hypothesis is obviously of paramount importance in a 
biological sense, challenging the simplistic view that receptor activation depended 
solely on ligand-receptor interaction. 
Emphasising the importance of 11B-HSD in the kidney, the bulk of plasma 
cortisone derives from the kidney [Whitworth et al., 1989b; Walker et al., 1992a]. 
Also, 11B-HSD may play a role in the ectopic ACTH syndrome, where ACTH is 
thought to directly inhibit the enzyme in the kidney - causing the characteristic 
hypokalaemia. This was based on exceptionally high plasma cortisol/cortisone 
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ratios individuals with Cushing's syndrome, and a high cortisol/cortisone ratio in 
healthy volunteers infused with cortisol or ACTH [Walker et al., 1992a]. 
Figure 1.8 Enzyme Mediated Receptor Protection 
The figure illustrates the concept of enzyme mediated receptor protection. The mineralocorticoid 
receptor (MR) is inherently non-specific with respect to cortisol (F) and aldosterone (Aldosterone) (and 
corticosterone). F is converted to E by 11 B-HSD allowing Aldo preferentially to bind to the renal 
mineralocorticoid receptor in spite of 100-1000 fold higher circulating levels of F. 
Recently, several reports have confirmed the relevance of llB-HSD to 
mineralocorticoid receptor activation in a variety of other mineralocorticoid targets 
(including toad bladder mucosa [Brem et al., 1993], colonic mucosa [Whorwood et 
al., 1993a], and cultured collecting duct cells [NarayFejesToth & Fejes-Toth 
1994]). 
1.4.3. lsoforms of 11 B-HSD 
The possibility of isoforms of llB-HSD was first noted by L6pez Bernal in 1980 
[L6pez Bernal et al., 1980b], when he found that the in-vitro activity of the 
enzymes present in human trophoblast and decidua responded differently to 
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inhibitors and had different apparent Km and specific activity. Later in 1985, the 
rat liver enzyme was found to have separable oxidase and reductase activities, 
achieved by means of phospholipases, detergents and alterations in pH (Lakshmi & 
Monder 1985], which was felt to be an indication of more than one type of 1113-
HSD. When considering the wide tissue distribution of this enzyme, its 
phylogenetic age (its presence in the toad bladder indicates evolutionary 
conservation for over 300 x 106 years [Gaeggeler et al., 1989]), the multiple 
effects of glucocorticoids, and the lack of substrate specificity, one has to say that 
it would be surprising if there was only one form of 1113-HSD. 
Could the current data fit with one isoform, the local environment determining 
tissue specific characteristics? In the liver, the enzyme's prevailing direction in-
vivo appears to be opposite to that in the kidney [Bush et al. , 1968; Stew art et al. , 
1988]. That conceivably could be brought about by differences in the redox state 
of the tissue involved and/or tissue specific differences in availability of NAD vs. 
NADP. Changes in pH is another possibility. The fact that in-vitro expressed 
1113-HSD [Agarwal et al., 1990] contained both activities actually supports this 
idea. I do however subscribe to the view, recently expressed by Monder and 
White [Monder & White 1993], that this is not likely to be the main explanation. 
The pH preferences of the liver and placental enzymes [Brown et al., 1993] for 
example are too discrepant and removed from physiological pH to be plausible 
regulators of enzyme direction. The same applies to the redox state. 
Steroid or other hormones might regulate the activity as well as the direction of 
reaction in tissue and/ or species specific manner. Thus the presence or absence (or 
a vs. B position) of several functional groups (at positions different from 11) can 
determine whether in a particular tissue preparation, the direction of reaction is 
oxidative or reductive with regard to that particular steroid [Monder & White 
1993]. Another example is the induction of placental liB-dehydrogenation by 
oestrogens in the baboon which appears to be species specific (not observed in 
humans, see later); 1113-HSD appears to convert cortisone to cortisol at mid-
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gestation, but at term the reverse [Pepe & Albrecht 1984b; Pepe et al., 1988]. 
Non-steroid hormones like thyroxine have also been shown to affect direction and 
activity of 11B-HSD in tissue and species specific manner (for review see Monder 
& White 1993). But do we then have data supporting the view that intra- and 
inter-tissue differences in 11B-HSD may not only be the result of variations in the 
intracellular environment but possibly due to post-translational modifications 
and/or represent products of separate genes? The answer to this question is yes. 
The first clue came from the kidney. The initial theory was that the enzyme 
protected the renal mineralocorticoid receptor in a paracrine fashion as there was 
positive immunostaining for the enzyme in proximal tubules only, upstream from 
the classical mineralocorticoid receptor sites [Edwards et al., 1988]. As inhibition 
of 11B-HSD had allowed glucocorticoids to bind to mineralocorticoid binding sites 
(distal tubule) [Edwards et al., 1988; Funder et al., 1988], this was somewhat 
peculiar, and later studies [NarayFejesToth et al., 1991; Bonvalet et al., 1990] 
confirmed bioactivity in the distal tubules, supporting the more plausible autocrine 
hypothesis. There were also several other characteristics (apart from not binding 
anti-sera raised against rat liver 11B-HSD), of the kidney enzyme distinguishing it 
from the enzyme in other sites. Thus the affinity for its substrate was higher 
[NarayFejesToth et al., 1993; NarayFejesToth et al., 1994b; Stewart et al., 
1994b], it utilises NAD rather than NADP as cofactor [Walker et al., 1992b; 
NarayFejesToth et al., 1994a], and is differentially regulated during ontogeny 
[Brem et al., 1994; Hundertmark et al., 1994; Maser et al., 1994] and by thyroid 
hormones [Whorwood et al., 1993b], and sex steroids [Low et al., 1993]. 
Recently, multiple mRNA species [Krozowski et al., 1990] and truncated 11B-HSD 
forms [Krozowski et al., 1992] have been identified in the kidney although they 
seem to be functionally inactive when expressed in-vitro [NarayFejesToth et al., 
1994a; Obeid et al., 1993]. 
The predominant placental isoform has very different Km, pH optima, detergent 
solubility, !ability, subcellular localisation, immunoreactivity and cofactor affinities 
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than the liver isoform [Lakshmi et al., 1993; Brown et al., 1993]. The amino acid 
sequence of the two is also very different [Brown et al. , 1994]. Increasingly, it 
therefore seemed that there must be at least two genes encoding tissue specific 
isoforms. The liver predominant isoform has now been cloned in the rat 
[Krozowski et al., 1992; Moisan et al., 1992a], squirrel monkey [Moore et al., 
1993], and man [Tannin et al., 1991]. The liver type cDNA encodes a reductase 
in intact mammalian cells [Low et al., 1994]. Several groups have been close to 
cloning a second gene in human placenta [Brown et al., 1993; Brown et al., 1994], 
human adult and foetal kidney [Stewart et al., 1994b; Stewart et al., 1994a], and 
cultured rabbit cortical collecting duct cells [N aray FejesToth et al., 1993; 
NarayFejesToth et al., 1994b]. However, Krozowski's group in Melbourne has 
recently announced the successful cloning of a cDNA for a 118-HSD-2 protein 
using expression cloning from human kidney [Krozowski 1994; Albiston et al., 
1994]. Sequence alignment shows only 14% identity of 118-HSD-1 and 118-HSD-
2 [Albiston et al., 1994]. 
The classical syndrome of AME (type 1) is almost certainly attributable to a defect 
in the 118-HSD-2 gene product, affecting only classical mineralocorticoid target 
sites. Recent studies reinforce this view, since no patients have displayed features 
of abnormal glucocorticoid receptor exposure and glucocorticoid receptor 
antagonists have no therapeutic effect, indicating that only mineralocorticoid 
receptors are involved in its pathogenesis [Speiser et al., 1993]. Thus, it is no 
longer surprising that no mutations in 118-HSD-1 were found in 4 patients with 
AME [Nikkila et al., 1993], although it should be remembered that the whole gene 
was not sequenced in these patients. 
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1.4.4. 11 B-HSD Beyond the Kidney 
Outside the kidney, one of the earlier observations from our laboratory was the 
potentiation of action of topically applied glucocorticoids by eo-application of 
glycyrrhetinic acid [Teelucksingh et al., 1990]; the skin vasoconstrictor assay, 
where skin pallor is observed following administration of glucocorticoids. Using 
mice, bioactivity was also shown in skin homogenates and immunoreactivity could 
be detected in the basal epidermal layers [Teelucksingh et al., 1990]. 
The above mentioned skin vasocol).strictor assay, is simply an estimate of dermal 
blood flow. This therefore, along with the observation in AME that although 
sodium retention occurs in the acute phase, blood pressure increase occurs only 
after a lag period [Stewart et al., 1988], implicated other sites (than the kidney) of 
118-HSD expression which might play part in blood pressure regulation. Another 
stimulating observation was also at hand, namely that dexamethasone suppresses 
hypertension in a proportion of what otherwise would be considered patients with 
essential hypertension [Hamilton et al., 1979; Whitworth et al., 1989a]. 
In rat vasculature, positive immunostaining and mRNA expression for 118-HSD is 
found in the smooth muscle [Walker et al. , 1991 b; Takeda et al. , 1994c; Kornel 
1994]. The density of 118-HSD was also found to be higher in the appropriate 
locations, i.e. resistance vessels [Walker et al., 1991b]. It was of course well 
known from animal experiments (for review see Walker & Williams 1992) that 
glucocorticoids affect vascular responses to a variety of agents. When these 
observations were followed up in man in-vivo, healthy volunteers consuming 
liquorice had increased dermal vasoconstriction to cortisol, the dermal 
vasoconstriction being still more intense in a subject with AME type-1 [Walker et 
al., 1992c]. Individuals with essential hypertension similarly had more intense 
dermal vasoconstriction in response to topically applied glucocorticoid than 
controls and about 30% of the hypertensive individuals had a prolonged half-life of 
11a3H-cortisol [Walker et al., 1991a]. Several reports on 118-HSD in animal 
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models of hypertension are now appearing. Thus IIB-HSD activity and expression 
is normal in the kidney but reduced in the liver of the Bianchi-Milan hypertensive 
strain [Stewart et al., 1993] and in the blood vessels of Dahl salt sensitive rats 
[Takeda et al., 1994a; Takeda et al., 1994b] and the Spontaneously Hypertensive 
Rat (SHR) [Takeda et al., 1993]. 
Fitting nicely with the original suggestion that IIB-HSD expression is only seen in 
tissues exhibiting aldosterone selectivity [Edwards et al., 1988], early studies on 
brain IIB-HSD failed to show significant bioactivity in homogenates [Funder et 
al., 1988; Edwards et al., 1988]. This was however later refuted by studies where 
addition of the cofactor NADP to the homogenate resulted in detectable bioactivity 
in various regions of the brain, notably the cerebellum, hippocampus and cortex 
[Lakshmi et al., 1991; Moisan et al., 1990a; Moisan et al., 1990b]. This 
bioactivity was localised mostly to neurons by immunohistochemistry [Lakshmi et 
al., 1991], and in-situ hybridisation [Moisan et al., 1990a; Moisan et al., 1990b]. 
These observations along with the observations of Teelucksingh [Teelucksingh et 
al., 1990], indicated that not only did IIB-HSD modulate access of glucocorticoids 
to the mineralocorticoid receptor (type I receptor), but also to the type II 
glucocorticoid receptor. Another support for this was the observation that 
expression of Na + IK+ ATPase subunit mRNA in the colon can be regulated with 
glucocorticoids [Fuller & Verity 1990], and effect reproduced by carbenoxolone 
but only in the presence of glucocorticoids. Later, IIB-HSD-1 bioactivity and 
mRNA expression was demonstrated in rat colon [Whorwood et al., 1992]. 
In addition to the established exogenous inhibitors of IIB-HSD, glycyrrhetinic acid 
and carbenoxolone, several endogenous compounds are competitive inhibitors of 
IIB-HSD in vitro, including progesterone derivatives and bile acids [Monder & 
White 1993; Latif et al., 1994]. It is an intriguing possibility that these act as 
endogenous regulators of enzyme activity and that they account for defective llB-
HSD in some clinical syndromes, including the ectopic ACTH syndrome (see 
above). Inhibitory activity may also account for the steroid sparing effects of some 
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herbal remedies in disorders like asthma [Homma et al., 1994]. Enhancing activity 
has been claimed for angiotensin converting enzyme inhibitors, as part of their pro-
natriuretic action [Riddle & McDaniel 1994]. Also, it has recently been suggested 
that llB-HSD may have a role in metabolising non-steroidal substances in the liver 
[Maser & Bannenberg 1994]. 
Morris and colleagues have found inhibitory activity for rat hepatic llB-HSD and 
56-reductase in human urine extracted on silica columns (Sep-Paks) and eluted with 
methanol [Morris et al., 1992]. This combined action is especially interesting 
since an unexplained feature of AME is an associated impairment of 56-reductase 
activity. They attribute the inhibitory activity to "glycyrrhetinic acid-like factors" 
(GALFs), and report that their excretion is increased in normal pregnancy [Morris 
et al., 1992], heart failure and essential hypertension [Semafuko et al., 1993]. 
However, the control groups in their studies were poorly matched. Morris' 
method has been reproduced by our group, but we found that GALF excretion is 
not increased in ectopic ACTH syndrome, and is not regulated by ACTH in health 
[Walker et al., 1993]. Although GALF excretion is increased in pregnancy, no 
additional increase in hypertensive compared with normotensive pregnant women 
was found [Williamson et al., 1994]. Finally, no increase in GALF excretion in 
essential hypertension was found and no significant relationship between GALF 
excretion and indices of mineralocorticoid receptor activation (plasma potassium, 
renin activity, and aldosterone) or llB-HSD activity (half life of lla3H-cortisol, 
ratio of cortisol to cortisone in plasma and urine, and ratio of cortisol and cortisone 
metabolites in urine) [Walker et al., 1994]. 
Rare cases of hirsutism have been attributed to impaired liB-reductase activity, 
resulting in increased cortisol clearance with increased ACTH drive to adrenal 
androgen production [Phillipou & Higgins 1985]. These patients do not have a 
defect in renal sensitivity to cortisol and no mutation was demonstrated in the llB-
HSD-1 gene in the one patient studied [Nikkila et al., 1993]. Given the above 
observation in hirsutism, it has been suggested that the hepatic conversion of 
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cortisone to cortisol could be defective in polycystic ovarian syndrome. In one 
study no abnormality of 118-HSD was demonstrated [Stewart et al., 1990a], but in 
a more recent study low ratios of cortisol to cortisone metabolites were 
documented in hirsute patients [Rodin et al., 1994]. 
There is now abundant evidence suggesting that glucocorticoids affect ovarian 
physiology [Inazu et al., 1990; Malbon & Hadcock 1988; Wang & Leung 1989; 
Adashi et al., 1981; Hsueh & Erickson 1978; Schreiber et al., 1982; Bald win & 
Sawyer 1974; Jia & Hsueh 1990; Albiston et al., 1990]. Although Ghraf did not 
find 118-HSD bioactivity in the rat ovary [Ghraf et al., 1975], human ovaries have 
been shown to be able to convert cortisol to cortisone [Murphy 1981], and to 
contain mRNA encoding 118-HSD [Tannin et al., 1991]. More recently this has 
been confirmed by myself [Benediktsson et al., 1992] and Cooke and eo-workers 
[Michael et al., 1993b; Michael et al., 1993a]. The latter showed glucocorticoids 
directly to inhibit LH-induced steroidogenesis in cultured granulosa lutein cells. 
This is modified by 118-HSD [Michael et al., 1993b]. 
Intriguingly the matter has been taken further by their subsequent finding [Michael 
et al., 1993a] that in-vitro fertilisation and embryo transfer patients that have 
detectable 118-HSD bioactivity in the cultured granulosa lutein cells are much less 
likely to become pregnant than those patients whose cells have no detectable 
bioactivity. The oocyte itself exhibits strong 118-HSD-1 immunoreactivity 
[Benediktsson et al., 1992]. This isoform is probably a reductase [Duperrex et al., 
1993; Low et al., 1994; Moore et al., 1993], preferring NADP/H [Brown et al., 
1993], in the oocyte promoting initial differentiation/maturation by increasing the 
availability of glucocorticoids and maybe suppressing local maternal 
immunological processes which at implantation would aim at destroying this partly 
foreign tissue. The granulosa lutein cells however prefer NAD, and thus possibly 
contain 118-HSD-2, which would be in keeping with the absence of 
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immunoreactivity (116-HSD-1) [Benediktsson et al., 1992]. For further discussion 
see Michael & Cooke 1994. 
In the testis, glucocorticoids also inhibit LH-induced steroidogenesis, also modified 
by 11fi-HSD [Monder et al., 1994a]. In male rats, testicular 11fi-HSD activity 
increases at puberty [Phillips et al., 1989], spermatid 11fi-HSD increases during 
maturation [Neumann et al., 1993], and dominant masculine behaviour was 
associated with higher testosterone and higher testicular 11fi-HSD activity [Monder 
et al., 1994b]. 
1.4.5. 11 B-HSD in Pregnancy 
The only study looking for 11fi-HSD in the umbilical cord failed to find any 
bioactivity [L6pez Bernal & Craft 1981]. Murphy [Murphy 1977b], looked at 
enzyme bioactivity in freshly minced uterine myometrium, and found 11fi-HSD to 
be not only present, but the direction of activity to change as pregnancy advanced 
( oxidative in non-pregnant and early pregnancy, but reductive at term). 
Giannopoulos [Giannopoulos et al., 1982] was later unable to find any activity in 
human myometrium, although the latter study's methodology was comparable. 
The same controversy has surrounded the question of the presence of 11B-HSD in 
human foetal membranes [L6pez Bernal et al., 1980b; L6pez Bernal & Craft 1981 ; 
Giannopoulos et al., 1982; Murphy 1977a; Murphy 1981]. Some studies 
[Giannopoulos et al., 1982] found activity in chorion only, employing careful 
scraping to remove adherent decidua. Tanswell [Tanswell et al., 1977] found 
activity in both directions in freshly minced membranes from various stages of 
pregnancy, but the reductive part always dominating, with activity increasing 
towards term. Murphy had found membranous activity to be the same in both 
directions in early pregnancy but agreed with Tanswell on reduction being 
dominant at term [Murphy 1981]. This prompted Murphy to propose that 
membranes were an important source of cortisol for the foetus [Murphy 1977a]. 
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L6pez Bernal found llfi-HSD activity in scraped or crude membrane preparations 
[L6pez Bernal & Craft 1981], but demonstrated in studies on membranes from 
dichorionic twins [L6pez Bernal et al., 1980a], that this activity could only be 
attributed to contamination of the membranes by decidua. Thus like amnion, the 
chorion itself is devoid of llfi-HSD. This view is in good agreement with 
histochemical studies mentioned below. 
Although cultured fibroblasts from human uterine tissue had been shown to be able 
to catalyse llfi-ol oxidation in 1958 [Sweat et al., 1958], it was not until 1960 that 
bioactivity studies by Osinski [Osinski 1960] demonstrated the presence of llfi-
HSD in term placenta. Histochemical studies in the sixties, using the tetrazolium 
blue reaction [Hart 1966; Ferguson & Christie 1967] (pink or blue pigment deposit 
where oxidation of an hydroxy group occurs), examined llfi-HSD type activity in 
the female genital tract. Two of these studies [Hart 1966; Ferguson & Christie 
1967] failed to show llfi-HSD in human term trophoblast or in foetal membranes, 
but found positive staining in the trophoblastic layer of the extraplacental chorion 
when using N AD as a cofactor. The third study found faint staining in the 
syncytium of term human trophoblast [Baillie et al., 1965] and no cofactor 
preference. The tetrazolium blue method's major drawback is that although it 
gives positive reaction where !!-dehydrogenation occurs, not all steroids are able 
to elicit this, even though they undergo liB-dehydrogenation. Thus it does not 
produce a positive reaction if the physiological glucocorticoid cortisol (or 
corticosterone) is used, and therefore investigators have resorted to using for 
example llfi-hydroxyandrostenedione, as here above. 
Osinki' s findings [Osinski 1960] have since been confirmed by numerous others in 
a variety of animal species. The role of the placental enzyme has been thought to 
be protection of the foetus [Murphy et al., 1974; Dancis et al., 1978; Beitins et al., 
1973; Dormer & France 1973] from the 2 - 10 times higher maternal 
glucocorticoid levels [Camp bell & Murphy 1977], thus preventing glucocorticoid-
mediated growth retardation [Reinisch et al., 1978; Katz et al., 1990; Benediktsson 
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et al., 1993] and possibly to allow the foetus to regulate its own hypothalamic-
pituitary-adrenal axis [Pepe & Albrecht 1985]. 
The story regarding cofactor preference of placental llB-HSD has been rather 
confusing, some finding NADP preference [Blasco et al., 1986; Osinski 196G; 
L6pez Bernal et al., 198Gb] some NAD [Pepe & Albrecht 1984a] and some no 
preference [Meigs & En gel 1961]. It is of course plausible that there is more than 
one isoform of 11B-HSD in the placenta, as described by L6pez Bernal [L6pez 
Bernal et al., 198Gb] and Lakshmi [Lakshmi et al., 1993], although it now seems 
clear that the predominant isoform which is responsible for the barrier function is 
N AD-preferring [Brown et al., 1993; Benediktsson et al., 1993], and a product of 
a gene distinct from the liver type enzyme [Brown et al., 1994]. 
If the placental enzyme's function is to protect the foetus from maternal 
glucocorticoids, one would expect its direction to be oxidative, inactivating 
glucocorticoids. This seems to be the case at term in most species, being 
compatible with our knowledge that the foetus grows fastest during the last 
trimester [Langman 1981]. The various organ systems, however, grow and mature 
at different stages of pregnancy and there are well known interspecies differences 
in that respect. One can therefore expect variable effects of excess glucocorticoids, 
depending on the direction of enzyme activity during these "windows" of organ 
development. Therefore, one might expect important inter-species differences in 
the ontogeny and direction of placental 11B-HSD. The data available so far seems 
to support the idea of inter-species differences. Pepe, Albrecht and eo-workers 
[Pepe & Albrecht 1984a; Baggia et al., 1990a; Baggia et al., 199Gb; Waddell et 
al., 1988a; Waddell et al., 1988b; Pepe et al., 1988; Pepe & Albrecht 1987; Pepe 
& Albrecht 1984b] have produced elegant studies in the baboon, where they 
injected radioactive glucocorticoids into pregnant animals, following the destiny of 
the steroids in both the mother and foetus. They subsequently manipulated their 
system with sex steroids and supplemented their in-vivo studies with in-vitro cell 
culture and bioactivity studies. In summary, they found that the prevailing 
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direction of enzyme activity changes during pregnancy, favouring reduction and 
production of active steroid at mid-gestation, but oxidation at term. This seems to 
be orchestrated by sex steroids, oestrogens inducing the conversion of cortisol to 
cortisone and repression being achieved by anti-oestrogens or foetectomy. The 
normally reductive enzyme at mid gestation could thus be made to become 
oxidative by treatment with oestrogens. At present the human story is similar with 
respect to term activity, placental 11B-HSD being strongly oxidative [Blasco et al., 
1986; Brown et al., 1993] and in the short term during labour, there is no change 
in in-vitro human placental 11B-HSD activity [L6pez Bernal et al., 1982b], thus 
always being strongly oxidative. In agreement with this was the in-vivo data of 
Beitins [Beitins et al., 1973], who injected cortisol and cortisone into the maternal 
circulation at term. They concluded that at term 25% of the foetal F and 90% of 
the foetal E is of maternal origin. 
Contrasting with the baboon data, the human placenta seems to predominantly 
oxidise cortisol to cortisone at mid-gestation. This has been shown in-vivo using 
comparable methodology to that used in the baboon. Thus Pasqualini [Pasqualini 
et al., 1970] injected a mixture of cortisol and cortisone into the foetal circulation. 
Only 3 - 6% of the total radioactivity reached the maternal circulation and although 
interconversion of cortisol and cortisone took place in the placenta, little if any of 
the cortisol formed from cortisone in the placenta reached the foetal circulation 
again. Murphy also carried out an in-vivo study in humans at mid-gestation (13-18 
weeks) [Murphy et al., 197 4] and came to the same conclusion. Studies looking at 
in-vitro 11B-HSD activity, in relation to stage of gestation, span week 7 to term 
[Blanford & Murphy 1977; L6pez Bernal & Craft 1981; Giannopoulos et al., 
1982] and find oxidation always prevailing. Thus the conclusion is that most of 
the cortisol crossing the human placenta is converted to cortisone and doesn't reach 
the foetus in a biologically active form, the placenta behaving as a barrier 
throughout gestation [Blasco et al., 1986]. 
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It is important to keep in mind the fact that in-vitro studies may not be able to tell 
us about what happens in-vivo. For example the oxidative or the reductive part of 
1113-HSD may be more robust during extraction/homogenisation, giving a false 
results [Lakshmi et al., 1993]. Thus baboon 1113-HSD in-vitro does always have 
predominant cortisol to cortisone conversion. This becomes more pronounced as 
pregnancy advances [Baggia et al., 1990a], contradicting the in-vivo perfusion data 
described above. Researchers have therefore turned to ex-vivo human placental 
perfusion, perfusing term isolated cotyledons. All the studies agree that at term 
oxidation is predominant [Levitz et al., 1978; Dancis et al., 1978; Addison et al., 
1993; Addison et al., 1991]. The studies looking at the reductive component find 
little or no reduction [Dancis et al., 1978; Addison et al., 1993]. Problems 
associated with these studies include i) the use of concentrations of steroids that are 
high and clearly not physiological (J.LM) [Dodds et al., 1993; Levitz et al., 1978; 
Dancis et al., 1978] and ii) the use of non-physiological steroids [Addison et al., 
1991]. Some authors (using J.LM steroid concentrations in recirculating systems) 
have suggested that other enzymes than 1113-HSD contribute to the placental 
metabolism of glucocorticoids [Addison et al., 1991; Dodds et al., 1993]. 
From first principles one can imagine that there could be mechanisms other than 
1113-HSD affecting the transfer of active glucocorticoids across the placenta. 
Prime candidates are the plasma proteins albumin (low specificity, high capacity) 
and CBG (high specificity, low capacity Corticosteroid Binding Globulin). The 
two studies that looked at this came to different conclusions. Murphy examined 
steroid uptake into placental villi [Murphy 1979] employing various preparations, 
and concluded that albumin had virtually no effect on the transfer of cortisol into 
human placental trophoblast, whereas CBG combined with placental cortisol 
metabolism to prevent excessive maternal cortisol from reaching the foetus. Using 
placental cotyledon perfusion, Dancis et al. [Dancis et al., 1978] concluded that 
while neither CBG nor albumin had any effect on the extent of conversion of 
cortisol to cortisone, binding to albumin (but not to CBG) reduced the clearance of 
cortisol across the placenta. 
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1. 5. PLACENTAL ANATOMY 
Placental anatomy differs between species and its structure is therefore an 
important consideration when choosing experimental animals models. A brief 
description of rat and human placental anatomy follows but for a more 
comprehensive account, see Davies & Glasser 1968; Page 1993; and Boyd & 
Hamilton 1970. Placentas are classified according to the shape of the mature 
placenta and allantoic and yolk sac development, but in addition, according to the 
amount of maternal tissue erosion by foetal tissue, and the number of layers 
interposed between the maternal and foetal blood. 
In both rats and humans, foetal tissue has eroded maternal tissue which is a major 
factor when classifying placentas. The anatomical classification introduced by 
Grosser in 1908 and 1909 classified placentas as i) epitheliochorial (no maternal 
tissue erosion following implantation), ii) endotheliochorial (partial maternal tissue 
erosion - maternal endothelium intact) and iii) haemochorial with complete 
maternal tissue erosion; maternal blood coming into direct contact with foetal 
tissue (rat and human). 
The haemochorial placentas can be further subdivided according to the number of 
foetal trophoblast layers separating maternal and foetal blood. In humans this is 
only the syncytiotrophoblast giving rise to the term haemo-monochorial, whereas 
the rat placenta is haemo-trichorial. The shape of both the rat and human placentas 
is discoid, and the rat yolk sac is a permanent structure, whereas it is transient 
humans. No allantoic development is observed in humans and is only transient in 
the rat. 
The human placenta (Figure 1. 9) consists of a basal (closest to the myometrium) 
layer of maternal origin termed decidua, but the bulk (where foeto-maternal 
exchange takes place) is composed of villous foetal tissue within which are the 
foetal vessels. This part of the human placenta is called trophoblast and can be 
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divided into functional units (cotyledons), each served by a branch of foetal 
chorionic vessels. The blood supply of the placenta is dual. The two umbilical 
arteries carrying blood from the foetus, branch on entering the chorionic plate and 
branches of them in turn dive deep into the placental substance branching further as 
they enter smaller and smaller villi, in the end becoming capillaries. The vessels 
then return, having become venules, enlarging until veins emerge on the chorionic 
plate's surface. Thus on inspecting the chorionic plate one will see pairs of 
arteries and veins traversing the surface, at intervals disappearing into the placental 
substance. Each of these pairs will supply a cotyledon although anastomoses 
between cotyledons are common, both on the chorionic plate's surface as well as 
more distally. 




~ Corionic plate 
t Umbilical cord 
The figure shows a cross section of a part of a human placenta. Three idealised cotyledons are 
visible. The arrow A in the middle cotyledon shows the path of maternal blood spurting out of a spiral 
artery. The path of the foetal blood vessels is indicated by the branching arrow 8 entering the 
chorionic villi (trophoblast). 
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The trophoblast villi (chorionic villi) float in maternal blood which fills the 
intervillous space. The maternal blood enters the intervillous space via the 
decidual spiral arteries, bathes the villi and then drains back into the maternal 
circulation via venous openings in the periphery of the cotyledon. This 
arrangement is however not as simple as I have described it as cotyledons defined 
from the foetal "point of view" may have more than one supplying spiral artery 
and vice versa, cotyledons defined macroscopically by inspecting the decidual 
surface post-partum may contain various numbers of villous trees. 




M e tria I gland 
Labyrinthine zone 
D --D -
A cross section through the a part of a rat uterus containing a placenta. The individual parts of the 
placenta as indicated. The maternal blood flow is via artery entering the mesometrial border of the 
uterus (A). Foetal blood enters the labyrinthine zone via the umbilical cord (B). 
Although both rat and human placenta are discoid in shape, the rat placenta (Figure 
1.10) is not divided into cotyledons. The part of the rat placenta corresponding to 
human trophoblast (i.e. where the foeto-maternal exchange takes place) is called 
the labyrinthine zone. The terminology is appropriate as the foetal vessels entering 
from the umbilical cord fuse and become a maze of interconnecting channels, thus 
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not forming villi as in the human placenta. The maternal blood arrives via a 
central artery through the basal zone and also travels along slits (channels) in the 
labyrinthine zone, separated by foetal tissue (having lost the maternal 
endothelium). In addition to the two zones of the rat placenta proper it also has 
third zone which may correspond to the human decidua but at term is reduced to a 
small lump in the centre of the basal zone, also extending into the fourth structure 
located in the mesometrial part of the uterus, called the me trial gland. The 
function of the metria! gland is unclear. 
Thus, the rat placenta has to be considered a close match for the human placenta. 
Both are haemochorial, foetal tissue eroding maternal tissue completely. Only 
foetal tissue separates maternal and foetal blood although hurnan placenta is 
haemomonochorial and the rat haemotrichorial (the 3 rd rat layer is discontinuous 
[Davies & Glasser 1968]). 
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1.6. SUMMARY AND AIMS OF THE THESIS 
Epidemiological data, from Professor Barker in Southampton and others, have 
shown that low birth weight is strongly predictive of deaths from ischaemic heart 
disease [Barker 1992b] as well as the development of several risk factors for 
ischaemic heart disease, including hypertension [Barker et al., 1993b]. The 
association between low birth weight and subsequent hypertension holds at all ages 
[Barker et al., 1989a; Law et al., 1991; Seidman et al., 1991; Barker et al., 1990; 
Law et al., 1993]. 
The strongest predictor for the development of hypertension is the unusual 
combination of low birth weight with high placental weight. The correlations with 
hypertension are continuous throughout the normal ranges of birth and placental 
weights, not merely apparent at the extremes of birth and placental weights [Barker 
et al., 1990]. The importance of these associations is emphasised by the fact that 
low birth weight is 3 times as powerful a predictor for the occurrence of ischaemic 
heart disease as smoking. The precise mechanism that might link prenatal events 
and later disease is not clear, although maternal malnutrition has been advocated 
[Barker et al., 1993a]. We have advanced the alternative hypothesis that 
glucocorticoid excess in-utero might be important [Edwards et al., 1993a]. 
The rationale for our hypothesis was existing data on glucocorticoid-induced foetal 
growth retardation both in humans and animals [Reinisch et al., 1978; Canavan & 
Goldspink 1988; Katz et al., 1990]. Furthermore, rats made diabetic with 
streptozotocin give birth to low weight offspring that also have high placental 
weights [Robinson et al., 1988; Canavan & Goldspink 1988]. These effects are 
only partially reversed by insulin treatment [Canavan & Goldspink 1988], and 
these animals have markedly raised maternal glucocorticoid levels [Hell er et al., 
1988]. By contrast, alloxan-induced diabetic rats have normal maternal 
glucocorticoid levels and do not exhibit this pattern of birth and placental weights 
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[Sybulski & Maughan 1971]. Exogenous glucocorticoids may increase or reduce 
placental weight, probably depending on dose [Gunberg 1957]. Of course 
glucocorticoids directly elevate blood pressure in adults and even in-utero, at least 
in foetal sheep as shown recently [Tangalakis et al., 1992]. We have demonstrated 
that treatment of pregnant rats with the synthetic glucocorticoid dexamethasone, in 
a modest dose which reduced average birth weight by 14% and did not alter litter 
size or gestation length, caused elevated blood pressures in the adult offspring, 
more than 5 months after exposure to exogenous glucocorticoid [Benediktsson et 
al., 1993]. The crucial question at this stage was twofold: 
1. What controls foetal exposure to the much higher maternal glucocorticoid 
levels? 
2. Does the glucocorticoid barrier vary under physiological conditions? 
It has long been accepted that the foetus is protected from the 2 - 10 times higher 
[Campbell & Murphy 1977] maternal glucocorticoid levels by placental 11B-HSD 
[Murphy et al., 1974; Dancis et al., 1978; Beitins et al., 1973; Dormer & France 
1973]. This enzyme's presence in the placenta was first described in 1960 [Osinski 
1960] and was then thought to be NADP dependent although subsequent 
researchers found either NADP [L6pez Bernal et al., 1980b; Blasco et al., 1986; 
Osinski 1960], N AD [Bush et al., 1968] or no [Burton & Turnell 1968] cofactor 
preference. The significance of this was at first not realised but we now know that 
at least two 11B-HSD isoforms exist [Seckl & Brown 1994] ; a low affinity, bi-
directional liver-derived enzyme (116-HSD-1) and a less well-defined, high 
affinity, dehydrogenase (116-HSD-2) in the distal nephron [Mercer & Krozowski 
1992; Stew art et al., 1994b; Krozowski 1994; Albiston et al., 1994] and also the 
placenta [Brown et al., 1993; Albiston et al., 1994]. 
The detailed distribution of 11B-HSD in the placenta and its relationship to the 
foetal and maternal circulations was not known when I undertook this project, the 
only tools then available for looking at this (using in-situ hybridisation and 
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immunohistochemistry) were derived from the rat liver 116-HSD-1 [Agarwal et 
al., 1989; Monder & Lakshmi 1990] although we have in our laboratory very 
recently isolated an encoding cDNA for a placental 116-HSD-2 [Brown et al., 
1994]. 
In summary, we postulated that a deficiency of placental 116-HSD could allow 
increased access of maternal glucocorticoids to the foetus, retarding growth and 
altering tissue development leading to subsequent adult disease. This has since 
been supported by studies showing that treatment of pregnant rats with inhibitors 
of 116-HSD results in low birth weight offspring that subsequently develop 
hypertension [Lindsay et al., 1994b; Lindsay & Seckl 1994]. In order to explore 
the above hypothesis it would be important to try and answer the following 
questions. 
1. Is placental 116-HSD the glucocorticoid barrier, and if so, what is the 
relationship between placental 116-HSD activity and foetoplacental growth? 
2. Are there species specific differences? 
3. Is 116-HSD expressed pre-implantation? 
4. What is the effect of toxins known to alter foetoplacental growth on the 
ability of placental 116-HSD to inactivate glucocorticoids? 
5. Are any markers in cord blood able to tell us about foetal exposure to 
glucocorticoids - and, what is their relationship to placental 116-HSD 
efficiency? 
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2. MATERIALS AND METHODS 
2.1. FLUID MEDIA 
Krebs-Ringer Bicarbonate Buffer (KRB): This buffer was used for all in-vitro 
enzyme bioactivity studies on 11B-hydroxysteroid dehydrogenase in both humans 
and animals (118 mM NaCl, 3.8 mM KCl, 1.19 mM KH2P04, 2.54 mM CaC12, 
1.19 mM MgS04 , 25 mM NaHC03). 
Human Placental Perfusate: The basis for the buffer used for perfusing the human 
placentas was also Krebs-Ringer bicarbonate buffer. It was modified for each 
separate circuit. For the "maternal" perfusion circuit, NaCl 119.9 mM, NaHC03 
21 mM, CaC12 1.26 mM, KCl 12.6 mM, KH2P04 1.18 mM, MgS04 1.18 mM, 
Glucose 5.6 mM. The foetal circuit perfusate was the same but in addition 
contained Dextran 20 g/1 (molecular weight 60000-90000, Sigma). The osmolality 
of this buffer was 294 mosmol/kg. 
2.2. PREPARATION OF RADIOLABELLED MATERIALS 
2.2.1. Tritiated Steroids 
3H -cortisone and 3H -11-dehydrocorticosterone were prepared from [ 1, 2, 6, 7-3H]-
cortisol (Amersham) and [1 ,2,6, 7-3H]-corticosterone (Amersham) respectively 
according to the following method. 
Krebs-Ringer bicarbonate buffer was adjusted to pH 7.4 by bubbling with 5% C02 
for 60 minutes. Using a Dounce tissue grinder, 1 g of fresh rat kidney cortex was 
homogenised in 20 m1 Krebs-Ringer bicarbonate buffer containing 2 mM N AD. 
-66-
Materials and Methods: Preparation of Radiolabelled Materials 
The homogenate was then incubated for 2 hours at 37° C in a glass test tube with 




H-corticosterone (typically 200 pJ of stock 
dried down and resuspended in KRB). This was centrifuged for 15 min at 
approximately 1500 G. The supernatant and pellet separated were each extracted 
four times with 2 volumes of ethyl acetate by shaking vigorously for 10 minutes. 
The extracts were allowed to settle and the ethy I acetate evaporated to dryness 
under a gentle stream of nitrogen at 37° C. Dry residue were reconstituted in 2 ml 
ethanol and spotted onto TLC plates (250 J ..d per plate). The TLC plates were 
developed for 1 hour in 92% chloroform - 8% ethanol. Authentic cold standards 
(Sigma) for cortisone (or dehydrocorticosterone) were spotted on the plates as well. 
The area corresponding to cortisone (or dehydrocorticosterone) was then identified 
under UV-light (254 nm). The relevant areas on the TLC plates were scraped into 
glass vials and the steroids eluted overnight from the silica with ethanol. The 
ethanol eluates were combined for recovery and purity assessment. 
The yield for 
3
H -11-dehydrocorticosterone was 42% and purity checked with 
HPLC was > 93%. For 3H -cortisone the yield was 39% and purity > 92%. 
2.2.2. Iodinated Steroids 
For cortisol and cortisone radioimmunoassays, iodinated labels were used. For the 
iodination of both, Cortisol-3-(0-carboxymethyl)oxime and Cortisone-3-(0-
carboxymethyl)oxime had first to be synthesised. The cortisol-3CMO was made 
in-house by Dr. J. Corrie and cortisone-3CMO was made in-house by Mr. D. 
Burt. The method has been published [Al-Dujaili & Edwards 1987] but briefly, 
the relevant cold steroid was dissolved in methanol, 
carboxymethoxylaminehemihydrochloride and anhydrous sodium acetate added. 
After stirring for 2 hours at room temperature, the methanol was evaporated under 
nitrogen and spotted on TLC plates. The relevant mono-oxime was identified by 
the tetrazolium blue reaction [Neher 1964]. The steroid was purified by two 
further TLC separations. 
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The iodination itself was a modification of the histamine conjugation method 
[Chard 1987] and is routinely carried out in our department by Mr. D. Burt. The 
procedure was in four steps and identical for the synthesis of both ligands. The 
final product ·of the iodination is "steroid" -3CM0-1251-histamine and will be 
abbreviated to 
125
1-cortisol and 1251-cortisone hereafter. 
1. Steroid activation: Cortisol-3CMO (or cortisone-3CMO) was dissolved in 
dimethylformamide (DMF) to give 5.8 mg/ml. Fifty ~tl were cooled to 10° 
C, 10 ~tl each of tributylamine and isobutylchloroformate (diluted 1:60 and 
1:110 with DMF respectively) added and kept at 10° C for 20 minutes. 
2. Histamine iodination: Ten microlitres of histamine (0.22 mg/ml in phosphate 
buffer) were added to 1 mCi Na 1251 (Amersham). To this were added 10 ~tl 
each of chloramine-T and sodium metabisulphite (5 mg/ml and 12 mg/ml in 
phosphate buffer respectively). The mixture was vortexed and cooled on ice. 
3. Conjugation: To the activated steroid mixture, 280 ~tl of cool (10° C) DMF 
was added and a 50 ~tl aliquot transferred to the ice cold 1251-histamine 
preparation. Following addition of 10 ~tl 0.2 M NaOH the mixture was 
vortexed and incubated for 1 h on ice. The mixture was acidified by adding 
1 ml of 0,1 M HCl and washed with 1 ml redistilled ethyl acetate. The ethyl 
acetate was discarded and the remaining mixture neutralised with 1 ml 0.1 M 
NaOH followed by addition of 1 ml KI (10 mg/ml in phosphate buffer). 
4. Extraction: The iodinated steroid was then extracted by ethyl acetate (3 
times) and the extract dried by adding a few crystals of Na2S04 • Purification 
was then by TLC and the relevant area identified by autoradiography. The 
band corresponding to iodinated steroid (of the usually 3 bands visible, one 
major band is used) is scraped off the TLC plate into glass vials and the 
steroid eluted with ethanol and stored at -20° C. The yield was typically 50-
60%. 
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2.3. RADIOIMMUNOASSAYS 
2.3.1. Cortisol 
This direct second antibody radioimmunoassay, which was modified from 
McConway [McConway & Chapman 1986], used 125I-cortisol (prepared in-house 
as detailed above) as ligand. Intra-assay CV was 5 - 11%. Inter-assay CV was 
15.8%. Cross reactivity with cortisone of the second antibody used in this assay is 
< 0.1% according to the manufacturer (Scottish Antibody Production Unit -
SAPU). 
The assay diluent was 0.1 M citrate-phosphate buffer with 1% gelatine, adjusted to 
pH 4 with NaOH and/or phosphoric acid. Duplicate aliquots of plasma or serum 
(10 J.Ll) were added to disposable LP4 (Luckhams) polystyrene tubes containing 
assay diluent (1 :40 dilution of sample). Next the ligand was added (approximately 
10000 cpm per tube) and then the first antibody (50 J.Ll making 1:130000 final) 
which was "sheep anti-cortisol" (SAPU: Scottish Antibody Production Unit). The 
tubes were vortexed gently and incubated at room temperature for 4 h. 
Then 50 J.Ll of the second antibody (donkey anti-sheep/goat serum @ 1:15 initial; 
SAPU) and 50 J.Ll non-immune sheep serum (@ 1:200 initial with 1 mM EDTA; 
SAPU) were added. The tubes were incubated at 4 o C overnight and then spun at 
4 o C for 45 min at 1720 G. The supernatant was decanted to waste and the bound 
fraction counted in a y-counter (LKB Wallac 1260 - counting efficiency of the 12 
wells was 98.3% with SD of 1.5% ). Cortisol (Sigma) standards were prepared in 
assay diluent and stored in aliquots at -20° C; duplicates were included in each 
run. 
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2.3.2. Cortisone 
This radioimmunoassay was an in-house assay described by Whitworth [Whitworth 
et al., 1989b]. It was a second antibody radioimmunoassay using 125I-cortisone 
(prepared in-house as detailed above) as ligand. As the antibody cross reactivity 
with cortisol was 3.5 - 4%, it was necessary to separate cortisol and cortisone 
before the radioimmunoassay with HPLC. Inter-assay CV was 4 - 6%. Intra 
assay CV was 11%. 
The samples were pre-extracted with hexane (250 J.tl plasma diluted 1:2 with 
distilled water), centrifuged and then extracted with 5 volumes ethyl acetate. 
Following washing with 0.1 M NaOH the sample was evaporated to dryness under 
nitrogen. The sample was reconstituted in mobile phase (50% methanol:water -
Rathburn Chemicals) and injected onto an HPLC system comprising an auto-
injector (Waters 712 WISP), an HPLC pump (Waters 510), an absorbance detector 
(Waters 441) with 254 nm filter and a Waters reverse phase JL-Bondapak-C18 (3.9 
x 300 mm) HPLC column. The flow rate was 1.3 ml/min. Retention time was 
checked at the beginning and end of each session with authentic cortisone standards 
(Sigma). The eluate corresponding to cortisone was collected. The eluate was 
reduced to less than half volume under nitrogen and extracted with 5 ml of ethyl 
acetate. Overall recovery was approximately 93%, while the HPLC recovery of 
cortisone checked with authentic tritiated cortisone (Amersham) was 97% - both 
were routinely checked for each batch of samples allowing accurate calculation of 
cortisone concentration in the original samples. 
For the radioimmunoassay, duplicate 1 ml aliquots of the organic phase were 
pipetted into glass tubes (Corning 12 x 75 mm) and evaporated to dryness under 
nitrogen. The assay diluent was citrate/phosphate buffer with 0.1% BSA adjusted 
to pH 4 as for cortisol. Into each assay tube, 300 J.tl of assay diluent were added, 
whirlimixed and left for 15 min. Next the ligand (approximately 10000 cpm per 
tube) was added, followed by the first antibody (50 J.tl making 1:140000 final) 
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which was "rabbit anti-cortisol" [Whitworth et al., 1989b]. The tubes were 
vortexed gently and incubated at room temperature for 4 h. Then 50 ~-tl of the 
second antibody (donkey anti-rabbit serum@ 1:10 initial; SAPU) and 50 ~-tl normal 
sheep serum (@ 1: 150 initial with 1 mM EDT A; SAPU) were added. The tubes 
were vortexed, incubated at 4 o C overnight and then spun at 4 o C for 45 min at 
1720 G. The supernatant was decanted to waste and the bound fraction counted in 
a y-counter (LKB Wallac 1260). Cortisone (Sigma) standards were prepared in 
assay diluent and stored in aliquots at -20° C; duplicates were included in each 
run. 
2.3.3. Osteocalcin 
This radioimmunoassay was performed by Dr. L. Tibi at the Department of 
Clinical Biochemistry, Royal Infirmary of Edinburgh. This was an in-house 
precipitated second antibody assay, based on the procedure described by Price 
[Price & Nishimoto 1980]. Purified bovine osteocalcin was used to raise the first 
antibody in rabbits and to prepare standards and iodinated ligand (chloramine-T 
method). The assay buffer composition was 20 mM Tris-HCl, 150 mM NaCl, 25 
mM Na4EDTA, 0.05% Tween-20, 0.02% sodium azide, at pH 7 .2. Duplicate 
aliquots of plasma (50 ~-tl) were incubated at 4 o C for 24 h with ligand and first 
antibody. Following addition of the second antibody (normal rabbit serum/donkey 
anti-rabbit serum), the tubes were shaken, washed (Brij-35 in H20), centrifuged at 
4 o C for 30 min (3000 G) and the bound fraction counted. Intra-assay coefficient 
of variation (CV) was 5%, inter-assay CV was 12%. 
2.4. IN-VITRO ENZYME ASSAYS 
Tissues were obtained fresh and immediately placed on ice. All rats were Wistars. 
Ovaries were obtained from animals in proestrus. Animal tissues were 
homogenised manually with a Dounce tissue grinder. Human placenta was 
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homogenised using an Y stral mechanical homogeniser, employing three 10 second 
bursts of with 10 seconds of cooling on ice in between bursts. All tissues were 
homogenised in KRB, without BSA or glucose. For the enzyme assays, the protein 
content of the various tissue homogenates was determined using the method of 
Bradford, [Bradford 1976] using a kit purchased from Bio-Rad which had a 
detection limit of 20 p,g protein per sample. 
2.4.1. 11 B-Hydroxysteroid Dehydrogenase 
The rat placental 118-HSD assay described below, was also used for human 
placentas and rat ovaries. It was a modification of the established "in-house" 118-
HSD assay protocol. The description below relates to the assay of 118-
dehydrogenase. For the reverse assay (11-reduction), NADH replaced NAD and 
3
H -cortisone or 
3
H -11-dehydrocorticosterone were substrates in place of 3H -cortisol 
and 
3
H -corticosterone respectively. Liver served as a positive control for the 
reductase assay, blanks were buffer only. 
lncubations were carried out in duplicates or triplicates (12 x 75 mm glass test 
tubes - Corning Pyrex) with 0. 5 mg/ml protein and a final concentration of 200 
p,M NAD and 12 nM 3H-corticosterone (aliquot of stock dried down and 
reconstituted in KRB on day of assay) in KRB (0.2% BSA and glucose added) for 
1 h at 37° C in a shaking water bath. The total incubation volume was 250 p,l and 
incubation of buffer alone provided an assay blank. Blank rates with boiled 
homogenate ( > 60° C for ~ 15 min) were no different for rat, human placenta or 
rat ovary. Rat kidney (known to have very high bioactivity) provided a positive 
control. The incubation was started by adding tritiated steroid and terminated by 
adding 2. 5 ml of ethy 1 acetate. 
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The test tubes were whirlimixed thoroughly to extract the steroids, then allowed to 
settle and the organic layer removed and dried down. The residue was 
reconstituted in 100 !J-l ethanol, and along with cold standards (corticosterone and 
11-dehydrocorticosterone) 40 !J-l spotted onto thin-layer chromatography plates 
(TLC plates: 20 x 20 cm Merck no. 5553) and developed for 1 h using a 
chloroform:ethanol solvent mixture (92:8 v/v respectively). The relevant regions 
were identified under UV -light (254 nm) and scraped into scintillation vials for 
counting (Packard B-counter). The enzyme activity was expressed as the 
percentage conversion of 
3
H -corticosterone to 3H -11-dehydrocorticosterone, 
calculated from the radioactivity of each fraction: [(Cpm productfcpm product + 
cpm substrate) x 1 00]. Activity of blanks was always subtracted and net activity 
used for data analysis. Another way of expressing enzyme activity was to use 
moles of product formed during a fixed incubation period. 
The above method using TLC plates and counting in a B-counter was time 
consuming and also generated some quantity of airborne B-emission due to 
scraping of the TLC plates. Therefore a new method was developed for extracting 
and separating the steroids. Slight variations in assay conditions are specified in 
the relevant Sections: variable NAD concentrations, time of incubation and protein 
content to ensure that the conditions used were on the linear part of the reaction 
progress curve with respect to the amount of enzyme added as well as incubation 
time to allow comparison between animals [Tipton 1992]. The substrate in all 
human experiments was the physiological human glucocorticoid cortisol (as 
opposed to corticosterone in the rat experiments). The separation and extraction of 
steroids was as detailed below. 
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Figure 2.1 High Performance Liquid Chromatography Setup 
The samples are placed in a carousel inside the autoinjector (8). The mobile phase is drawn from 
reservoir 1 by the HPLC pump (A), which drives the mobile phase through the autoinjector (B) where 
the sample enters the circuit. Having passed as the arrows indicate through the UV-monitor (C), the 
sample goes through the HPLC column itself (D) and is mixed with the scintillation fluid, which is 
drawn from reservoir (2) by a time controlled pump (E). The sample scintillates in the radioactivity 
monitor (F) before draining to waste as indicated. The setup is orchestrated by a computer (G) which 
records and stores the data from (C) and (F), allowing later analysis. 
Following termination of the reaction by addition of ethyl acetate, the tubes were 
whirlimixed, allowed to settle and dried down as before, but now reconstituted in 
600 JLl HPLC grade methanol:water mixture (Rathburn Chemicals). An aliquot 
(200 JLl) of the sample were then injected onto an HPLC column. The HPLC set-
up (Figure 2.1), consisted of an auto-injector (Waters 712 WISP), an HPLC pump 
(Waters 51 0), an absorbance detector (Waters 441) set at 254 nm for detecting the 
elution profile of authentic cold steroid standards, a Waters reverse phase JL-
Bondapak -C 18 (3. 9 x 300 mm) HPLC column linked to a radioactivity detector 
(Berthold LB506 Cl), scintillation fluid pump (Berthold LB5035) and a computer 
for analysing and storing data (Berthold HPLC program v. 1.51). The flow rate 
for the mobile phase was 1. 3 ml/min for separating cortisol and cortisone using 
50% methanol:water, but 1.8 ml/min for separating corticosterone and !!-
dehydrocorticosterone. 
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Details of intra- and inter-assay variation as well as recovery data are presented in 
the relevant results chapters under assay evaluation. 
2.4.2. Alkaline Phosphatase and N-y-L Glutamyl B-
Naphthylaminidase 
Both assays were photometric assays, validated and carried out by Dr. T. Bramley 
(University Department of Obstetrics and Gynaecology, Centre for Reproductive 
Biology, Edinburgh). Both enzymes are stable on storage at -70° C. Briefly, the 
human trophoblast samples were homogenised as for 11B-HSD with an Y stral 
mechanical homogeniser and an aliquot immediately frozen and stored at -70° C 
until assay. The protein content of the homogenates was determined as for 11B-
HSD. 
The alkaline phosphatase assay was carried out in 13 x 100 mm polystyrene test 
tubes at 37° C for 35 minutes. Assay medium composition was 0.1 M piperazine-
HCl, 5 mM magnesium acetate, 0.2% triton X-100, 0.01 M ZnS04 . The substrate 
was p-nitrophenyl phosphate at 3 mM final concentration. Total assay volume was 
1010 J.tl. The reaction was stopped by adding 3 ml of "stop solution" (20 g/1 
NaOH + 5 g/1 EDTA). Optical density was read at 420 nm and results expressed 
as nmoles/min/mg protein. 7777 
The N-y-L glutamyl B-naphthylaminidase assay was carried out in 13 x 100 mm 
glass test tubes at 37° C for 3 h. Assay medium composition was 0.1 M tris-HAc, 
5 mM EDTA, 100 mM glycylglycine. The substrate was N-y-L glutamyl B-
naphthylaminidase at 0.4 mM final concentration. Total assay volume was 1025 
JLL The reaction was stopped by adding 1 ml of 10% trichloracetic acid. Tubes 
were mixed gently and centrifuged at 3000 rpm for 10 min. 1 ml aliquot of the 
supernatant was incubated in 16 x 100 mm glass test tubes with 0.5 ml 0.2% 
sodium nitrite for 3 min. Then 1 ml of 0. 5% ammonium sulphamate was added 
and incubated for further 3 min. Lastly, 2 ml of N-1-naphthyl ethylenediamine di 
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HCl (0.05%) were added and incubated for 45 min. Optical density was read at 
580 run and results expressed as nmoles/min/mg protein. 
2.5. IMMUNOHISTOCHEMISTRY 
This was done with technical assistance from L.P .Brett (Department of Pathology, 
Western General Hospital, Edinburgh). Adult Wistar rats (240 g) were deeply 
anaesthetised with pentobarbitone and perfused through the ascending aorta with 
250 ml ice-cold saline followed by 500 ml ice-cold paraformaldehyde ( 4 M) in 
phosphate buffer (0.1 M, pH 7 .4). Proestrus ovaries, term placenta and uterus 
were removed and post-fixed overnight. Sections ( 4 p.m) were cut and 
immunostained as described by Moisan [Moisan et al., 1990a], using two separate 
polyclonal rabbit antisera (5-125 at 1:50 dilution and 5-126 at 1:100 dilution) 
raised against purified rat liver 118-HSD as described by Monder & Lakshmi 
[Monder & Lakshmi 1990] (the antibody was a gift from Dr. C. Monder of the 
Population Council, New York). Detection was by the peroxidase-antiperoxidase 
method [Sternberger et al., 1970], using reagents from D AKO. Control sections 
were immunostained using preimmune rabbit serum. 
2.6. IN-SITU HYBRIDISATION 
This was done with technical assistance from Dr. J. L. W. Yau (Department of 
Medicine, Western General Hospital, Edinburgh). Adult Wistar rats (240 g) were 
killed by cervical dislocation, the ovaries rapidly removed and immediately frozen 
on dry ice. 10 JLm cryostat sections were mounted onto gelatine and poly-L-lysine-
coated microscope slides and stored at -85 o C. Tissue sections were post-fixed in 
4% paraformaldehyde/0. 1 M phosphate buffer and washed in 3 changes of 2 x SSC 
containing 0.02% diethylpyrocarbonate. 
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T3 RNA polymerase was used to transcribe a 598 bp 35S-UTP-labelled antisense 
cRNA probe from Sty 1-linearized pBluescript vector containing the 1,265 bp llB-
HSD cD N A insert [ Agarwal et al. , 1989]. The probe was denatured and added at 
a final concentration of 10 x 106 cpm/ml to hybridisation buffer (50% formamide, 
0.6 M NaCl, 10 mM Tris, pH 7.5, 0.02% ficoll, 0.02% polyvinylpyrrolidone, 
0.1% BSA, 1 mM EDTA, 0.1 mg/ml salmon sperm DNA, 0.1 mg/ml yeast tRNA, 
0.1g/ml dextran sulphate and 10 mM dithiothreitol) as described by Yau [Yau et 
al., 1991]. In brief, 65 1Ll aliquots of probe were pi petted onto sections and 
covered with a coverslip (22 x 50 mm) which was sealed with DPX. Slides were 
incubated overnight at 50 o C. 
Following hybridisation, coverslips were removed by rinsing 3 - 4 times in 2 x 
SSC at room temperature, sections treated with RNase A (30 1lg/ml, 45 min at 37° 
C) and washed in reducing salt concentrations to a final stringency of 0.1 x SSC/ 14 
mM 2-mercaptoethanol at 60° C. After dehydration in increasing concentrations 
of ethanol in 0.3 M sodium acetate, slides were dried in air, dipped in 
photographic emulsion (llford) and exposed in light-tight boxes at 4 o C for 21 days 
before being developed (D19, Ilford) and counterstained with haematoxylin-eosin. 
Controls were hybridised with similarly labelled non-complementary "sense" RNA 
probes under identical conditions. 
2. 7. NORTHERN BLOTTING 
This was done with technical assistance from Dr. S. C. Low (Department of 
Medicine, Western General Hospital, Edinburgh). Ovary, hippocampus, kidney 
and liver were rapidly removed from female Wistar rats (240 g) following cervical 
dislocation, snap frozen and stored at -85 o C. Total RNA was extracted from each 
tissue by the acid guanidinium thiocyanate method, [Chomczynski & Sacchi 1987]. 
Approximately 20 1lg of total RNA was fractionated on a 1% agarose-0.7 M 
formaldehyde gel and blotted onto nitro-cellulose (Hybond C extra, Amersham) by 
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capillary transfer overnight. Hybridisation was performed at 42 o C overnight in 
50% formamide with a random primed 32P-labelled 118-HSD cDNA probe cloned 
from a rat liver cDNA library [Agarwal et al., 1989] consisting of the excised 
p11DH insert and the membrane washed to a final stringency of 0.2 x SSC (1 x 
SSC is 0.5 M NaCl and 0.015 M sodium citrate) 0.1% sodium dodecyl sulphate 
(SDS) at 60 o C and exposed to Kodak XAR film for 2 days, as described by 
Moisan [Moisan et al., 1990b]. 
2.8. EX-VIVO PLACENTAL COTYLEDON PERFUSION 
2.8.1. General Methods and Equipment Setup 
The method used and the construction of the perfusion chamber was based on the 
description by Schneider [Schneider & Huch 1985; Schneider et al., 1972]. 
Immediately following a normal delivery the placenta was put into a plastic bag, 
immersed in ice-water and carried to the laboratory which was within 2 minutes 
walking distance of the delivery room. Care was taken to avoid handling of the 
placenta at delivery and only gentle traction on the umbilical cord was used when 
aiding delivery. When in the laboratory, the placenta was floated in ice cold water 
(still protected from the water by a plastic bag), foetal surface facing upwards. 
A suitable pair of chorionic vessels was identified, supplying a well defined and 
macroscopically intact cotyledon. The foetal vessels were cannulated, with custom 
made stainless steel cannulas (foetal input cannula internal diameter was 1 mm, 
outer diameter 2 mm and effluent or venous cannula internal diameter 1. 6 mm 
while outer diameter was 3 mm), sutured in place and the foetal circulation started. 
Foetal flow rate was 6 ml/min, the perfusate being gassed with 95% N2:5% C02 
(BOC). This was accomplished within 21 min of delivery (mean 14.8 min, see 
Table 6.1, page 161). Occasionally when vessel anatomy required, collaterals to 
adjacent cotyledons were tied off. 
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The relevant cotyledon was isolated by cutting it from the rest of the placenta, 
allowing a generous margin to avoid fluid leaks. The cotyledon was turned 
around, the maternal surface now facing upwards. The cotyledon was then 
embedded between the two parts of a perfusion chamber which was custom made 
in the Medical Physics Workshop at the Western General Hospital, Edinburgh 
(Figure 2.2). 
M ate rn a I C a the te rs 
Cotyledon 
Foe ta I C a the te rs 
Figure 2.2 The Perfusion Chamber. 
The chamber is made of transparent plexiglas (wall thickness 4 mm). The top and bottom parts are 8 
cm wide and 5 cm high. The two parts are held together with pointed threaded pins (30 x 2 mm) 
securing the cotyledon between the two parts as indicated with the open arrows in the figure. The 
maternal and foetal catheters enter the chamber as indicated. 
The top of the lower part was covered with "lab film" to prevent sagging of the 
cotyledon, thereby preventing undue stretch on vessels and other tissues. The 
relevant area on the maternal side of the cotyledon was identified by virtue of 
slight blanching, and pierced to a depth of 1 - 2 cm (depending on the thickness of 
the selected cotyledon) using two 21G cannulas. The separate maternal circulation 
was started at 10 ml/min, the perfusate gassed with 95% 0 2:5% C02 (BOC). The 
maternal circulation was established within 30 minutes of delivery (mean 23.3 min, 
see Table 6.1, page 161). Exit of the foetal perfusate was via the foetal circuit 
effluent catheter. Maternal outflow was via the venous openings in the periphery of 
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the cotyledon, collecting on top of the cotyledon (thus keeping it moist) inside the 
perfusion chamber, then siphoned to waste (Figure 2.3). The chamber itself was 







Figure 2.3 Setup Diagram 
The diagram is not to scale. Arrows indicate direction of perfusate flow, driven by the multichannel 
peristaltic pump. PC: perfusion chamber, containing cotyledon, within temperature controlled 
incubator (lsolette®; Air Shields Europe). F: foetal reservoir, M: maternal reservoir. WB1 and 2: water 
baths. FMe: flow meter in foetal inflow. Another flow meter was located in foetal outflow allowing 
detection of fluid leaks. BT: bubble trap in foetal inflow. Another bubble trap was located in the 
maternal inflow. The computer continuously monitors temperature and pressure. Sampling ports (®) 
were located as close to the cotyledon as possible. 
The two circulations were driven by a peristaltic pump (drive 503S with 8 roller 5 
channel microcassette pumphead 308MC; Watson-Marlow). Different flow rates 
for the two circulations were achieved by using different bore tubing segments for 
the pump (maternal bore 2.54 mm, foetal bore 1.85 mm). Most types of tubing 
are very permeable to gases which necessitated special tubing materials for the two 
circuits. The tubing segment for the pump itself was Marprene II (W atson-
Marlow) and the tubing for the rest of the circuits was Tygon (Watson-Marlow; 
bore 3.2 mm). The dead-space of the circuits was 28 ml and 31 ml maternal and 
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foetal respectively. To prevent bubble formation within the tubing, the perfusates 
were gassed after warming (WB1 in Figure 2.3). Bubble traps (custom made -
plexiglas) were also employed. Due to a marked drop in temperature (4 - 5o C) on 
passing through the pump it proved necessary to include a second water bath 
before the tubing entered the incubator housing the perfusion chamber. Three way 
taps located as close to the cotyledon as possible allowed samples to be taken for 
analysis. 
2.8.2. Monitoring of the Perfusion 
Although human placental ex-vivo cotyledon perfusion has been in use for decades, 
different laboratories have used widely different methods to evaluate/validate their 
systems. Universally, authors claim suitability/success of their particular 
methodology. It appears that the placenta is a relatively sturdy organ in metabolic 
terms (although early hypoxic and/or perfusion related ultrastructural changes can 
be shown [Kaufmann 1985]), exhibiting remarkable tolerance to and ability to 
recover from the insult of delivery (evidence summarised by [Schneider 1991]). 
There is little agreement on which parameters should be used to monitor viability. 
Most researchers report lactate production, gas transfer (step-up across the foetal 
cotyledon), circuit pressure, and foetal circuit volume loss, but several other 
parameters like glucose consumption, lactate/pyruvate ratio, nucleotide 
concentration, morphology, transport of specific substances or production of 
placental proteins like B-hCG are also used [Abramovich et al., 1987; Brandes et 
al. , 1983; Challier 1985; Contractor & Stannard 1983; Hauguel et al., 1983; 
Illsley et al., 1984; Kuhn et al., 1988; Miller et al., 1985; Penfold et al., 1981; 
Wier & Miller 1985; Young & Schneider 1984]. It follows that it is difficult to 
compare results from different laboratories since methodologies differ in many 
respects: composition of the perfusion medium, flow rates and materno-foetal flow 
ratio, number of maternal cannulae, size of cotyledon perfused, etc.. The choice 
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of parameters to estimate viability in the series of perfusions presented in this 
thesis was as follows. 
1. Morphology: Morphological changes are early and sensitive signs of 
inadequate perfusion due to either hypoxia or to high ( > 60 mmHg) circuit 
pressure [Kaufmann 1985; Jauniaux et al., 1991]. Morphology is not 
compromised by using perfusate devoid of red blood cells for an extended 
period [Miller et al., 1985]. For the series of perfusions presented here, both 
light and electron microscopy were employed, trophoblast samples being 
taken before the start of perfusion, (i.e. within 21 min of delivery, see Table 
6.1, page 161) and after the perfusion at 3 h from perfused as well as 
adjacent non-perfused tissue. 
For light microscopy, samples (approximately 0.5 cm in diameter) were fixed 
in formalin for a minimum of 24 h. The samples went through routine tissue 
processing at the Department of Pathology (Western General Hospital, 
Edinburgh) using Ames VIP automatic vacuum impregnation tissue 
processor. Briefly, the specimens went through various stages of 
impregnation with ethanol, xylene and paraffin before being embedded in 
Tissue Tek 11 wax. 3 - 4 J..Lm sections were cut on a rotary microtome and 
picked up on a 50° C water bath onto poly-L-lysine coated slides. They 
were dried at 37° C for a minimum of 1 h and then stained with 
haematoxylin-eosin. 
For electron microscopy, specimens (approximately 1 - 2 mm in diameter) 
were immediately fixed in 3% glutaraldehyde in 0.1 M sodium 
cacodylate/HCl buffer (pH 7.2- 7.4) overnight at 4° C. The samples then 
went through routine processing at the Department of Pathology (W estem 
General Hospital, Edinburgh) as follows. Specimens were washed in 
deionised water 3 times for 20 min. Secondary fixation was in 1 % osmium 
tetroxide in deionised water for 45 min at room temperature. The specimens 
- 82-
Materials and Methods: Ex-Vivo Placental Cotyledon Perfusion 
were then dehydrated in 50%, 75%, 100% methylated spirits, each for 10 
min and then in absolute ethanol for 3 x 10 min. Linking was with propylene 
oxide (10 min x 3) and impregnation in Emix resin (Fisons) overnight at 
room temperature. Polymerisation took place at 70° C for 18 - 24h .. 90 run 
sections were cut, mounted on 300 mesh copper grid and stained with uranyl 
acetate/lead citrate. The microscope was Jeol 100CXII Transmission 
Electron Microscope operating at 60 kv. Photomicrographs were taken on 
Kodak 4489 film. 
2. Volume conservation (fluid leaks): As crude indicators of fluid leakage, 
while the perfusion was running, two glass flow meters were used (Meterate 
L14X; Jencons), one in the foetal inflow and the other in the foetal outflow. 
If there was discrepancy between the two, the perfusion was abandoned. The 
average foetal output was also measured by collecting the foetal effluent over 
5 min intervals, knowing that the input was 6 ml/min. Keeping foeto-
maternal flow ratios between 0. 3 - 3 seems important to minimise leakage 
[Schneider & Huch 1985]. In-vivo flow rates on both maternal and foetal 
sides have been estimated as being about 20 mllmin per 30 globule [Kirkinen 
et al., 1983]. This however will result in villous oedema in ex-vivo perfusion 
[Kaufmann 1985]. Foeto-maternal flow ratio here was 0.6. 
3. Metabolic activity: As the primary indicator of constant metabolic activity 
throughout the perfusion, the activity of 11 B-HSD was followed for an 
extended period. Lactate generation was also looked at by sampling the 
foetal effluent, looking for a fall in the lactate output following establishment 
of the perfusion. Thus, perfusate samples (1.5 ml) were taken periodically 
from the foetal effluent, placed into pre-weighed glass tubes containing 5 ml 
of cold (4 o C) 5% perchloric acid and immediately refrigerated. The 
analysis was carried out in the Department of Clinical Biochemistry, Royal 
Infirmary of Edinburgh by Dr. S. Walker. The lactate concentration was 
measured using a Cobas Bio (Roche) centrifugal analyser, monitoring the rate 
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of reduction of NAD to NADH+ fluorimetrically at an excitation wavelength 
of 340 run in 0.5 M glycine buffer (pH 9.6) in the presence of 0.2 M 
hydrazine hydrate and lactate dehydrogenase. Lactate standards were used. 
The perfusate concentration was calculated after correcting for dilution with 
the perchloric acid. The sensitivity was 0.2 mM lactate (translates into 
minimum production rate detectable of 32 p,mollmin/kg), CV was 6 - 8%. 
Other indicators of metabolic activity employed were C02 generation and 
pH, both in the foetal input and output. Both were analysed with an arterial 
blood gas analyser (pH Blood Gas Analyser 213 with Temperature Controller 
227; Instrumentation Laboratory). The precision was ± 0.003 pH and ± 
0. 5 mmHg for pC02• Although oxygen consumption frequently is used as an 
estimate of metabolic function in a variety of experimental set-ups, it has 
been criticised for giving potentially misleading information in placental 
perfusion systems. Thus measured (apparent) 0 2 consumption has been 
reported in the absence of tissue [Penfold et al., 1981], using conventional 
methodology, and Kuhn [Kuhn et al., 1988] reported very low 0 2 
consumption (compared to several other researchers) in a series of 
experiments where morphology was conserved as was transfer of antipyrine. 
4. Circulatory Overlap: Following cannulation of the foetal circuit, slight 
blanching of the maternal surface could be observed which guided as to the 
area to insert the maternal cannulae. The insertion was not via the spiral 
arteries (which was abandoned as it proved to be very difficult technically 
and time consuming [Schneider et al., 1972]) and therefore slight inequalities 
in overlap of the maternal and foetal circulations are unavoidable. The extent 
of overlap was monitored by looking at 0 2 transfer across the placenta, 
gassing the two circuits with different composition gasses (95% 0 2 on the 
maternal side and no oxygen for the foetal perfusate), step-up of p02 from 
the foetal input to the foetal effluent indicating overlap of the circulations. 
The p02 was measured with an arterial blood gas monitor (pH Blood Gas 
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Analyser 213 with Temperature Controller 227; Instrumentation Laboratory, 
precision ± 1 mmHg). If no oxygen was delivered via the maternal 
perfusate or if there was inadequate overlap of the circulations, a step-down 
in p02 was observed. 
5. Pressure and Temperature: Foetal perfusion pressure > 60 mmHg has been 
reported to cause diffuse damage to foetal villi during ex-vivo perfusion 
[Jauniaux et al., 1991]. Pressure transducers (Elcomatic EM 750A) inserted 
in the afferent section of each circuit continuously recorded pressure and 
were linked to a computer program written by the Department of Medical 
Physics (Western General Hospital, Edinburgh). Sampling rate was 1 Hz. 
Temperature was simultaneously recorded continuously in both circuits 
(afferent arm) by virtue of in-line K-type thermocouples connected to a 
digital thermometer (Fluke 52 K/J; resolution 0.1 o C.; accuracy 0.1% of 
reading + 0. 7 o C). The perfusion was considered unsuccessful if pressure in 
the foetal circuit exceeded 60 mmHg. 
2.8.3. Comparison of Results and Sample Preparation 
Comparison of results: A well recognised problem with placental cotyledon 
perfusions is comparison of results between laboratories and indeed also within 
laboratories. To enable that comparison, a reference molecule is usually included 
in the perfusion. The most commonly used reference substance is antipyrine, a 
small inert lipid soluble salt. Antipyrine is a model for fast and flow dependent 
transport (diffusion). In order to compare the results here with previous 
publications on steroid transport and metabolism using ex-vivo perfusion, 14C-
Antipyrine was included in the maternal perfusate. 
Sample preparation: Perfusate samples for analysis of steroid and antipyrine 
concentrations were collected from the foetal effluent over either 3 or 5 minutes. 
Initial perfusions were performed with cold steroid only and the foetal effluent 
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samples extracted by mixing with two volumes of ethyl acetate, shaking vigorously 
for 10 min (an adaptation of the extraction following the in-vitro 116-HSD assay as 
detailed above). The samples were allowed to settle and the organic phase 
removed, evaporated to dryness before reconstituting in 600 J.tl of mobile phase 
(50% methanol:water; Rathburn) and analysed on the same HPLC system 
described in Section 2.4.1. 200 J.tl of each sample were injected, the elution time 
determined by comparison with authentic cold cortisone and cortisol standards 
(Sigma). 
As for tritiated or 
14
C-labelled substances, the amount contained in a peak detected 
with the UV-method (see above) could be deduced by calculating the area under 
the curve, using the computer program. To transfer the UV -units into meaningful 
values, a set of standards with known amount of the steroid of interest was 
included in each HPLC run. Each standard was injected in duplicate and a linear 
regression line fitted (least squares) to allow calculation of steroid concentration in 
the unknown samples. The detection limit of the system for cortisol was 2.5 x 10-
12 moles injected. By collecting the foetal effluent over a minimum of 3 min, and 
concentrating to 600 J.tl (injecting 200 ~-tl), peaks several orders taller than 2 times 
the variation in baseline were obtained. 
Although some data could be obtained using the above method, there were several 
problems associated with it. Firstly, the typical volume of the perfusate samples 
was 30 ml which meant using 60 ml of ethyl acetate per sample, too large a 
volume to handle with ease. Secondly, there were numerous unidentified 
substances that travelled with the steroids in the lipid soluble phase and interfered 
with the UV absorption in such a way that the elution profiles from up to 50% of 
the samples were uninterpretable. Therefore, trace amounts of tritiated steroid ( < 
0.5% of the cold concentration) were used along with cold steroid and similarly 
14C-antipyrine (as opposed to cold) as a reference substance. Thus it was possible 
to measure the amount of steroid transferred as well as that of antipyrine in one 
and the same sample with the HPLC system set for dual-label estimation. 
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The amended method for preparing the samples (used for all but the very first 
perfusions), was modification of a method described for extracting steroids from 
plasma samples [Cannell et al., 1982], but using Sep-pak Plus~ cartridges (Waters) 
and ethyl acetate for elution. Following collection, the perfusate samples were 
centrifuged for 5 min at 2500 - 3000 rpm and the supernatant decanted to fresh 
containers to get rid of debris and red blood cells. As the samples were stable on 
freezing they were either frozen at -20° C or the sample preparation completed as 
follows. 
First the samples were acidified to pH 2 using HCl (checked with pH paper). The 
~ . 
Sep-pak Plus cartndges were mounted on a vacuum manifold (Super Separator-24; 
Amersham). The cartridges were preconditioned with 5 ml ethyl acetate followed 
~ 
by 5 ml H20 (10 ml if using Sep-pak Plus for the second time - no difference in 
extraction recovery as compared to first extraction - n = 12). Next the samples 
were loaded followed by a wash with 5 ml H20. Finally, elution was with 5 ml 
ethyl acetate. Care was taken not to let the vacuum exceed 15 inHg, and to keep 
the flow rate steady, not exceeding 30 ml/min. The eluate was evaporated to 
dryness using a sample concentrator, at less than 40° C under a gentle stream of 
air. The dry residue was reconstituted in 600 JLl mobile phase (50% methanol in 
water) for 10 min in a water bath at 37° C. The tubes were carefully whirlimixed 
and centrifuged (~ 2500 rpm) and the samples transferred to small HPLC-vials for 
injection (200 JLl) onto the HPLC column. The flow rate of the mobile phase was 
1.3 ml/min and run time 15 min per sample. Retention (elution) time was checked 
with standards of cortisol and cortisone (Sigma) included in the beginning and at 
the end of each session. 
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3. RAT OVARIAN 11 B-HSD 
3.1. INTRODUCTION 
There is now abundant evidence suggesting that glucocorticoids affect ovarian 
physiology. Thus systemic administration of exogenous glucocorticoids has been 
shown to reduce ovarian weight [Inazu et al., 1990] and inhibit ovulat.ion [Bald win 
& Sawyer 1974]. Although the inhibition of ovulation has been thought to reflect 
glucocorticoid actions at the anterior pituitary, where they inhibit the preovulatory 
LH surge [Baldwin & Sawyer 1974], the presence of glucocorticoid receptors 
[Schreiber et al., 1982] and glucocorticoid-responsive gene products [Malbon & 
Hadcock 1988; Albiston et al., 1990] in the ovary, suggests that direct effects also 
occur. 
In support of this, glucocorticoids have been shown to inhibit FSH-stimulated 
aromatase activity [Hsueh & Erickson 1978] and augment progesterone 
accumulation [Adashi et al., 1981] in granulosa cells in-vitro. Similarly, 
glucocorticoids stimulate the production of plasminogen activator by isolated 
granulosa cells [Wang & Leung 1989; Jia & Hsueh 1990], an action thought 
important in ovulation control [Reich et al., 1985]. 
In the male, systemic excess of cortisol like in Cushing's syndrome reduces sexual 
function and one of the responses to stress in the male is a reduction in sex drive. 
During stress, for example in subordinate primates, systemic glucocorticoid levels 
are raised in conjunction with reduced testosterone levels [Sapolsky 1985] (also 
observed in human stress [Kreuz et al., 1972]). These could possibly be central 
effects, but direct effects of glucocorticoids on the testis might also be responsible. 
Thus, just like the female gonads, male gonads contain glucocorticoid receptors 
[Evain et al., 1976], and cortisol has been shown to directly inhibit testicular 
- 88-
Rat Ovarian 11 8-HSD: Methods 
steroidogenesis [Bambino & Hsueh 1981]. It is therefore not surprising that 11B-
HSD has been found in this glucocorticoid target tissue. Already in 1965, the 
presence of llB-HSD was noted on immunohistochemistry (tetrazolium blue) 
[Baillie et al., 1965], and in 1989, Monder' s group [Phillips et al., 1989] showed 
its presence in the rat testis interstitium using a specific antibody developed in 
rabbits against purified rat liver liB-dehydrogenase. In this study, testis 11B-HSD 
appeared to be developmentally regulated, being absent in the foetus, and not 
appearing postnatally until at day 26, paralleling the postnatal increase in Leydig 
cell numbers and maturation [Raider et al., 1990]. In a later study [Monder 1991], 
bioactivity and immunoreactivity were found to co-exist in the rat testis, but 
bioactivity only and not immunoreactivity could be demonstrated in the 
epidydymis, raising of course the possibility of 2 isoforms. 
Thus by analogy with the testis, llB-HSD could be expectrd to be found in the 
ovary. Previous studies have not found 11B-HSD bioactivity [Ghraf et al., 1975] 
or immunoreactivity [Phillips et al., 1989] in the rat ovary, but in contrast, human 
ovaries have been shown to be able to convert cortisol to cortisone [Murphy 1981], 
and to express mRNA encoding llB-HSD [Tannin et al., 1991]. Therefore, this 
study was undertaken, re-examining 11B-HSD bioactivity and messenger RNA 
expression in the ovary of the rat. 
3.2. METHODS 
The methods employed have been detailed previously (Section 2), but will briefly 
be reiterated here. All tissues were obtained from animals in prooestrus. For 11B-
HSD activity, ovaries were homogenised in KRB, incubated with 3H-corticosterone 
and NAD at 37° C. Steroids were extracted using ethyl acetate, followed by 
separation and quantification by HPLC. Animals were lethally perfused with 
paraformaldehyde and ovaries post fixed for immunohistochemistry but for in-situ 
hybridisation and northern blotting, fresh rat ovaries were immediately at surgery 
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frozen on dry ice. Cryostat sections were mounted onto slides and post fixed for 
in-situ hybridisation. An antisense cRNA probe was transcribed from a vector 
containing 118-HSD cDNA insert [Agarwal et al., 1989] and hybridised to the 
sections. Controls were hybridised with similarly labelled e5S-UTP) non-
complementary "sense" RN A probes under identical conditions. 
For northern blotting, total RNA was extracted from each tissue by the acid 
guanidinium thiocyanate method, [Chomczynski & Sacchi 1987]. Following 
fractionation on agarose gel and blotting onto nitro-cellulose, hybridisation was 
with a cD N A probe derived from the same rat liver library [Agarwal et al., 1989]. 
For immunohistochemistry, detection was by the peroxidase-antiperoxidase method 
[Sternberger et al., 1970], using an antibody against rat liver 118-HSD raised in 
rabbits, kindly donated by Dr. C. Monder [Monder & Lakshmi 1990]. Preimmune 
rabbit serum served as control. 
3.3. RESULTS 
3.3.1. I m mu no his toe hem i stry 
Consistently strong positive immunostaining was found in the oocyte (Figure 3.4). 
Additionally, positive immunostaining of moderate or low intensity was detected in 
cells comprising the luteal bodies (not shown). This varied between luteal masses, 
rather than within a given luteal body, presumably reflecting their varying stages 
of maturation. No staining was observed in the granulosa cells, theca cells, stroma 
or other ovarian components. No staining of any ovarian subregion was 
demonstrated with preimmune serum. 
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3.3.2. mRNA Expression 
Northern blotting was used to detect mRNA expression and a single band 
hybridising to the 1113-HSD probe (cDNA derived from rat liver 1113-HSD) was 
detected in ovarian total RNA which corresponded to the major 1113-HSD mRNA 
species demonstrated in rat liver and hippocampus . This was in contrast to the 
multiple bands found in kidney (Figure 3.1). In-situ hybridisation was used to 
localise 1113-HSD m.RNA expression to oocytes and also to a variable extent to 
luteal bodies , varying between luteal masses rather than within individual bodies 
and paralleling the immunohistochemical findings (Figure 3. 5) . 
._18S 
Figure 3.1 Rat Ovary: Northern Blotting. 
This is an autoradiograph of total RNA hybridised with 32P-Iabelled cDNA probes to 11 r..-HSD m RNA. 
0 = ovary, H = hippocampus, K = kidney, L = liver. Note multiple hybridising species in kidney but 
only one ovarian band corresponding to the one found in hippocampus and liver. 
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3.3.3. Bioactivity 
11B-HSD activity in the dehydrogenase direction was found in all ovarian 
homogenates using NAD. The time curves for the different protein concentrations 
(Figure 3. 2) indicate linearity with respect to time for up to 10 minutes at both 
cofactor concentrations. 
At protein concentration of 0.25 mg/ml incubated for 10 minutes, ovarian activity 
was 10% of kidney activity (ovary, n = 3: 179.6 ± 30.5 finales product formed, 
kidney, n = 2: 1742.4 ± 44.1 finales product formed). Increasing protein 
concentration produced a linear increase in finales 11-dehydrocorticosterone 
produced up to 0.5 mg/ml, beyond which a decrease in activity was observed 
(Figure 3.3). 
No conversion of 3H -11-dehydrocorticosterone to 3H-corticosterone (reductase) 
was found using 200 JLM NADH as cofactor. Multiple attempts to assay 11B-HSD 
activity in freshly harvested rat oocytes from superovulated animals (a gift from 
Dr. J. Mullins, Centre for Genome Research, University of Edinburgh) as well as 
in 1 and 2 cell embryos (with both NAD and NADP) were without success. 
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Figure 3.2 Rat Ovarian Bioactivity 1: Time Course 
11 11-HSD bioactivity (as fmol 3H-dehydrocorticosterone formed from 3H -corticosterone) in ovarian 
homogenates at three different protein concentrations and two different cofactor concentrations. Each 
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Figure 3.3 Rat Ovarian Bioactivity 11: Protein Concentration. 
11 11-HSD bioactivity (as fmol 3H-dehydrocorticosterone formed from 3H-corticosterone) in ovarian 
homogenates with increasing protein concentrations. Incubation time was 10 min, cofactor was NAD 
at 200 ~M. substrate at 12 nM final. Each point represents mean ± SEM from 2 - 4 animals (each 
incubated in duplicate). 
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Figure 3.4 Immunohistochemistry of a Rat Ovary 
The top shows immunostaining of rat ovary using antiserum to purified rat liver 11 13.-hydroxysteroid 
dehydrogenase, displaying marked staining of the oocyte. Bottom is control using pre-immune serum, 
showing no immunostaining. Magnification is 400 times. 
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Figure 3.5 Rat ovary In-Situ Hybridisation 
Rat Ovarian 11 fJ -HSD: Results 
Top is in-situ hybridisation showing a concentration of silver grains over the oocyte indicating 
hybridisation of the cRNA probe containing 35S-Iabelled UTP to 11 11-HSD m RNA. The bottom part is 
in-situ hybridisation using "sense" probe, showing no silver grain concentration . Magnification: x600. 
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3.4. DISCUSSION 
The purpose of the studies reported in this Section, was first and foremost to try to 
answer the question whether 118-HSD was present in the ovary, a question which 
has been surrounded with controversy. Thus in 1975, Ghraf [Ghraf et al., 1975] 
and colleagues reported absence of 118-HSD bioactivity in the rat ovary but in 
contrast, Murphy, in 1981 found considerable bioactivity in human ovaries 
[Murphy 1981]. Furthermore, glucocorticoids do affect gonadal function in both 
sexes and 118-HSD has been found in male rat gonads [Phillips et al., 1989] as in 
other glucocorticoid target tissues. One would therefore expect to find 118-HSD in 
the ovary where, by analogy with the testis (see introduction, page 88) it might 
have a developmental role. 
This study has demonstrated the presence of 118-HSD bioactivity in homogenised 
whole ovaries using NAD as cofactor, in agreement with Murphy's findings 
[Murphy 1981]. Murphy did not however use cofactors, and in adult ovaries 
found equal activities for both 11-oxidation and 11-reduction, whereas only 
oxidation was detected in this study. In foetal and childhood gonads, Murphy 
found only oxidation [Murphy 1981]. The discrepancy between the data presented 
here and those of Ghraf [Ghraf et al., 1975] (who used both NAD and NADP), are 
unclear but may relate to the very high pH (9 .5) used in the latter study. The 
activity at identical protein concentrations is only 10% of the kidney activity, the 
kidney being a tissue known to have abundant 118-HSD. This could be due to: i) 
sparse/scanty cellular expression of the enzyme in the ovaries (as has been 
demonstrated here - see below), and/or ii) a narrow (perhaps cyclical) window of 
expression, possibly related to the oestrous cycle (or follicle development), and/or 
iii) the presence of inhibitors of the enzyme in the ovary. The last possibility is in 
fact supported by Figure 3.3, where the reaction appears inhibited at protein 
concentrations beyond 0.5 mg/ml (only looking at incubation time of 10 min, with 
200 p.M NAD and 12 nM 3H-corticosterone). There are of course a number of 
candidate steroids that might act as inhibitors in the ovary, including progesterone, 
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as reviewed in detailed by Monder & White [Monder & White 1993]. The 
findings reported here have since been confirmed, i.e. 116-HSD bioactivity is 
present in cultured ovarian cells, more specifically, in cultured granulosa lutein 
cells, where the direct inhibition of LI-I-induced steroidogenesis by glucocorticoids 
is modified by 116-HSD [Michael et al., 1993b]. 
Using both immunohistochemistry and in-situ hybridisation, liver-type 116-HSD 
(the antibodies and cDNA derived from liver-type enzyme) was localised to the 
oocytes themselves, and to a lesser extent to luteal bodies. Thus 116-HSD is not 
ubiquitous, many components of the ovary not expressing the enzyme. The 
northern blot indicates only one species of this liver type enzyme, in agreement 
with the data of Tannin [Tannin et al., 1991], and as observed in hippocampus, 
cerebellum and testis [Moisan et al., 1990a; Moisan et al., 1990b], which contrasts 
with multiple hybridising forms found in the kidney, both in this study and others 
[Krozowski et al., 1990; Moisan et al., 1992b]. These multiple forms are due to 
differential promoter usage of the 11B-HSD-1 gene [Moisan et al., 1992a], which 
when expressed in-vitro are inactive [Mercer et al., 1993; Obeid et al., 1993]. The 
possibility of multiple forms (derived from different genes rather than variants of 
11B-HSD-1), is also apparent in male rat reproductive organs where bioactivity is 
found in both testis and epidydymis but immunoreactivity to liver-derived 11B-
HSD is only observed in testis [Monder 1991]. 
Data from our laboratory [Brown et al., 1993] has shown that the liver type (11B-
HSD-1) is exclusively NADP dependent and reflects a separate gene product from 
placental (and renal) 11B-HSD-2, which is NAD dependent (see also report of 
cloning of 11B-HSD-2 [Albiston et al., 1994]). The bioactivity reported in this 
study was NAD dependent (NADP was not looked at except in isolated oocytes -
see results page 92), and recent reports [Piercy et al., 1993] point to the bioactivity 
in human cultured granulosa-lutein cells also being NAD dependent. However, in 
contrast to the NAD dependent bioactivity, liver-type 11B-HSD immunoreactivity 
and rnRNA expression was found here, - localised to the oocyte and luteal bodies. 
It is of course not possible to localise at a cellular level the NAD dependent 
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bioactivity in crude ovarian homogenates but this raises several possibilities. 
Firstly the NAD supported bioactivity might be explained by a variant of 11B-
HSD-1 which immunoreacts with the antibody, but can use NAD, although this is 
unlikely as no such activity has been found for any of the variant transcripts of the 
118-HSD-1 gene [Mercer et al., 1993; Obeid et al., 1993]). Secondly the enzyme 
might be an unknown variant of 118-HSD-2 which is recognised by the antibody 
against liver-type 118-HSD. As 118-HSD-2 is thought to be an almost exclusive 
dehydrogenase [Brown et al., 1993; Albiston et al., 1994], the lack of reductase 
activity here supports this, but against it is the observation that purified placental 
118-HSD-2 is not immunoprecipitated by 118-HSD-1 antisera [Brown et al., 
1993]. The third possibility, namely the two isoforms co-existing is also not 
unlikely, each playing separate roles - as possibly is the case in the baboon 
placenta where direction of reaction seems to change as pregnancy advances (see 
later chapters). The fourth possibility is of course that this polyclonalliver-derived 
antibody is not detecting authentic 118-HSD, but simply cross-reacting with 
something else, a notion supported by the presence of cross reacting species on 
western blots [Phillips et al., 1989]. Finally, this "something else" could of course 
be a third as yet not characterised isoform of 118-HSD (i.e. product of a third 
gene). 
This study found a specific pattern of 118-HSD mRNA expression, like in the 
testis where 118-HSD is found specifically in the Leydig cells of the testis-proper 
(as opposed to for example the epidydymis). Perhaps surprisingly, no indication of 
the presence of 118-HSD in granulosa cells was found, although these cells have 
previously been shown to contain glucocorticoid receptors [Schreiber et al., 1982] 
and to be metabolically regulated by glucocorticoids [Hsueh & Erickson 1978; 
Adashi et al., 1981; W ang & Leung 1989]. Also, this study failed to demonstrate 
the presence of 118-HSD in theca cells, although the synthetic glucocorticoid 
dexamethasone has been shown to alter their content of the enzyme carbonyl 
reductase [Inazu et al. , 1990] . This does however not preclude the presence of 
118-HSD-2 in these locations. The finding of 118-HSD immunoreactivity and 
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mRNA expression in the luteal cells, but not the theca cells, may be another 
example of cellular ontogeny, as we have previously shown in the skin 
[Teelucksingh et al., 1990], where 1113-HSD is not detected in the basal cell layer, 
but is located in the upper epidermal cells. The ontogeny/differentiation idea has 
been supported by Michael and colleagues who have subsequently [Michael et al., 
1993b] found bioactivity in cultured granulosa cells that have undergone 
luteinisation. 
The specific pattern of localisation and the presence of N AD dependent bioactivity 
is very interesting and throws open the question of what the role of ovarian 1113-
HSD might be. The proposed physiological function of 1113-HSD-1 is activation of 
inactive steroids (reductase activity), in the liver explaining why oral cortisone is 
active as a glucocorticoid, a notion which has been supported recently by data from 
our laboratory where the protein encoded by a liver derived cDNA functions as a 
reductase in intact mammalian cells [Low et al., 1994]. The liver-type enzyme 
may however be bi-directional as suggested by findings in the testis, where 1113-
HSD-1 immunoreactivity is found [Phillips et al., 1989], and bioactivity is 
predictably NADP dependent [Camp bell et al., 1992] but the role appears to be to 
inactivate steroids (liB-dehydrogenation) [Monder et al., 1994a; Monder et al., 
1994b]. 
Could the role of ovarian 1113-HSD be to increase availability of glucocorticoids to 
the maturing oocyte? In the context of our knowledge of the deleterious effects of 
glucocorticoids on growth in-utero (see introduction to thesis), what beneficial 
effects could possibly be derived from that? A well known example of a beneficial 
effect of glucocorticoids is term foetal lung maturation/surfactant production, 
which is induced by glucocorticoids [Hundertmark et al., 1994]. For the oocyte, 
suppression of local maternal inflammatory /immunological responses to this half 
foreign body may be beneficial at implantation, and induction of oocyte enzymes 
necessary for development could also be important. 
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There is some recent data supporting this idea that glucocorticoids may be 
necessary for very early development. Thus a recent publication [Michael et al., 
1993a] found that the absence of 11B-HSD in cultured human granulosa cells 
aspirated from subjects undergoing in-vitro fertilisation-embryo transfer (IVF-ET), 
predicted implantation success i.e. pregnancy. The authors felt that this implied 
that lack of glucocorticoid inactivation by 11B-HSD was beneficial. It is however 
hard to see how lack of 11B-HSD activity in cultured granulosa lutein cells can 
predict successful implantation, the cells having been cultured for 3 days 
(luteinised) before 11B-HSD activity was measured. Another problem is the 
classical understanding that steroidogenesis by the luteal bodies is necessary for 
maintenance of pregnancy. This steroidogenesis is inhibited by glucocorticoids, 
and the inhibition is alleviated by 11B-HSD [Michael et al., 1993b]. The absence 
of 11B-HSD would therefore lead to greater inhibition of steroidogenesis by 
glucocorticoids. It is of course possible that one or both of the 11B-HSD isoforms 
in the ovary have nothing to do with glucocorticoid metabolism, and that the 
substrate is a different steroid(s). 
In summary, the original quest for the presence of 1 113-HSD in the ovary has been 
successful. Subsequently, others have published very interesting data highlighting 
the potential role of 11B-HSD as a modulator of development before implantation. 
This opens up numerous avenues which would be exciting to explore. The 
immediate next step would of course be to do in-situ hybridisation and northern 
blotting using the probes against NAD dependent placental 11B-HSD-2, which only 
just now is becoming available. 
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4. RAT PLACENTAL 11 B-HSD 
4.1. INTRODUCTION 
Recent epidemiological studies show that low birth weight is associated with death 
from ischaemic heart disease [Barker et al., 1989a], and increased risk of 
developing several risk factors for ischaemic heart disease, including high blood 
pressure. The association with higher blood pressures holds in children [Barker et 
al., 1989a; Law et al., 1991; Cater & Gill 1984], adolescents [Seidman et al., 
1991], and adults [Barker et al., 1989a; Barker et al., 1990; Gennser et al., 1988]. 
Some of the studies have found that the unusual combination of low birth weight 
with a large placenta, is strongly associated with later hypertension [Barker et al., 
1990]. The pathogenesis is obscure but has been attributed to maternal 
malnutrition [Barker et al., 1993a]. However, this combination of low birth 
weight and high placental weight has also been observed in rats with 
streptozotocin-induced diabetes mellitus [Robinson et al., 1988; Canavan & 
Goldspink 1988]. These animals have increased maternal glucocorticoid levels 
[Helier et al., 1988]. Previous work has shown that exogenous glucocorticoids 
retard foetal growth in both humans and animals [Reinisch et al., 1978; 
Benediktsson et al. , 1993; Katz et al. , 1990] and that exogenous glucocorticoids 
given to pregnant rats can increase placental weight, possibly depending on timing 
and dose [Gunberg 1957]. We treated pregnant rats with the synthetic 
glucocorticoid dexamethasone [Benediktsson et al., 1993]. The offspring were 
lighter than controls at birth, and although reared normally (as were controls) from 
birth, developed elevated blood pressure 5 months later. Thus, was it possible that 
glucocorticoid excess in-utero might be responsible for imprinting (programming) 
of cardiovascular disease? What is the barrier that normally protects the foetus 
- 101 -
Rat Placental 11 13-HSD: Introduction 
from the much higher maternal glucocorticoid levels? Could there be an intrinsic 
variation in the effectiveness of this barrier? 
Several authors have proposed that this placental glucocorticoid barrier is the 
enzyme 11B-hydroxysteroid dehydrogenase [Murphy et al., 1974; Dancis et al., 
1978; Beitins et al., 1973; Dormer & France 1973] which catalyses the conversion 
of the metabolically active cortisol (118-hydroxysteroid), to the inactive cortisone 
(11-oxosteroid). Although cultured fibroblasts from human uterine tissue had been 
shown to be able to catalyse 11B-ol oxidation in 1958 [Sweat et al., 1958], it was 
not until in 1960 that bioactivity studies by Osinski [Osinski 1960] demonstrated 
the presence of 11B-HSD in term human placenta. 
Several other investigators have since confirmed this in humans and in various 
other species, although controversy has surrounded several aspects of the story (see 
Section 1.4.5 for a detailed account). In humans, 85% of maternally injected 
radiolabelled cortisol at 13 - 18 weeks of pregnancy, was converted to cortisone on 
transplacental transfer [Murphy et al., 1974]. Deduced from similar human 
experiments at term, only 25% of term foetal cortisol is derived from the mother, 
while 90% of foetal cortisone is of maternal origin [Beitins et al. , 1973]. Using 
ex-vivo perfusion of intact human placentas at term, Dancis found that most of 
maternal cortisol was converted to inactive cortisone during passage across the 
placenta [Dancis et al., 1978]. Several in-vitro studies have supported this, L6pez 
Bernal's group suggesting that human placental 11B-HSD was an effective barrier 
to maternal glucocorticoids throughout gestation [L6pez Bernal & Craft 1981; 
Blasco et al., 1986]. There seem however to be important inter-species 
differences. Thus in the baboon, 11B-HSD at mid-gestation appears to catalyse 
cortisone to cortisol conversion, while at term the reverse (dehydrogenation, 
inactivating cortisol) [Pepe & Albrecht 1984b]. It appears that in the baboon, 
- 102-
Rat Placental 118-HSD: Methods 
oestrogens which induce cortisol to cortisone conversion, are responsible for this 
change in enzyme direction [Pepe et al., 1988]. 
In order to test the hypothesis that i) a considerable natural variation exists 1n 
placental 11B-HSD activity (this variation presumably resulting in variable foetal 
glucocorticoid exposure), and ii) that this variation, if found, correlates with foetal 
growth, a study of 11B-HSD activity in normal Wistar rats was undertaken. Rats 
were chosen as an experimental model for initial exploration of this hypothesis 
since i) the in-utero dexamethasone programmed hypertension model was the rat, 
ii) the rat placental anatomy with regard to materna-foetal exchange resembles 
closely human anatomy (Section 1.5), iii) a cDNA for, and antibody to rat liver 
11B-HSD-1 was available, and iv) the species is easy to mate, handle and was 
readily available. 
4.2. METHODS 
The methodology of the 11B-HSD activity assay is described in detail in Section 
2.4.1. In brief, on day 20 of pregnancy (term is 20 - 22 days), rats were killed by 
cervical dislocation. The placentas and foetuses were immediately placed on ice 
and weighed. The placentas were homogenised in KRB and the protein content of 
the homogenate estimated according to the method of Bradford [Bradford 1976]. 
The enzyme assay was carried out in duplicate incubations at 37 oc. Substrate was 
3H-corticosterone and NAD was cofactor, as for all assays, it was made up fresh in 
KRB before each assay and stored on ice, protected from light. Total incubation 
volume was 250 J.Ll and incubation of buffer alone provided an assay blank. The 
incubation was started by adding tritiated steroid and terminated by adding 2.5 ml 
of ethyl acetate, which also served to extract the steroids before separation with 
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automated HPLC. Enzyme activity was expressed as % conversion 3H-
corticosterone to 3H-11-dehydrocorticosterone. 
Animals were lethally perfused with paraformaldehyde and placentas post fixed for 
immunohistochemistry. Detection was by the peroxidase-anti peroxidase method 
[Sternberger et al., 1970], using an antibody against rat liver 11B-HSD raised in 
rabbits, kindly donated by Dr. C. Monder [Monder & Lakshmi 1990]. Preimmune 
rabbit serum served as control. For in-situ hybridisation, fresh placentas were 
immediately at surgery frozen on dry ice. Cryostat sections were mounted onto 
slides and post fixed for in-situ hybridisation. An anti sense eRN A probe was 
transcribed from a vector containing 11B-HSD cDNA insert [Agarwal et al., 1989] 
and hybridised to the sections. Controls were hybridised with similarly labelled 
e5S-UTP) non-complementary "sense" RNA probes under identical conditions. 
4.3. RESULTS 
4.3.1. Bioassay Evaluation 
As the literature on cofactor preference of placental 1113-HSD was discrepant (see 
Section 1.4.5), NAD/NADP preference was examined. As shown in Figure 4.1, 
the rat placental enzyme activity is highly inducible with NAD, the enzyme 
showing clear preference of NAD over NADP at 200 ~-tM and 2000 ~-tM. There 
did not seem much additional advantage of using higher concentration than 200 ~-tM 
N AD which was therefore used for all subsequent assays. 
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Figure 4.1 Cofactor Preference of Rat Placental118-HSD In-Vitro 
Enzyme activity of 11 B-HSD expressed as % conversion B to A without cofactor added and at three 
different final concentrations of NAD and NADP. Each column represent mean + SEM for 3 placentas 
incubated in duplicate. Protein content was 0.5 mg/ml, 3H-corticosterone was 12 nM final, incubated 
for 60 min. 
The next step was plotting the progress of reaction as a function of enzyme 
concentration (protein concentration) and time. The left hand panel in Figure 4.2 
shows that the progress of the reaction slows down beyond protein concentration of 
0.2 mg/ml. The progress of reaction is linear with respect to enzyme added 
beyond 0.2 mg/ml. The progress of reaction with increased incubation time and 
protein concentration of 0.5 mg/ml is shown in the right hand panel of Figure 4.2. 
Linearity was observed up to approximately 20 minutes. 
Although blank rates were always negligible and identical to blanks using 
denatured homogenate, it was still important to show that the conversion was due 
to llB-HSD, and thus could be inhibited with classic llB-HSD inhibitors. The 
active constituent of liquorice, glycyrrhetinic acid, and the synthetic hemisuccinate 
of glycyrrhetinic acid, the water soluble ulcer healing drug carbenoxolone were 
used. The results are shown in Figure 4.3. Approximate IC50 for both 
glycyrrhetinic acid and carbenoxolone was very similar, being 0.9 x 10-5 M and 1 
X 1 o-5 M respectively. 
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Figure 4.2 Rat PlacentalllB-HSD In-Vitro Assay 
The vertical axis indicates % conversion corticosterone (B) to 11-dehydrocorticosterone (A). On the 
left panel the progress of reaction is in two phases, linearity with respect of protein added being 
observed beyond protein concentration of ea. 0.2 mg/ml. On the right hand panel the progress of 
reaction is linear for the first 20 min using 0.5 mg/ml protein. Each point represents mean of 4 
placentas incubated in duplicate. Bars indicate ± SEM. Cofactor was NAD 200 IJM final, substrate 3H-
corticosterone at 12 nM final. 
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Figure 4.3 Rat PlacentalllB-HSD Inhibition In-Vitro 
100 
The effect of three concentrations of carbenoxolone and glycyrrhetinic acid on the conversion of 3H-
corticosterone to 3H-11-dehydrocorticosterone. The data is activity in the presence of inhibitor as a 
percentage of control activity set at 100% (in the absence of inhibitor). Points represent mean of 3 - 5 
experiments, while bars indicate± SEM. The horizontal axis is logarithmic. 
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Figure 4.4 Storage of Rat Placental Homogenate 
The figure shows a linear decline in homogenate 11 f!-HSD bioactivity when stored on ice. Time zero 
is first incubation, 1 h after homogenisation. Storage time therefore represents additional hours. Data 
is expressed as % of original activity for 3 different placentas, each incubated in duplicate. Points 
represent mean and bars ± SEM. 
Several reports in the literature comment on the instability of 11B-HSD with 
storage although some researchers have not noted that. In order to examine that 
possibility, two placentas were cut in half, one half assayed fresh and the other half 
immediately frozen at -70° C. The following day the frozen halves were thawed, 
homogenised and assayed as usual. The enzyme proved very unstable, the mean 
activity for the two placentas (each incubated in duplicate) being 81%, dropping 
down to 18% on freezing, i.e. maintaining only 22% of the original activity. But 
was this enzyme only unstable on freezing? Looking at the stability of the 
homogenate, kept immersed in ice, a linear decline in activity with time was found 
(Figure 4.4), activity declining by approximately 15% per hour. Thus timing had 
to be very precise, keeping the time from homogenisation to start of incubation 
fixed. The time from killing of the animal to start of homogenisation was constant 
(30 min) and similarly the time from homogenisation to start of incubation (60 
min). The recovery of radioactive label was 71% and CV = 5% ·(n = 7). Intra-
assay coefficient of variation was 3% at approximately 50% conversion (n = 11). 
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The inter-assay variation could not of course be assessed due to the instability of 
the placental enzyme. 
4.3.2. Relationship of 11 B-HSD to Rat Foetal Growth 
In order to determine whether rat placental 11 P-HSD was capable of excluding 
active maternal glucocorticoid from the foetal circulation, relative dehydrogenase 
(inactivating glucocorticoids) and reductase (generating active glucocorticoid) 
activities were looked at. The substrate for reductase was 3H -11-
dehydrocorticosterone, using NADH as cofactor at 200 JLM. At 3 stages of 
gestation, early (12 d; n = 2), mid (16 d; n = 4) and term (20 d; n = 3), no 
reductase activity was found and the dehydrogenase activity was similar at all 
stages. 
As discussed in the introduction to this thesis, the rat placenta consists of two 
zones, the labyrinthine zone where the materna-foetal exchange takes place, and 
the basal zone. Although maternal blood has to travel through the basal zone, 
localisation in the labyrinthine zone would probably be most efficient for 11B-HSD 
to function as a barrier. The data presented so far was derived from whole 
homogenised placentas. Demonstrating that bioactivity was specifically present in 
the labyrinthine zone was thus important. A natural plane of cleavage exists 
between the basal and labyrinthine zones, pulling on the basal zone with pliers 
easily peeled it off the labyrinthine zone. Each part was homogenised separately as 
previously described. The result is shown in Figure 4.5. 118-HSD bioactivity is 
present in both parts, under the conditions studied the activity in the labyrinthine 
zone was slightly, but not significantly, higher than the activity in the basal zone. 
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Figure 4.5 Zonal Distribution of 118-HSD Bioactivity 
Although the bioactivity is slightly higher in the labyrinthine zone, this does not reach statistical 
significance using t-test. Data are mean± SEM, n = 4; triplicate incubations. 
Could there be a physiological variation in this barrier (which seems to be 
predominantly oxidative throughout pregnancy)? This question was addressed by 
estimating placental enzyme activity in 56 placentas from 8 normal Wistar rats at 
term. A strong, positive (r = 0.46, r2 = 0.21), highly significant (p < 0.0005) 
correlation was found between placental 11B-HSD activity and term foetal weight 
(Figure 4.6). This indicates that those foetuses that were smallest at term had the 
lowest placental 11B-HSD activity and were thus presumably exposed to the 
greatest amount of maternal glucocorticoids. Processing the data as means per 
litter showed the same, albeit stronger, positive correlation (r = 0.96, r2 = 0.92, p 
< 0. 001; n = 8). An apparent outlier with regard to foetal weight is indicated 
with an arrow in Figure 4.6. Excluding this outlier from the analysis gives r = 
0.65, r2 = 0.42 and p < 0.0000001. 
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Figure 4.6 Term Rat Foetal Weight and 116-HSD Bioactivity 
A highly significant positive correlation of term placental enzyme activity (x-axis) with term foetal 
weight (abscissa). Pearson's r is+ 0.46, ~ = 0.21, p < 0.0005, n =56. The solid line is the regression 
line and dotted lines indicate the 95% confidence interval for the regression. Note an outlier (arrow), 
which is included in data analysis. 
Again using Pears on's product moment correlation, but this time for the 
relationship between term placental weight and term placental 11B-HSD activity 
(Figure 4.7), a strong negative (r = -0.63, r2 = 0.40), highly significant (p < 
0.00001) correlation was found. Similar results were obtained when data were 
analysed as means per litter (r = -0.66, p < 0.05, n = 8). There was no apparent 
placental weight outlier. Thus the biggest placentas have lowest 11B-HSD activity, 
on a per unit weight basis. 
The question at this point was of course (with reference to the human data on the 
combination of low birth weight and high placental weight predicting high blood 
pressure): What is the form of the relationship between placental 11B-HSD activity 
at term and both foetal- and placental weights simultaneously? In other words, do 
small rat foetuses which also have a large placenta, have low placental 11B-HSD 
activity, and those that are large with small placentas high placental 11B-HSD 
activity. This is explored in Figure 4.8, where the data has been plotted in 3 
dimensions, enzyme activity on the vertical axis while placental and foetal weights 
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are displayed on the two horizontal axes. What is evident is the general trend for 
small foetuses with large placentas t? have lower placental 118-HSD activity than 
big foetuses with small placentas, although the relationship seems to be less clear at 
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Figure 4.7 Term Rat Placental Weight and 116-HSD Bioactivity 
100 
A highly significant negative correlation of term placental enzyme activity (x-axis) with term placental 
weight (abscissa). Pearson's r is -0.63, ,-2 = 0.40, p < 0.00001, n = 56. The solid line is the regression 
line and dotted lines indicate the 95% confidence interval for the regression. 
It is possibly more relevant with regard to foetal glucocorticoid exposure, to look 
at some measure of total placental capacity to metabolise glucocorticoids. A way 
of doing that would be to multiply the % conversion 3H -corticosterone to 3H -11-
dehydrocorticosterone per g of placental homogenate by the total placental weight 
(see discussion for criticism). Using this approach, a strong positive correlation of 
term foetal weight and "total placental 11B-HSD activity" was again found (r = 
0.45, r2 = 0.20, p < 0.0005). It is of course meaningless to correlate total 
placental 11B-HSD activity with placental weight as placental weight then 
contributes substantially to both sides of the equation. 
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Figure 4.8 Rat Placentalllfi-HSD Activity, Term Foetal and Placental Weight 
The data points (not shown) have been fitted with a contour map employing a "least squares" method. 
lt is important to appreciate that this figure can only indicate trends as the actual data points do not 
reach the corners of the figure. 
4.3.3. Immunohistochemistry and mRNA expression 
Using the same antibody as was used for ovarian immunohistochemistry (donated 
by Dr. C. Monder; raised in rabbits to rat liver 11B-HSD), a strong positive 
continuous band of staining was found in the barrier separating the maternal and 
foetal circulations in the labyrinthine zone of the placenta (Figure 4.9). 
Additionally, there was immunostaining of moderate intensity the vacuolated 
glycogen cells [Davies & Glasser 1968], of the basal zone. The in-situ 
hybridisation pattern paralleled the immunohistochemistry findings, being positive 
in the barrier between the two circulations and over the vacuolated glycogen cells 
(Figure 4.10). 
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Figure 4.9 Immunohistochemistry of Term Rat Placenta 
The figure shows a portion of rat placental labyrinthine zone. The top shows positive immunoreactivity 
in the barrier separating the maternal and foetal circulations (brown colour}, indicating presence of 
11 r1-HSD-1 protein . Bottom is control using pre-immune serum, showing no staining . 
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Figure 4.10 Term Rat Placenta In-Situ Hybridisation 
The figure shows a portion of rat placental labyrinthine zone. The top panel is in-situ hybridisation 
showing a concentration of silver grains over the barrier between the maternal and foetal circulations, 
indicating hybridisation of the cRNA probE! containing 35S-Iabelled UTP to 11 ~-HSD m RNA. In-situ 
hybridisation using "sense" -probe, showing uniform silver grain distribution. 
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4.4. DISCUSSION 
This study has found abundant NAD dependent 11B-HSD dehydrogenase activity in 
rat placentas throughout pregnancy, which was present in both the basal and 
labyrinthine zones -the labyrinthine zone being where the materno-foetal exchange 
takes place. Before this study was performed there was considerable discrepancy 
apparent in the literature regarding cofactor preference of placental 11B-HSD. 
Thus some found NADP preference [Blasco et al., 1986; Osinski 1960; L6pez 
Bernal et al., 1980b] some NAD [Pepe & Albrecht 1984a] and some no preference 
[Meigs & Engel 1961]. More recently, the findings presented here have been 
confirmed, as the human placenta has been found to predominantly express a NAD 
dependent isoform [Brown et al., 1993; Lakshmi et al., 1993], catalysing the 
conversion of cortisol to cortisone but being virtually devoid of any reductase 
activity. 
Furthermore, it has a Km in the low nanomolar range, thus probably being better 
suited to function as a barrier to maternal glucocorticoids than liver-type 11B-HSD 
(118-HSD-1) which has a Km 100 times higher (rat liver) [Brown et al., 1993], and 
which probably functions physiologically to convert cortisone to cortisol (or 11-
dehydrocorticosterone to corticosterone, i.e. reductase) [Duperrex et al., 1993; 
Low et al., 1994; Moo re et al., 1993]. This "placental isoform" is a product of a 
gene distinct from the gene for 118-HSD-1 [Brown et al., 1994], and is very 
similar to (one amino acid difference) the recently cloned human kidney 118-HSD-
2 [Albiston et al., 1994]. 
It is of course entirely plausible that there is more than one isoform of 11B-HSD 
present in the placenta, as suggested by L6pez Bernal [L6pez Bernal et al., 1980b] 
and Lakshmi [Lakshmi et al., 1993]. Although in the studies presented here, no 
reductase activity could be found (early-, mid-, late-gestation), others have found 
minimal amounts of reductase [Giannopoulos et al., 1982; Lakshmi et al., 1993; 
Brown et al., 1993], but the dehydrogenase activity was always predominant. The 
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reductase seems to be more fragile [Brown et al., 1993; Lakshmi & Monder 1985; 
Lakshmi et al., 1993], and thus could have been destroyed here during tissue 
processing. Thus, in spite of the lack of reductase bioactivity, it is not possible on 
the basis of the findings here to exclude the presence of 116-HSD-1. Similarly, if 
both isoforms are active in the preparation, but dehydrogenation is dominant, it 
would be impossible to detect any activity attributable to 116-HSD-1 (reduction), 
as the product (corticosterone) would immediate I y be converted back to 11-
dehydrocorticosterone. 
The data presented do in fact support the presence of 11 B-HSD-1 as well as N AD 
dependent 116-HSD-2. First, some NADP dependent dehydrogenase activity was 
demonstrated although NAD dependent activity was predominant. NADP 
dependent placental activity has also been found by others (see above), and has 
been attributed to a different (from the NAD dependent form), but co-existing 
isoform, as judged by analysis of Eadie-Hofstee plots [Brown et al., 1993]. Other 
tissues, for example testis Leydig cells also express 116-HSD-1 [Phillips et al., 
1989], but show NADP dependent dehydrogenation of active corticosterone to 
inactive 11-dehydrocorticosterone [Monder et al., 1994a; Monder et al., 1994b]. 
The second line of evidence for the presence of 11 B-HSD-1 , arising from the data 
presented in this thesis is the presence in the rat placenta of i) immunoreactivity 
using an antibody raised against 11B-HSD-1 (rat liver), and ii) the expression of 
11 B-HSD-1 mRN A. The presence of protein and/ or mRN A is not the equivalent 
of bioactivity - the protein could be inactive. 
Not only is the reductase known to be unstable in the placenta, but in this study the 
NAD dependent dehydrogenase was also found to be fragile (Figure 4.4). The 
explanations for this could for example be the presence of proteases in the 
homogenate, inappropriate pH (although pH 7.4 may be physiological, that may 
not promote stability in homogenates), mechanical disruption etc. . This fragility 
would serve to dilute any relationship between foetal growth and placental 11B-
HSD activity and thus importantly, the time from tissue harvesting until assay was 
kept constant. 
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The progress of reaction slowed down beyond approximately 0.2 mg/ml, although 
it was linear with respect of amount of enzyme added. This could be due to the 
presence of an endogenous reversible inhibitor in the homogenate. Dozens of 
steroids have been shown to reversibly inhibit 1113-HSD [Monder & White 1993], 
but those most likely to be the culprits in this tissue are pregnenolone or rather 
progesterone [Pepe & Albrecht 1984a], while other steroids of placental origin like 
17 -hydroxyprogesterone are not likely [Pepe & Albrecht 1984a]. Oestrogen 
probably induces placental 1113-HSD, at least in the baboon [Baggia et al., 1990b]. 
Accumulation of product ( 11-dehydrocorticosterone), is of course another 
possibility. 
The IC50 for the placental enzyme was here found to be approximately 1 o-5 M for 
both carbenoxolone and glycyrrhetinic acid. This is in keeping with previously 
published values for human placenta [Teelucksingh et al., 1991a], and values 
presented in Section 6. 3. 2. The homogenate used here was rather coarse, making 
the presence of some intact cells likely. The IC50 for intact cells in other tissues 
expressing 1113-HSD-2 [Monder et al., 1989], or in crude homogenates of tissues 
expressing 116-HSD-1 [Walker 1992] is also comparable to the values obtained 
here, whereas in purified tissue preparations (microcosms etc.), IC50 seems to be 
several orders of magnitude lower (10-7 - 10-9 M) [Monder et al., 1989; Schleimer 
1991], which is probably explained by better access of the inhibitors to the 
enzyme. 
The anatomical localisation of bioactivity to the labyrinthine zone (in addition to 
the basal zone), where the materna-foetal exchange takes place, is compatible with 
the proposed role of placental 1113-HSD, that is, to be a barrier to maternal 
glucocorticoids. However, conclusive proof for 1113-HSD being the barrier can 
only be obtained by inhibiting 11B-HSD in intact perfused placentas, demonstrating 
abolition of the barrier. Supportive evidence can though be claimed for the studies 
presented here, where glucocorticoid metabolism was completely inhibited with the 
classical 1113-HSD inhibitors, glycyrrhetinic acid and carbenoxolone. The 
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corticosterone to 
3
H -11-dehydrocorticosterone) found here is also compatible with 
the hypothesis that different foetuses are likely to be exposed to variable amounts 
of maternal glucocorticoids with potential adverse effects. 
The highly significant direct correlation with term foetal weight, of the ability of 
placental 11B-HSD to inactivate corticosterone (r = 0.46, p < 0.0005), observed 
in this study, is supportive of the notion that placental 11B-HSD plays a crucial 
role in ensuring low foetal glucocorticoid levels, allowing normal development of 
the foetus. It is well established that exogenous glucocorticoids do retard foetal 
growth in both humans and animals [Reinisch et al., 1978; Katz et al., 1990], and 
key in this context, are our studies on in-utero induced hypertension by treatment 
of pregnant rats with the synthetic glucocorticoid dexamethasone (which is 
incompletely metabolised by 11B-HSD) [Benediktsson et al., 1993]. Further 
studies in the rat have also shown that treatment of pregnant animals with 
carbenoxolone results in low birth weight, and hypertensive offspring [Lindsay et 
al., 1994b], actions which are dependent on the presence of intact maternal adrenal 
glands [Lindsay & Seckl 1994]. 
How glucocorticoids might programme adult hypertension is obscure but perinatal 
programming (imprinting) is well recognised for glucocorticoids and other steroid 
hormones. The potential mechanisms are discussed in detail in 1. 1. 3. But what 
about the malnutrition hypothesis? Malnutrition is a stress, and thus leads to 
increased glucocorticoid levels, but additionally, protein malnutrition in pregnant 
rats (which also leads to offspring hypertension [Langley & Jackson 1994]) has 
recently been shown to potently depress placental 11B-HSD activity [Phillips et al., 
1994], potentially marrying the two hypotheses. 
The findings here that firstly, the placental enzyme activity on a per gram basis is 
lowest in the heaviest placentas (r = -0.63, p < 0.00001), and secondly, that these 
heaviest placentas correspond to the lightest foetuses, are intriguing. These 
animals are likely to be exposed to the greatest amount of maternal glucocorticoid. 
Supporting the view that this is not a spurious relationship, are the epidemiological 
- 118 -
Rat P/acenta/11 6-HSD: Discussion 
data on the prediction of higher blood pressure levels by the combination of low 
birth weight and high placental weight [Barker et al., 1990], exactly the pattern 
found here. 
Not all the epidemiological studies have found this, and the mechanism of 
disproportional placental enlargement remains unexplained; rather than being a 
direct glucocorticoid effect on the placenta it could be secondary (or compensatory) 
to a failure of foetal growth as observed in hypoxia and anaemia [Alexander 1978; 
Godfrey et al., 1991]. The work of Robinson, Owens and De Barro [Robinson et 
al., 1994] might also provide an explanation. They have shown in sheep, that the 
response of the placenta to malnutrition at mid-pregnancy is critically dependent on 
the nutritional state of the mother at conception. Compared to well fed ewes (at 
mating and throughout pregnancy), the foetal/placental weight ratio was lower 
(relative placental enlargement) if the ewes were light (malnourished) at mating, 
with the ratio even lower if those malnourished ewes received unrestricted nutrition 
during mid-pregnancy. 
The foetus itself has also been shown to independently regulate placental growth 
and placental IGF-2 production [Putney et al., 1991]. This pattern of low birth 
weight and high placental weight, is found in offspring of rats made diabetic with 
streptozotocin [Robinson et al., 1988; Canavan & Goldspink 1988], an 
experimental model where maternal glucocorticoid levels are markedly raised 
[Helier et al., 1988]. Interestingly, this model has elevated foetal expression of 
IGF binding proteins 1 and 2 [Ooi et al., 1990], but glucocorticoids potently 
regulate IGF-2, the type 1 IGF receptor and binding proteins 1 and 2 [Li et al., 
1993; Price et al., 1992]. 
The findings discussed in the previous paragraphs, are based on enzyme activity 
per gram of placental homogenate. This standardisation allows comparison of 
different placentas. A weakness is of course that the placenta does contain a 
considerable amount of blood, which will be present in the homogenate, and thus 
contribute to its protein content. It is also possible that what is important for the 
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foetus, is not the enzyme activity per gram of placenta, but rather, total placental 
capacity to metabolise glucocorticoids. Multiplying the activity per g by the total 
placental weight, again showed a significant direct correlation with term foetal 
weight (r = 0.45, p < 0.0005). 
There are however problems with this approach. Thus (apart from the question of 
blood content raised above), there might be areas in the placenta, which do not 
contain any enzyme activity and therefore total wet placental weight might be 
misleading. Of course no association can be sought, using this approach, for 
placental weight and total placental activity as placental weight is a major 
component on both sides of the equation. The only way of sorting this out 
conclusively would be to do perfusions of intact placentas, preferably in-vivo, and 
at different stages of gestation. That would also bypass any potential problems 
with isoform contributions, cofactor preferences and the predominant direction of 
the reaction. 
What then is the role of 1113-HSD-1 in the placenta? Although the precise role of 
the vacuolated glycogen cells in the basal zone of the rat placenta (where 1113-
HSD-1 protein and mRN A is present - bioactivity was also found in the basal zone) 
is not clear, the presence of glycogen and the eo-localisation of 1113-HSD-1 protein 
and mRNA to these cells, proposes a role for 1113-HSD-1 in placental energy 
metabolism. Another potential role is in placental growth (see above), since 
insulin-like growth factor 2 (IGF-2), which has been shown to be important in 
placental growth [Barker et al., 1993a; Li et al., 1993], is regulated by 
glucocorticoids [Price et al., 1992]. Also, a modulatory role in placental 
steroidogenesis is conceivable by analogy to the testis and ovary [Michael et al., 
1993b; Monder et al., 1994a]. 
As regards the labyrinthine zone, where both 1113-HSD-1 protein and mRNA are 
present in the barrier between the maternal and foetal circulations, the potential 
role is intriguing. Does it function as a reductase as has been proposed elsewhere 
[Duperrex et al., 1993; Low et al., 1994; Moore et al., 1993]? Are 
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glucocorticoids needed for foetal growth? Or does it operate there as a 
dehydrogenase, as it appears to do in the testis [Monder et al., 1994a; Monder et 
al., 1994b ]? Some evidence for a placental reductase is available from studies in 
the baboon, where overall placental 11B-HSD activity seems to favour generation 
of active glucocorticoids at mid-gestation, but at term the reverse [Pepe & Albrecht 
1984b]. This seems to be regulated by oestrogens, and may serve to regulate the 
development of the foetal hypothalamic-pituitary-adrenal axis [Pepe et al., 1988]. 
In summary, some evidence has been presented here implicating a role for 
placental 11B-HSD in the development of adult disease, particularly hypertension. 
There are however some problems, and it was felt important to look at this 
question in humans, where the epidemiological observations had been made. Thus 
a study of human placental 11B-HSD was undertaken, although some of the 
problems encountered here with homogenates would be likely to crop up again. 
Thus only looking at intact fresh human placenta would be likely to provide 
conclusive answers. 
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5. HUMAN PLACENTAL 11 B-HSD IN-VITRO 
5.1. INTRODUCTION 
In humans, low birth weight, sometimes in association with high placental weight, 
predicts higher blood pressures in later life. This is observed already at a few 
weeks of age and the association grows stronger with the age of the population 
studied [Law et al., 1993]. We put forward the hypothesis that this association 
might be due to relative glucocorticoid excess in-utero, caused by a dysfunction of 
the presumptive placental glucocorticoid barrier, 11B-HSD [Benediktsson et al., 
1993; Edwards et al., 1993a]. 
In support of this hypothesis we demonstrated in the rat (Section 4) a strong direct 
association between placental 11B-HSD activity in-vitro and term foetal weight (r 
= 0.42; p < 0.0005) and a negative association with term placental weight (r = -
0.63; p < 0. 00001). The foetuses presumably exposed to the greatest amount of 
maternal glucocorticoids (low placental 11B-HSD activity) were not only smallest 
but also had the largest placentas, which is the pattern predicting higher human 
blood pressures in some studies (not all epidemiological studies have demonstrated 
the inverse relationship between adult blood pressure and placental weight; a 
mechanism explaining this variation is lacking). In addition we could induce 
offspring hypertension in rats by treating the pregnant mothers with dexamethasone 
[Benediktsson et al., 1993], and moreover, treatment of pregnant rats with 
inhibitors of 11B-HSD (carbenoxolone) also resulted in low weight offspring which 
went on to develop adult hypertension [Lindsay et al., 1994b; Lindsay et al., 
1994a; Lindsay & Seckl 1994]. 
At least two isoforms of 11B-HSD exist. 11B-HSD-1, initially purified from liver, 
is a reversible, NADP dependent enzyme that may predominantly reactivate inert 
cortisone (or 11-dehydrocorticosterone) [Duperrex et al., 1993; Low et al., 1994; 
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Moo re et al., 1993]. In contrast, the human placenta expresses a distinct high 
affinity predominantly NAD dependent [Brown et al., 1993] isoform, 118-HSD-2 
(the rat placenta also expresses predominantly this isoform: Section 4.3.1), that 
appears from in-vitro studies, to have biochemical properties appropriate to allow 
effective metabolism of the maternal cortisol load [Brown et al., 1993], protecting 
the human foetus from maternal cortisol throughout pregnancy [Murphy et al., 
197 4; Beitins et al., 1973; Pasqualini et al., 1970; Blasco et al., 1986]. However, 
this barrier appears not to be complete, some maternal cortisol reaching the foetus, 
and the relationship if any between placental 118-HSD efficiency in-vivo and foetal 
growth in man is unknown. 
It was of course important to try and determine if placental 118-HSD played a 
similar role in humans as it appeared to do in the rat. In order to address this it 
was necessary to examine whether human placental 118-HSD activity was related 
to foetal and placental growth, and to look at the relationship between human 
placental 118-HSD activity and markers of foetal glucocorticoid exposure. It was 
also important to determine whether any other enzymes metabolised cortisol in the 
human placenta, (i.e. whether 118-HSD was in fact the placental glucocorticoid 
barrier) and whether the correlation with birth weight (if found) was a general 
phenomenon, observed with any enzyme, or specific to 118-HSD. 
There was a catch however; 118-hydroxysteroid dehydrogenase activity in either 
homogenised or whole rat placentas is very unstable in-vitro (Figure 4.4). This 
instability has also been observed for human placental homogenates [Brown et al., 
1993; Lakshmi et al., 1993]. Any in-vitro data (in homogenates) has therefore to 
be interpreted with care, and it would be of key importance to supplement any in-
vitro enzyme activity studies with data obtained using different methodologies more 
closely related to the in-vivo function of the intact placenta. One such method, 
which is thought to closely mimic the in-vivo situation, is the "ex-vivo human 
placental cotyledon perfusion" of freshly isolated intact placentas. This approach 
was therefore developed (see Section 6). Section 7 deals with in-vivo markers of 
glucocorticoid exposure and human placental 118-HSD. Nevertheless, the 
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remainder of this Section reports data from the initial studies which estimated 11B-
HSD activity in homogenates of human placenta, using the same methodology as 
used in the rat. In an attempt to see if any correlation with birth weight was a 
general phenomenon (not specific for 118-HSD), 2 other enzymes known to be 
stable on storage (Dr. T. Bramley) were assayed, namely alkaline phosphatase 
(ALP) and N-y-L glutamyl B-naphthylaminidase (GNA), both membrane markers, 
unrelated to steroid or fuel metabolism. 
5.2. METHODS 
5.2.1. Subject Selection and Sample Collection 
Validation experiments were carried out on freshly isolated human placentas 
obtained from the Simpson Memorial Maternity Pavilion in Edinburgh. 
Immediately following delivery the placenta was put in a plastic bag, cooled on ice 
and used as soon as possible. For correlation of enzyme activity with birth weight 
we had the opportunity to take part in a prospective study in collaboration with 
Professor Barker's group in Southampton. This was an ongoing study which 
involved collecting placental samples from 528 consecutive singleton deliveries. 
At delivery, placental and birth weights were measured in a standardised manner. 
Trophoblast specimens (1 -2 g) were taken from a healthy looking part of each 
placenta and immediately frozen and stored at -70 °C. These samples were then 
used to study in-vitro 118-HSD, ALP and GNA activities in trophoblast 
homogenates. 
5.2.2. Assays 
Assay methodology is described in detail in Section 2.4. In brief, trophoblast 
samples were homogenised in KRB, the protein content of the homogenate 
estimated according to the method of Bradford [Bradford 1976], and a portion of 
the homogenate immediately frozen at -70°C for assay of ALP and GNA activities. 
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The 11B-HSD enzyme assays were carried out in duplicate incubations at 37 °C. 
In preliminary validation studies, assay conditions were defined. Optimal 
conditions were defined as being on the linear part of the "rate of reaction curve" 
for time, cofactor and protein concentrations (see below). The total incubation 
volume was 250 Jll and incubation of buffer alone provided an assay blank. As an 
internal standard to allow inter-assay coefficient of variation (CV) to be calculated, 
individually frozen samples from the same fresh placenta were defrosted on the day 
of each assay. The incubation was started by adding tritiated steroid (12 nM 3H-
cortisol) and terminated by adding 2.5 ml of ethyl acetate, which also served to 
extract the steroids before separation with automated HPLC (Section 2.4). 
The assays for ALP and GNA were validated and carried out by Dr. T. Bramley at 
the Centre for Reproductive Biology, Edinburgh. These were both photometric 
assays (described in Section 2.4), both enzymes are stable on storage at -70 °C. 
5.3. RESULTS 
5.3.1. 11 B-HSD Bioassay Evaluation 
There was a clear cofactor preference in the rat placental 11B-HSD assay, the 
enzyme favouring NAD as shown in Figure 4.1. In order to ascertain the 
preference of human placenta using this methodology, fresh human placental 
homogenate was incubated in the presence of variable concentrations of NAD and 
NADP. As in the rat, there was a preference for NAD (Figure 5.1). 
Evaluation studies for fresh human placental 118-HSD activity are shown in Figure 
5.2, where cofactor concentration is 40 JlM and 3H-cortisol was 12 nM. The 
progress of reaction at 0.2 mg/ml was linear for up to about 15 min, as shown in 
the left hand panel. The right hand panel plots the effect of increasing protein 
concentration for an incubation time of 15 min. The reaction progress is linear for 
protein concentration up to 0.4 mg/ml. The conditions chosen for future assays 
were 40 JlM NAD, 12 nM 3H-cortisol, 0.2 mg/ml protein, incubated for 10 min. 
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Figure 5.1 Cofactor Preference of Human Placental118-HSD In-Vitro 
Enzyme activity of 1111-HSD expressed as % conversion F to E without cofactor added and at three 
different final concentrations of NAD and NADP. Each column represents the mean of 3 experiments. 
Bars indicate SEM. Placental samples were incubated in duplicate. Protein content was 0.5 mg/ml, 
3H-cortisol was 12 nM final, incubated for 60 min at protein concentration of 0.5 mg/ml. 
As the samples were kept frozen, it was important to show that the enzyme activity 
could be preserved on storage and that the enzyme behaved similarly in thawed 
specimens and fresh. Thus before embarking upon the collaborative study on birth 
weight, 4 placentas were assayed fresh and several samples from those placentas 
(whole trophoblast) then individually frozen. These specimens were thawed, 
homogenised and assayed with the same conditions as when fresh on a number of 
occasions. As shown in Figure 5.3, the activity was apparently stable for up to 35 
days (p = 0.68 on ANOVA). The frozen-thawed placentas were then taken 
through the same series of experiments as presented in Figure 5.2, in order to 
check whether the assay conditions were still appropriate. These data are 
presented in Figure 5.4, which shows that the previously chosen assay conditions 
still are on the linear part, the curves on both panels showing remarkable 
similarity. The same assay conditions were thus chosen for determining llB-HSD 
activity in both fresh and frozen-thawed trophoblast specimens, including the study 
on birth weight in collaboration with Professor Barker's group. 
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Figure 5.2 Human Placental 116-HSD In-Vitro Assay: Fresh Trophoblast 
Each curve in the left hand panel indicates progress of reaction with time at different protein 
concentrations. From top 1.6 mg/ml, 0.8 mg/ml, 0.4 mg/ml, 0.2 mg/ml (solid line with error bars), 0.1 
mg/ml, 0.05 mg/ml. For clarity, error bars are omitted from and dotted lines indicate each protein 
concentration except for 0.2 mg/ml. The right hand panel shows progress of reaction at 10 m in for 
different protein concentrations. Each point is n = 3, error bars indicate mean ± SEM. 3H-cortisol was 
12 nM final and NAD was 40 ~M final. 
Recovery of label was 91%, CV was 14% (n = 10). Intra-assay CV was 3% 
(fresh placenta, n = 10) and inter-assay CV 18% (frozen trophoblast samples, n = 
31). Only one product was detected, i.e. the only two peaks on the HPLC were 
cortisone and cortisol. The question of inhibition with known inhibitors of 118-
HSD (glycyrrhetinic acid and/or carbenoxolone) had been addressed for the rat in 
Section 4. 3.1, and for humans it was more important to assess the effect of those 
inhibitors on the enzyme in the ex-vivo perfusion (Section 6.3.2). No reductase 
activity (conversion of 11-dehydrocorticosterone to corticosterone) was detected 
with 40 p.M NADH and 12 nM 3H-11-dehydrocorticosterone. 
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Figure 5.3 Short Term Storage of Human Placental116-HSD 
Storage at time = 0 (the column farthest to left) is 11 11-HSD activity in fresh placentas. The activity 
remained unchanged for up to 35 days (as judged by ANOVA, p = 0.68) compared to fresh activity. 
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Figure 5.4 Human Placental 116-HSD In- Vitro Assay: Stored Trophoblast 
Each curve in the left hand panel indicates progress of reaction with time at different protein 
concentrations. From top 1.6 mg/ml, 0.8 mg/ml, 0.4 mg/ml, 0.2 mg/ml (solid line with error bars), 0.1 
mg/ml, 0.05 mg/ml. For clarity, error bars are omitted from and dotted lines indicate each protein 
concentration except for 0.2 mg/ml. The right hand panel shows progress of reaction at 10 m in for 
different protein concentrations. Each point is n = 3, error bars indicate mean± SEM. 3H-cortisol was 
12 nM final and NAD was 40 !JM final. 
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5.3.2. Birth Weight and Human 11 B-HSD In-Vitro 
Overall details of the study subjects are shown in Table 5.1. Note that the full data 
set was not available for all 528 enrolled subjects. 522 had placental samples 
taken. The spread of both birth weights and placental weights is very large. Birth 
weight was significantly correlated with length of gestation (r = 0.56, p < < 10-6, 
n = 524), and with placental weight (r = 0.60, p < < 10-6). The activity of 11B-
HSD was expressed in the conventional way as % conversion of substrate to 
product ([Efp + E] x 100). The activities of ALP and GNA were expressed as 
nmoles/minfmg protein. Mean 11B-HSD activity was 16.6% under the conditions 
used, and showed considerable variation (SD = 10.6). No correlation was found 
between birth weight in the total study population and placental 11B-HSD activity 
(Figure 5 .5). This result along with the data for ALP and GNA correlations are 
summarised in Table 5.2. As for 11B-HSD, no correlation was found with birth 
weight. No correlations were found between any enzyme and placental weight. 
Table 5.1 Human 116-HSD In-Vitro: Study Details 
Variable N Mean Range SEM 
Length of gestation [weeks] 524 39.9 28.0-43.4 0.1 
Birth Weight [kg] 524 3.38 1.24- 5.02 0.01 
Placental weight [g] 517 519 215 - 1048 5 
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Table 5.2 Human 118-HSD In- Vitro: Pearson's Correlation Coefficients 
Enzyme N Birth Weight (p) Placental Weight (p) 
I 
11B-HSD 500 - 0.05 (ns) - 0.02 (ns) 
ALP 495 + 0.01 (ns) - 0.08 (ns) 
GNA 497 + 0.08 (ns) + 0.08 (ns) 
6 
5 0 0 0 0 0 
0 0 0 
0 
g 0 0 0 0 0 
c; 
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Figure 5.5 Human Birth Weight and 118-HSD Bioactivity In-Vitro 
The figure plots net (duplicate mean minus blank) 1111-HSD activity for 500 placentas prospectively 
collected in Southampton in collaboration with Professor Barker's group. The solid line through the 
data points represents the regression line while the dotted lines indicate 95% confidence intervals for 
the regression. Pearson's r =- 0.05, pis ns. 
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A few confounding factors are present. Firstly, 235 of the women had had a 
previous live birth. As birth weight tends to increase with successive pregnancies, 
this would serve to obscure any correlation of 118-HSD activity and birth weight. 
Also, 19 babies whose placental 118-HSD activity was available, had birth weights 
< 2500 g (19 had placental sampling), the traditional value separating frankly low 
birth weight babies from normals - this would again serve to obscure any 
correlation of 118-HSD and birth weight. There was however no difference in 
118-HSD activity between the normal and low birth weight groups (data not 
shown). The low weight babies also had significantly lower gestational age than 
the normals (36.0 ± 0.7 weeks vs. 40.0 ± 0.1 weeks normals, p < 0.0000001). 
Nine of the 19 were small for gestational age, but showed no difference in 118-
HSD activity when compared to those not small for gestational age. By 
categorising babies born within 38 - 42 weeks as either small for gestational age 
(birth weight < lOth percentile; n = 41) or normal (n = 385) and then looking at 
118-HSD activity, no difference was found. Taking all of the above into account, 
i.e. analyse those with normal length of gestation (38 - 42 weeks), including only 
first deliveries between lOth and 90th percentiles (birth and placental weights), there 
was no correlation of 118-HSD activity and birth weight (n = 150). 
As discussed in the Section on rat placental 118-HSD, a more relevant estimate of 
placental glucocorticoid metabolic capacity may be the total placental activity, 
obtained by multiplying the activity per gram placental homogenate with total wet 
placental weight. This showed a significant correlation with birth weight (r = 
0.16, p < 0.0005, n = 515), but one has to bear in mind that placental weight was 
strongly positively correlated with birth weight (see above). This correlation is 
therefore meaningless. 
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Figure 5.6 Long Term Storage of Human Placentall16-HSD 
Samples have been categorised according to storage time (6 - 15 months) into 8 equally long time 
periods. The oldest category is 1 (to the left), the most recent samples in category 8. The points 
(fitted line) indicate mean 11 11-HSD activity for each category. The shaded area denotes the range 
(minimum - maximum) of 11 11-HSD activities in each category. Note the marked trend for less 
variability in the older sample categories when compared with the more recent categories. This is due 
entirely to lower maximum values, while the mean for each group is constant. 
Finding no correlation of birth weight with term placental 11B-HSD activity m 
humans was disappointing. Was there an explanation? Was it possible that the 
samples were not stable on long term storage? Was the pilot study on trophoblast 
stability flawed - too short term? Although there was no correlation between the 
age of the samples and 11B-HSD activity (the youngest sample was 6 months old , 
and they spanned 15 months), analysing them in a slightly different way generated 
an interesting result. For this analysis , the samples were divided into 8 groups , all 
representing equally long time intervals . There was no difference in the mean 11B-
HSD activity in these groups , but there was a definite trend in the variability of the 
llB-HSD values (Figure 5 .6) . Thus the oldest samples had much less variability in 
llB-HSD activity . It therefore seemed that some of the samples, notably those 
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with high initial llB-HSD activity were deteriorating. In order to test the 
hypothesis that the samples with the highest original llB-HSD activity were in fact 
deteriorating, a random sample was assayed twice with approximately 2 months 
separating the two assays. The result is shown in Figure 5. 7. It is clear from this 
experiment that some but not all of the samples are deteriorating. In fact, the 
samples with the highest initial activities (x - axis) seem to lose greatest amount of 
activity. Thus the fitted line departs more and more from the x = y dotted line as 
the initial enzyme activity is higher. 
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Figure 5.7 Repeat 118-HSD Assay of Stored Human Trophoblast 
29 placentas were selected at random and assayed twice, approximately 2 months apart. The 
horizontal x - axis indicates 11 11-HSD activity at first assay and the vertical y - axis indicates 11 11-HSD 
activity at re-assay two months later. The solid line is "least squares" fitted through the data points 
while the dotted line indicates x = y. 
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5.4. DISCUSSION 
The data presented here on cofactor preferences of human placental 11B-HSD are 
in keeping with the notion that human placenta expresses predominantly an NAD 
dependent 11B-HSD isoform (BROWN 1993}. There seems to be considerable 
endogenous 11B-HSD activity (without adding cofactor) which is in contrast to the 
observations on rat placenta in-vitro (Section 4.3.1). As in the rat placenta, some 
NADP dependent dehydrogenase activity was found. 
No reductase activity was found in the current study confirming other researchers' 
results, namely that placental 11B-HSD predominantly is an steroid inactivating 
dehydrogenase [Brown et al., 1993] protecting the human foetus from maternal 
glucocorticoids throughout pregnancy [Murphy et al., 1974; Pasqualini et al., 
1970; Dancis et al., 1978; Beitins et al., 1973]. It is however not possible from 
the data presented here, to exclude the presence of 11B-HSD-1, especially in light 
of positive immunohistochemistry and presence of mRNA for 11B-HSD-1 in the rat 
placenta throughout gestation as shown in Section 4.3.3 (although in the rat as in 
humans, there is no detectable reductase bioactivity in-vitro). 
Therefore, as the mRNA is translated into protein (positive immunohistochemistry 
in the rat) either the reductase component is inactive due to special intracellular 
conditions, or it acts as 11B-HSD-2, as a dehydrogenase. The third possibility 
would be degeneration of the reductase with tissue homogenisation, since the 
reductase has previously been found to be more sensitive to tissue manipulation 
than the dehydrogenase, [Lakshmi et al., 1993; L6pez Bernal et al., 1982a]. 
Finally it is possible that both isoforms are present and active, 11B-HSD-1 as a 
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reductase and 118-HSD-2 a dehydrogenase, the latter being more active and thus 
using the current methodology, it would not be possible to detect any production of 
3
H-cortisol as it is immediately converted back to 3H-cortisone. 
It should however be kept in mind that there seem to be important inter-species 
differences present, as in the baboon considerable reductase activity can be 
detected in the placenta at mid-gestation [Pepe & Albrecht 1984b], in contrast to 
data from humans in-vitro, in-vivo, and using ex-vivo perfusion [Brown et al., 
1993; Blasco et al., 1986; Dancis et al., 1978; Murphy et al., 1974; Pasqualini et 
al., 1970; Beitins et al., 1973]. 
The lack of correlation of placental 11B-HSD activity with birth weight was 
disappointing for several reasons. Firstly, the epidemiological data presented by 
Professor Barker's group on birth weight and ischaemic heart disease (including 
blood pressure) is very strong and has been repeatedly observed by that group in 
several different populations at different ages. The same observations have also 
been made by other authors in populations with distinct genetic background 
[Seidman et al., 1991; Gennser et al., 1988]. Secondly, although the mechanism is 
not proven, several lines of evidence point to a possible role of maternal 
glucocorticoids in this respect - see the rat placental 11B-HSD data presented in 
Sections 4 and 1.1.3. 
Further support comes from unpublished observations which show that the effect of 
11B-HSD inhibitors (reduction in birth weight), can be prevented by maternal 
adrenalectomy [Lindsay & Seckl 1994]. Finally, new data are emerging, 
indicating that 11B-HSD might be a final common pathway by which more than 
one stimulus can induce offspring hypertension, since maternal protein malnutrition 
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during pregnancy, which reduces birth weight and results in hypertensive offspring 
[Langley & Jackson 1994], appears to impair placental 11.B-HSD activity [Phillips 
et al., 1994]. 
Of lesser concern was the fact that no correlation was found between placental 
weight and placental 11.B-HSD activity. The phenomenon of low birth weight and 
high placental weight has been inconsistent and sub-analysis of some of the studies 
has allowed identification of several patterns of birth and placental weights 
predicting hypertension (see Section 1 for further discussion). Thus, birth weight, 
although a crude measure of foetal growth is probably the prime index which 
should be used for the analysis. 
Finding a highly significant, albeit weak (r = 0.16, p < 0.0005, n = 515) 
correlation of birth weight with "total placental" 11.B-HSD activity is not 
unexpected, but is meaningless, as "total placental" 11.B-HSD activity is obtained 
by multiplying 11.B-HSD activity per gram homogenate protein, with wet placental 
weight. As birth weight showed a strong and significant correlation with placental 
weight (r = 0.60, p < < 10-6), the correlation of "total placental" 11.B-HSD is 
attributable to the placental weight - birth weight correlation. Also, the protein 
content of the homogenate may not represent placental protein only (blood etc.) 
and areas not available for materno-foetal exchange, possibly devoid of 11.B-HSD, 
may have been included in the homogenate. Similarly, any correlations of 
placental weight with "total placental" ll.B-HSD activity will be meaningless. 
However, as mentioned in the introduction to this Section, the problem 
encountered here (lack of correlation of birth weight and placental ll.B-HSD 
activity), is not entirely unexpected as there are important differences between the 
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methodology used in the rat experiments and those used in this Section on human 
placental 1113-HSD in-vitro. The difference which is most likely to explain the 
discrepancy in correlations is the fact that placental 1113-HSD is unstable on 
storage, and for the rat studies fresh placentas were used, while frozen-thawed 
trophoblast was used in this Section on human placenta. 
Although part of the validation studies in this Section concerned storage of the 
placental tissue, they might not have been extensive enough. For example the 
storage experiment (Figure 5.3) looked at storage over 35 days while the placental 
trophoblast samples from Southampton were collected over a 15 month period, the 
youngest being 6 months old when assayed. Thus sample deterioration (after 35 
days storage - which might then be accelerated) was possible and is in fact highly 
likely as judged by Figure 5.6, where the oldest samples seem to exhibit less 
variability of 1113-HSD activity. This was then confmned (Figure 5.7) by showing 
that the initially high 1113-HSD activity samples, specifically deteriorated over a 
two month period, while the initially low activity samples remained unchanged. 
Furthermore, although in the short term, the kinetics of the 1113-HSD assay were 
similar using fresh and frozen specimens, that validation rests on a small number 
of sample placentas which had roughly similar (and low) activities. Thus even 
though assay conditions were on the linear part of the reaction progress curve, the 
variation might have been too small to enable differences to be detected over the 
course of a few days (bear in mind that the range of placental 1113-HSD activities 
in the study itself was considerable, and age of specimens variable, ranging from 6 
to 21 months). 
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Thus it is most likely that human placental 11B-HSD is unstable on long term 
storage at -70 oc as other authors have previously suggested [Lakshmi et al., 
1993; L6pez Bernal et al., 1982a; Brown et al., 1993]. Possibly there are labile 
and stable parts of the enzyme, the loss of the labile form resulting in the initially 
high activity specimens losing more activity. Thus all the samples would "settle" 
at a similar low level of activity -as was indeed found. 
This problem can only be resolved by using fresh human placental homogenates, 
which is impossible on the scale of this study. Therefore it is even more important 
to look at 11B-HSD activity with the ex-vivo perfusion methodology where intact 
placentas are used. The results of such a study are described in Section 6. An 
important aspect of this later study is comparison of the activity of placental 11B-
HSD activity ex-vivo with that in-vitro in frozen-thawed stored specimens of the 
same placenta. 
It is tempting to maintain that the lack of correlation of birth weight with either 
ALP or GNA signifies that the correlation of birth weight with 11B-HSD activity 
described for the rat is specific and not a general phenomenon. In the light of the 
results on human 11B-HSD described/discussed here, that is however not 
appropriate. 
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6. HUMAN PLACENTAL 11 B-HSD EX-VIVO 
6.1. INTRODUCTION 
Several recent epidemiological studies have consistently implicated prenatal events 
in the development of common adult cardiovascular and metabolic disorders. 
Thus, low birth weight is strongly predictive of the later occurrence of 
hypertension [Barker et al., 1990; Law et al., 1993]. The link between low birth 
weight and hypertension has been demonstrated in several distinct populations and 
holds in children [Law et al., 1991; Cater & Gill 1984; Barker et al., 1989a], 
adolescents [Seidman et al., 1991] and adults [Gennser et al., 1988; Barker et al., 
1989a; Barker et al., 1990]. Indeed, the well-recognised "tracking" of blood 
pressure from infancy to adulthood in man [Lever & Harrap 1992] clearly 
implicates early events in the determination of blood pressure throughout life. 
The mechanisms linking prenatal events and later disease are unknown, although 
maternal malnutrition has been advocated [Barker et al., 1993a]. We advanced the 
hypothesis that glucocorticoid excess in-utero might be important [Edwards et al., 
1993a], as glucocorticoids retard foetal growth and treatment of pregnant rats with 
dexamethasone resulted in elevated offspring blood pressure [Benediktsson et al., 
1993]. The mode of glucocorticoid action is unclear, but steroids, including 
glucocorticoids, exert well-recognised pre- or perinatal effects determining tissue 
maturation [Slotkin et al., 1992b; Slotkin et al., 1992a] and permanently 
programme anatomy, biochemistry and function [ Seckl 1994]. 
The foetus is thought to be protected from maternal glucocortcoids by the placental 
enzyme 11B-hydroxysteroid dehydrogenase (11B-HSD) [Murphy et al., 1974; 
Beitins et al., 1973]. In support of our hypothesis we found that placental 11B-
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HSD shows considerable natural variation in the rat, with the lowest activity (and 
presumably the greatest foetal exposure to maternal glucocorticoids) in the smallest 
offspring (Section 4) [Benediktsson et al., 1993]. Moreover, when pregnant rats 
are treated with an 118-HSD inhibitor, birth weight is reduced and the adult 
offspring blood pressure raised [Lindsay et al., 1994b]. 
When the same in-vitro methodology that had been used in the rat experiments was 
applied to human placentas (Section 5), the results were very disappointing in that 
no correlation was found between birth weight and placental 11B-HSD activity in 
frozen-thawed term trophoblast samples. The explanation for this was most likely 
(as discussed in Section 5 .4) to be instability of 11B-HSD when stored at -70 °C. 
It was therefore of key importance to look at 118-HSD function in fresh placentas, 
preferably using methodology where the question of which 11B-HSD isoform to 
look at, could be bypassed, and importantly, where placental anatomy (the 
physiological glucocorticoid barrier) was intact. 
For this purpose, ex-vivo dual circuit cotyledon perfusion of freshly isolated intact 
human placentas was undertaken. This methodology has been extensively used for 
looking at various aspects of placental physiology including glucocorticoid 
metabolism [Addison et al., 1993; Addison et al., 1991; Dancis et al., 1980; 
Dancis et al., 1978; Dodds et al., 1993; Levitz et al., 1978; Smith et al., 1988]. 
The studies on glucocorticoids have used both open- and re-circulating maternal 
and foetal perfusates and have looked at both naturally occurring and synthetic 
glucocorticoids. All studies agree on extensive inactivation of the relevant 
steroids, all however used supraphysiological concentrations (p,M range) of free 
steroid (the concentration used was not clearly stated in some), and some have in 
fact invoked other enzymes than 11B-HSD in the metabolism of cortisol [Dodds et 
al., 1993] and prednisolone [Addison et al., 1991] in human placentas, casting 
doubt on the crucial barrier role of 11B-HSD. 
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Before carrying out a formal study on human placental 1113-HSD activity and birth 
weight using this methodology, it was necessary to carry out validation studies, for 
example looking at the behaviour of cortisol transport, the viability of the 
preparation, and to address the question whether 1113-HSD was in fact the placental 
glucocorticoid barrier. 
6.2. METHODS 
6.2.1. Subject Selection 
To develop and validate the ex-vivo perfusion methodology, term placentas were 
taken at random. Pregnancies complicated by hypertension, smoking, hepatitis B 
or HIV infections were excluded. 
To study the relationship between birth weight and placental 1113-HSD activity, 20 
consecutive singleton, term, first pregnancies were enrolled during the 3rd 
trimester. All women gave informed consent to the study, which was fully 
approved by the local Ethics of Medical Research Committee. Exclusion criteria 
were smoking, alcohol consumption, drug abuse, chronic illness including 
bronchial asthma, the presence of high risk infections (hepatitis B, HIV), regular 
medication of any kind or pregnancy-induced hypertension (blood pressure > 
140/90 mmHg or increase of > 30/15 mmHg compared to the first trimester). 
Data are presented for 16 subjects, whose placentas were successfully perfused. 
Two were excluded because the placentas were very tom at delivery and had gross 
fluid leaks, and two had high foetal circuit pressures (see below). Birth weight 
was recorded to the nearest 5 g in a standardised manner within 1 h of delivery and 
total wet weight of the placenta was measured to the nearest gram after careful 
removal of the umbilical cord and membranes. 
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6.2.2. Perfusion System 
The methodology has been described in detail in Section 2.8. Briefly it was based 
on the description by Schneider [Schneider et al., 1972; Schneider & Huch 1985]. 
On delivery the placenta was immediately immersed in ice-water (protected by a 
plastic bag). Handling of the placenta at delivery was performed with extreme care 
and minimised. A suitable pair of chorionic vessels supplying a well-defined and 
macroscopically-intact cotyledon were cannulated and sutured in place. 
Occasionally, when vessel anatomy dictated, collaterals to adjacent cotyledons 
were tied off. The foetal circulation was started slowly, increasing to 6 ml/min 
(higher foetal flow rates resulted in foetal fluid loss and altered morphology on 
electron microscopy - this flow rate compares with several other investigators). 
This allowed the perfused cotyledon to be identified, isolated and embedded in a 
custom-made plexiglas perfusion chamber. 
The congruent area on the maternal side of the cotyledon, identified by virtue of 
slight blanching, was pierced to a depth of 1 - 2 cm using two 21 G cannulae and 
the maternal circulation separately perfused at 10 ml/min. Both perfusates were 
modified Kreb's buffer (the foetal perfusate also contained dextran), the maternal 
gassed with 95% 0 2:5% C02, the foetal with 95% N2:5% C02 both warmed to 37 
°C. This gas composition used for the foetal perfusate is believed to be needed in 
order to retain morphological and biochemical integrity of the preparation [Kuhn et 
al., 1988]. The two separate circulations were driven by a multi-channel peristaltic 
pump. To maintain temperature, the entire perfusion chamber was housed in an 
incubator at 37 oc (see diagram of setup: Figure 2.3). No albumin or 
corticosteroid binding globulin was included in the perfusates as cortisol 
metabolism by llB-HSD is not affected by either protein [Dancis et al., 1978]. 
Circulatory overlap was assessed by visualisation of blanching on the maternal side 
after starting the foetal circuit and by observing the step-up of p02 across the foetal 
cotyledon using an blood gas analyser. The pressures in both circuits were 
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continuously recorded by in-line (afferent) transducers and computer-assisted 
monitoring. The temperature of both maternal and foetal perfusates was monitored 
using in-line thermocouples and a digital thermometer. In addition to timed 
collections of the foetal output, flow meters were included in the foetal afferent and 
efferent lines to allow immediate detection of any fluid loss from the foetal circuit. 
Perfusion was considered unsuccessful if no 0 2 step-up across the cotyledon 
(indicating no materna-foetal circuit overlap) was observed, if foetal circuit 
pressure exceeded 60 mmHg, (this has been suggested as essential for preservation 
of placental ultrastructure [Jauniaux et al., 1991]) or if a foetal circuit fluid leak 
was observed. The wet weight of the perfused cotyledon was obtained at the end 
of the experiment, after the perfused area had been defined by injecting ink into the 
foetal circulation. 
6.2.3. Sampling and Analytical Methods 
This has been described in detail in Section 2.8. Briefly, foetal outflow samples 
were collected over either 3 or 5 min intervals, and in the case of the prospective 
study over two consecutive 5 min intervals at steady state, and data averaged for 
analysis. 14C-antipyrine and steroids were extracted using a modification of the 
method described by Cannell [Cannell et al., 1982] for extracting steroids from 
plasma. Thus the foetal effluent samples, were centrifuged to pellet debris, 
acidified to pH 2 (checked with pH paper for each sample) with HCl, extracted 
through Sep-pak Plus cartridges (Waters, UK) and eluted with ethyl acetate. 
Cortisol, cortisone and antipyrine were separated and quantified using isocratic 
HPLC as described on page 85 and in Figure 2.1. Some of the perfusions did not 
include any labelled cortisol, but only cold; these were also analysed with HPLC 
but including standards with known amounts of steroids in each run allowing 
concentration of cortisol in the samples to be calculated as described in detail in 
Section 2.8.3). 
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The activity of 11B-HSD (the efficiency of cortisol inactivation) was determined in 
the conventional way as percent conversion cortisol to cortisone ([E/ (E+ F)l x 
100), in the foetal effluent per unit perfused cotyledon weight and also for total 
placental weight. Clearances were calculated as: (foetal concentration x perfusion 
flow rate )/maternal concentration. The glucocorticoid clearance index was total 
corticosteroid clearance/ antipyrine clearance. 
6.3. RESULTS 
6.3.1. Validation and Viability of the Preparation 
The placenta suffers an ischaemic insult at delivery and it has become customary to 
allow 30 - 60 min recovery period (no precise agreed guidelines exist in the 
literature as to which specific time to pick) after the perfusion has started, in order 
to allow various metabolic functions to recover. For the series of experiments 
presented here it was, in relation to this, felt appropriate to examine how much 
time was needed to allow near complete washout of endogenous glucocorticoids 
retained in the placenta (cortisol and cortisone). The pattern of washout of cortisol 
and cortisone is shown in Figure 6.1, which shows that both steroids are 
undetectable after 40 minutes. 
Further support for choosing at least 40 min as the washout/recovery period for all 
further perfusions came from studying the profile of lactate production by the 
perfused cotyledon in this setup (Figure 6.2). This study (n = 5) showed that 
lactate reached a nadir before 40 min and did not rise again during the perfusion 
period. 
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Figure 6.2 Pattern of Cotyledon Lactate Washout/Production 
The figure shows lactate concentration (mM) in foetal effluent with progress of perfusion. Lactate 
levels become undetectable before 40 min and do not rise during the following period of study (up to 
100 min). The horizontal dashed line identifies detection limit of the assay. Each point represents 
mean of data from 5 perfusions while bars represent ± SEM. 
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To confirm that the preparation was metabolically viable with respect to llB-HSD 
activity (or efficiency) for an extended period of time following delivery, 3 
placentas were perfused with 50 nM cold cortisol only, on the maternal side. The 
foetal effluent was collected over 3 min at intervals throughout the perfusion, 
including 2 collections during the washout period (t < 40 min, i.e. estimating llB-
HSD activity in-vivo from the ratios of endogenous cortisol and cortisone). As can 
be seen from Figure 6.3, llB-HSD activity remains constant throughout the 3 h 
period with no differences between individual samples detected by ANOVA. 
Apart from confirming the viability of the preparation, this has further 
implications, namely that the ex-vivo estimated llB-HSD efficiency is 
representative of in-vivo behaviour of llfi-HSD. As only cold cortisol was used, 
not all the samples could be analysed due to background interference on the HPLC 
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Figure 6.3 Stability of 116-HSD Activity in the Perfused Human Cotyledon 
The activity of 11 11-HSD in-vivo (estimated from the endogenous levels of glucocorticoids, the first two 
left columns - solid) is no different from the activity ex-vivo (ANOVA), i.e. after starting perfusion with 
50 nM cortisol on the maternal side (beyond 40 min - dotted columns). Placental 11 11-HSD in the 
perfused setting remains viable for 180 min. The width of the bars equals the collection period and 
represents the mean for 2- 3 perfusions while bars represent mean+ SEM. 
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Further data on the viability of the preparation came from histological specimens, 
taken immediately after perfusion (3 h) from the perfused cotyledon and adjacent 
non-perfused tissue. These were processed for light and electron microscopy, 
which confirmed ultrastructural integrity of perfused trophoblast cells, microvilli 
and subcellular organelles. Sections post 3 h perfusion were identical to sections 
from fresh placentas. U nperfused parts of the same placentas showed classical 
degenerative changes [Kaufmann 1985] with swelling of cells, vacuolation, swollen 
mitochondria and endoplasmic reticulum (Figure 6.4 and Figure 6.5). 
The final validation experiments addressed the kinetics of cortisol to cortisone 
conversion and transplacental passage. For this purpose 50 nM cold cortisol along 
with a tracer of 3H-cortisol ( < 0.5% of total cortisol) was used since using cold 
steroid alone hampered analysis of samples due to background "noise" or 
interference by unknown substances in the perfusates. However, there was the 
possibility of an "isotope" effect, the placenta handling 3H-cortisol differently from 
cold cortisol. To examine this, a 40 min washout period was allowed as before, 
followed by perfusion with exogenous cortisol mixture from 40 to 80 min. The 
foetal effluent was collected over continuous 5 min periods and the results 
expressed as concentration of tracer eH -cortisol and 3H -cortisone) in the perfusates 
in counts per ml (Figure 6.6). 
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Figure 6.4 Light Microscopy Photomicrographs of Human Placenta 
The figures show a remarkable conservation of morphology after 3 h perfusion (bottom) as compared 
to unperfused section of the same placenta (top) . 
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A 
Figure 6.5 Electron Microscopy Photomicrographs of Human Placenta 
Part A shows trophoblast from an unperfused fresh placenta fixed within 20 min of delivery. Part B 
shows a section of trophoblast from a placenta which has been perfused as detailed in the text for 3 
h. Note absent vacuolation and normal looking endoplasmic reticulum and mitochondria, while in Part 
C which is a section from an adjacent non-perfused cotyledon of the same placenta vacuolation , and 
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Figure 6.6 Kinetics of 3H-Cortisol Transfer and Metabolism During Perfusion 
Top is maternal circuit concentration of 3H-cortisol. Middle is foetal effluent counts/m! of cortisol (black 
area outlines mean ± SEM) and cortisone (lightly shaded area) . Bottom is 11 B-HSD activity. Solid 
lines are fitted through the mean (circles, n = 4) while the dotted lines are fitted through± SEM. 
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The top panel in Figure 6. 6 demonstrates that the cortisol concentration in the 
maternal perfusate is constant as judged by ANOVA (as was expected). This was 
estimated by sampling the maternal perfusate (the last 30 seconds of each 5 min 
interval were collected) and processing the samples as the foetal samples. No 3H-
cortisone was ever detected in the maternal perfusate and blanks were "pre 40 
min" perfusate samples which always showed a flat baseline (same applied to the 
foetal blanks which were also taken from each perfusion before 40 m in). 
The middle panel in Figure 6.6 shows build-up of 3H-cortisol and 3H-cortisone in 
the foetal effluent. The level of 3H -cortisone reaches steady state at t = 50 - 55 
min (10 - 15 min after start of perfusion with 3H-cortisol). 3H-cortisol however 
showed an early "overshoot", either due to an "isotope" effect or due to physical 
leakage of the placental barrier. 
The bottom panel of Figure 6.6 shows the activity of 118-HSD, calculated from the 
data presented in the middle panel. For 118-HSD activity at different time points 
(5 min intervals): 40 - 45 min < 45 - 50 min = 50 - 55 min < 55 - 60 min = 
subsequent intervals (ANOVA and Duncan's post-hoc test for means). Thus, 
steady state for 11B-HSD activity (or efficiency of cortisol to cortisone conversion) 
was any time later than 15 min after concentration change. Thus, in all subsequent 
perfusions, 15 minutes were allowed before foetal effluent sampling was 
undertaken. 
It is also noteworthy that the concentration of radioactivity in the maternal 
perfusate is much greater than the concentration of radioactivity in the foetal 
effluent, indicating either that i) cortisol is being sequestered in the placental tissue 
or ii) the two circuits do not overlap perfectly or iii) there is a physical barrier 
apart from 11B-HSD which maintains a gradient between the mother and foetus in 
spite of the lipid soluble nature of steroids (see later). 
Details of sample preparation and recovery of radioactivity in the foetal perfusate 
samples are depicted in Figure 6.7. Note that less than 0.3% of total radioactivity 
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is lost in the water soluble waste suggesting that no enzymes (sulphatases etc.) are 
metabolising cortisol to form water soluble/conjugated steroids to any significant 
extent in this preparation. The samples used for these analyses were foetal effluent 
perfusates, the maternal circulation having been perfused with 50 nM 3H-cortisol. 
For the rest of the recovery experiments, foetal effluent perfusates were collected, 
pooled and subsequently divided into 15 ml samples, spiked with 3H-cortisol and 
cold cortisol to approximately 106 cpm and approximately 200 nM respectively. 
The total counts were obtained by drying down samples in glass scintillation vials 
and re-dissolving in scintillant before counting in a B-counter. 
Sep-Pak pre-wash with 
Ethyl Acetate and H20 
Acidified perfusate 
passed through 
I H20wash I 
I Ethyl Acetate elution I 
Water soluble waste 
contains < 0.3% of total 
radioactivity ( n = 10 ) 
,, 
j Dry down I 
Figure 6. 7 Details of Perfusate Extraction and Recovery of 3H-cortisol 
The figure shows details of sample preparation and the extraction recovery for cortisol (Section 2.8.3). 
The samples were foetal perfusates, the maternal circulation being perfused with 50 nM cortisol ("high 
normal" free physiological concentration). The passage through the Sep-pak Plus was driven by a 
vacuum pump, enabling 24 samples to be processed simultaneously. Samples were dried down 
under a gentle stream of air at 3rC. Using air as opposed to nitrogen for drying down did not affect 
the ratio of cortisol and cortisone, the only steroids in the samples 
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6.3.2. The Barrier Role of Human Placental 11 B-HSD 
Does placental 11B-HSD control the access of maternal glucocorticoid to the 
human foetus in-utero? This has been suggested by several authors [Murphy et al., 
1974; Dancis et al., 1978; Beitins et al., 1973; Dormer & France 1973], but 
recently, other enzymes (20a/B-hydroxysteroid dehydrogenase, 58-reductase) have 
been proposed as contributors to placental metabolism of glucocorticoids [Addison 
et al., 1991; Dodds et al., 1993]. These latter studies used ex-vivo placental 
perfusion with recirculating perfusates and pharmacological concentrations of 
cortisol and the synthetic glucocorticoid prednisolone. The physiological relevance 
of these studies is therefore unclear. First, the use of pharmacological 
concentrations may have resulted in metabolism by enzymes normally quiescent. 
Secondly, synthetic glucocorticoids may be protected from metabolism by specific 
structural alterations (an example is dexamethasone which is metabolised by NAD-
preferring 11B-HSD but not NADP-preferring 11B-HSD [Siebe et al., 1993]). 
Finally, the practice of recirculating perfusates will subject the primary product of 
active glucocorticoid metabolism to further metabolism. 
The data presented in the last Section, regarding recovery of radioactivity, add to 
confidence with regard to the proposal that 11B-HSD is of primary importance in 
inactivating cortisol, as 92% of the radioactivity was recovered from the extraction 
procedure and no radioactivity was lost in the water soluble waste. Thus we could 
be confident that while perfusing the preparation with a "physiological free 
concentration of cortisol" [Meulenberg & Hofman 1990], all potential metabolites 
(see Figure 1.5) would be present in the sample injected onto the HPLC column. 
But was the isocratic HPLC employed able to separate the various potential 
metabolites? 
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To look at that, samples (cold) of all the potential metabolites were purchased 
(Sigma UK) and run against cortisol and cortisone on HPLC, using as always flow 
rate of 1.3 ml/min and 50% methanol:water as mobile phase. The result is 
depicted in Figure 6. 8, which shows clearly that none of the potential metabolites 
co-elutes with either cortisol or cortisone. 20a- and 20B-dihydrocortisol might 
have produced a shoulder on the cortisone and cortisol peaks respectively. In fact 





H-cortisone is shown in Figure 6.9, which clearly shows 
that cortisone is the only metabolite of cortisol in this setting. This was true for a 
range of cortisol concentrations, from low (20 nM) to high physiological (200 nM) 
and also during inhibition of 11B-HSD with carbenoxolone or glycyrrhetinic acid. 
It had been noted (see previous Section) that a materna-foetal concentration 
gradient of cortisol was apparent across the placenta. In order to look at this 
further, 4 placentas were perfused, first for 40 min without steroid, then from 40 -
70 min with 20 nM cortisol, from 70- 100 min with 50 nM cortisol and then from 
100 - 130 min with 200 nM cortisol (i.e. low normal physiological free 
concentration - high normal physiological free concentration and finally very high 
physiological or pharmacological concentration). The perfusions also included 
stepwise increasing concentrations of 14C-antipyrine, which is a small inert lipid 
soluble salt which doesn't interfere with cortisol metabolism [Dancis et al., 1978]. 
The purpose of including antipyrine was to provide a reference substance which, as 
cortisol, was lipid soluble, allowing calculation of steroid clearance relative to 
antipyrine for comparison with the literature. Two samples were taken at steady 
state (for both antipyrine and steroids), which were the last two 5 minute periods 
before the concentration was changed. The data from both 5 min periods were 
combined for analysis. 
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Perfusion of the maternal circuit with 20 nM, 50 nM and 200 nM cortisol 
produced a linear increase in the transfer of total glucocorticoid across the placenta 
at steady state (cortisol + cortisone in the foetal circulation) and also in antipyrine 
transfer as can be seen in Figure 6.10, which shows concentration of radioactivity 
in both the maternal and foetal circuits at each time point. Note that the fitted line 
for the antipyrine data intercepts both axes very close to zero whereas that is not 
the case for cortisol. This probably means that there is initial sequestration of 
steroids, at maternal concentrations below 20 nM, such that no steroid transfer is 
observed. 
Again, as in Figure 6.6, there was a concentration gradient for both substances 
across the placenta, and the magnitude of this gradient (i.e. the total corticosteroid 
clearance = foetal concentration/maternal concentration x foetal flow rate) did 
change as the concentration of cortisol in the maternal circuit was altered. Thus, at 
20 nM maternal cortisol, the total steroid clearance is 0.27 ± 0.08; at 50 nM it is 
0.45 ± 0.13 and at 200 nM it is 0.61 ± 0.09. The antipyrine clearance does 
however not change to the same extent, resulting in an increase in the relative 
corticosteroid clearance (Figure 6.11), probably reflecting slight differences in 
lipid solubility of steroid and antipyrine. Figure 6.11 also shows that although the 
absolute and relative corticosteroid clearances increased with increasing maternal 
concentration, the efficiency of 118-HSD remained constant over this wide range 
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Figure 6.8 Elution Profiles of Cold Potential Cortisol Metabolites on HPLC 
The flow rate was 1.3 ml/min and mobile phase was 50% methanol/water, column was reverse phase 
J,J-Bondapak-C18. Note good separation of all peaks. Some substances (for example J) showed 
multiple minor peaks (identified by '), probably due to impurities/degeneration. Cortisol (E) and 
cortisone (C) shown in solid, other in dotted lines. A: 6B-hydroxycortisol; 8: 20a-dihydrocortisol; D: 
20B-dihydrocortisol; F: 11-hydroxyandrostenedione; G: 5a-dihydrocortisol; H: 5B-dihydrocortisol; 1: 
tetrahydrocortisol; J: allo-tetrahydrocortisol. 
In separate studies, the maternal circuit was perfused with 50 nM cortisol with and 
without the 11B-HSD inhibitor glycyrrhetinic acid at three concentrations. The 
washout period was 0 - 40 min as before, followed by perfusion with cortisol only 
(40 - 70 min), then co-perfusion of cortisol and glycyrrhetinic acid 10-8 M, (70 -
100 min) then 10-6 M (100 - 130 min) and finally 104 M (130 - 160 min). Samples 
were taken over two 5 min periods at steady state ( + 20 min), analysed separately 
and data combined for analysis. 
Co-perfusion of cortisol with glycyrrhetinic acid resulted in marked and rapid 
inhibition of cortisone production by the placenta, so that most of the cortisol 
perfused on the maternal side was transferred intact to the foetal circulation (Figure 
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6.12). IC50 was approximately 3 x 10-
6 M which is similar to that previously 
reported for intact renal tubular cells which also express 11B-HSD-2[Monder et al., 
1989]. The other commonly used inhibitor of 11B-HSD is carbenoxolone, a water 
soluble synthetic hemi-succinate derivative of glycyrrhetinic acid. For the sake of 
completion, one perfusion was undertaken with 50 nM cortisol and carbenoxolone 
co-perfused at 104 M. The result is shown in Figure 6.13, which shows that while 
approximately 85% (in this placenta) of cortisol is metabolised, addition of 
carbenoxolone to the maternal perfusate permits all the cortisol to pass 
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Figure 6.9 Typical HPLC Trace of a Foetal Effluent Perfusate Sample 
The peak to the left is 3H-cortisone and the one to the right is 
3
H-cortisol, both elution times checked 
against authentic cold standards. No peaks were found beyond 16 min. 
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Figure 6.10 Maternal Concentration and Transfer of Cortisol and Antipyrine 
To the left are data on 
3
H-cortisol transfer, the horizontal axis showing maternal cts/ml and the vertical 
axis cts/ml recovered in the foetal effluent. Bars are mean ± SEM for 4 perfusions. The 
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The black columns show a constant % conversion cortisol to cortisone over a wide range of maternal 
cortisol concentrations (left vertical axis) while the lighter shaded bars show the increase in relative 
corticosteroid (cortisol + cortisone) clearance (right vertical axis) over the same range of maternal 
steroid concentrations. Columns are means for 4 perfusions while bars indicate + SEM. Clearance 
index is steroid clearance over antipyrine clearance. 
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Figure 6.12 Inhibition of Human 116-HSD in the Perfused Placenta 
The figure shows the potent inhibition of human placental 11 ~-HSD ex-vivo, using the active lipid 
soluble constituent of liquorice, glycyrrhetinic acid. Columns represent means of 4 perfusions, bars 
are + SEM . No inhibitor is t = 40 - 70 min and then each glycyrrhetinic acid concentration was 
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Figure 6.13 The Effect of Carbenoxolone on Placental116-HSD Ex-Vivo 
The first 40 minutes were washout as usual, followed by perfusion with 50 nM cortisol only from 40 -
80 min . Carbenoxolone was then added to the medium (10-4 M) from 80- 160 min. Both lines indicate 
concentration of label appearing in the foetal effluent at the indicated time points. Cortisone 
generation from cortisol is completely inhibited by carbenoxolone. 
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Ex-Vivo Human Placental 11 B-HSD Activity and 
Birth Weight 
To study the relationship between human 1113-HSD activity and foetal growth using 
methodology closely approximating the in-vivo situation, a prospective study was 
carried out. The subjects were enrolled as described in Section 6.2.1 on page 141. 
Exclusion criteria were smoking, alcohol consumption, drug abuse, chronic illness 
including bronchial asthma, the presence of high risk infections (hepatitis B, HIV), 
regular medication of any kind or pregnancy-induced hypertension (blood pressure 
> 140/90 mmHg or increase of > 30/15 mmHg compared to the first trimester). 
80% of the perfusions were successful leaving 16 experiments for analysis (see 
Section 6.2.1 for details). 
The first 40 min were washout, followed by 40 min of perfusion with 50 nM cold 
cortisol and < 0.5% 3H-cortisol tracer, (chosen to reflect estimates of high 
physiological "free" glucocorticoid levels [Meulenberg & Hofman 1990], and 14C-
antipyrine allowing calculation of relative corticosteroid clearance. For the two 
last 5 minute intervals (t = 70 - 75 and 75 - 80 min) the foetal effluent was 
collected and analysed as before. Of the 16 successful perfusions there were 7 
male and 9 female babies. 
Of maternally administered cortisol, 69 - 90% was converted to cortisone during 
transplacental passage at steady state. Placental 1113-HSD activity, or efficiency in 
converting cortisol to cortisone was estimated from the relative concentrations of 
cortisol and cortisone in the foetal effluent: [ElF+ E x 100] per gram of tissue 
perfused. The 1113-HSD efficiency was significantly correlated with birth weight, 
with the smallest babies having placentas with the poorest 1113-HSD efficiency (n 
= 16, r = 0.67, r2 = 0.45, p < 0.005, Figure 6.14). A similar relationship was 
found between total placental 1113-HSD efficiency (1113-HSD efficiency per gram 
times total placental wet weight) and birth weight (n = 16, r = 0.61, r2 = 0.37, p 
< 0.02; Figure 6.15). 
- 160-
Human Placenta/1113-HSD Ex-Vivo: Results 
Table 6.1 Human 118-HSD Ex-Vivo: Subject and Study Details 
Age at delivery [years] 16 27.3 19.8-34.1 1.0 
Length of gestation [weeks] 16 40.4 38.4- 41.7 0.3 
Birth weight [kg] 16 3.6 3.1-4.1 0.1 
Placental weight [g] 16 483 394- 569 13 
p02 step-up across foetal cotyledon [mmHg] 14 79 38- 120 7 
Time to start of foetal circulation [min] 16 14.8 11 - 21 0.8 
Time to start of maternal circulation [min] 16 23.3 20-30 0.8 
pH in foetal inflow 14 7.40 7.32- 7.46 0.01 
pH in foetal outflow 14 7.28 7.20- 7.35 0.01 
Foetal circuit temperature [°C] 14 37.2 36.6- 37.7 0.1 
Foetal output flow rate [mllmin] 16 6.1 5.3 - 6.6 0.1 
Antipyrine clearance [mllmin] 16 3.3 0.9- 8.2 0.5 
Corticosteroid clearance (F + E) [mllmin] 16 2.5 1.0- 4.3 0.3 
Steroid Clearance Index 16 0.9 0.3 - 1.8 0.1 
Conventionally, 11B-HSD activity (efficiency) is calculated as % ratio of cortisone 
to total corticosteroids, but one could argue that the ability to generate cortisone 
would be just as good a measure of 11B-HSD activity. Analysing the data in this 
way, the smallest offspring have placentas with the lowest ability to generate 
cortisone. For foetal effluent cortisone concentration (cts/ml) per g perfused 
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placenta: r = 0.53, p < 0.04. This did not reach statistical significance for total 
placenta (i.e. cts/ml/g times wet placental weight) although the same trend was 
seen: r = 0.46, p < 0.08. No correlation was found between placental llB-HSD 
efficiency and placental weight - one should note that llB-HSD activity is 
expressed per weight of placenta and thus placental weight is a major determinant 
in both the parameters being correlated. 
At the beginning of each perfusion, samples from an adjacent cotyledon were 
immediately frozen at -70 oc for later llB-HSD assay in-vitro. There was no 
correlation between in-vitro activity of the frozen specimens and ex-vivo activity, 
and no correlation was found between in-vitro activity and either birth weight or 
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Figure 6.14 Human Birth Weight & PlacentalllB-HSD Efficiency Ex-Vivo: A 
Human placental 11 B-HSD ex-vivo correlates highly significantly with birth weight. Pearson's r = 0.67, 
p < 0.005, n = 16. The solid line is the regression line with dotted lines outlining 95% confidence 
intervals for the regression. 11 B-HSD efficiency: (E/E+F)/g perfused placental tissue. 
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Figure 6.15 Human Birth Weight & PlacentalllB-HSD Efficiency Ex-Vivo: B 
Total human placental 11 B-HSD ex-vivo correlates highly significantly with birth weight. Pearson's r = 
0.61, p < 0.02, n = 16. The solid line is the regression line with dotted lines outlining 95% confidence 
inteJVals for the regression. Total placental 11 B-HSD efficiency is foetal effluent (E/E+F)/g perfused 
placental tissue times wet placental weight. 
6.3.4. Human Placental 11 B-HSD Activity Ex-Vivo, 
Alcohol & Smoking 
Various environmental influences are known to be important in determining foeto-
placental growth. For example, life at high altitude (hypoxia) induces the 
interesting combination of low birth weight and high placental weight [Kriiger & 
Arias-Stella 1970], as does maternal iron deficiency anaemia [Godfrey et al., 
1991] . Streptozotocin-induced diabetes and ethano 1 produce similar effects in rats 
[Sybulski & Maughan 1971; Sanchis et al., 1986], and the growth retarding actions 
of smoking are well documented. The postnatal effects of prenatal ethanol 
exposure are modified by maternal adrenalectomy [Redei et al. , 1993], and 
unpublished in-vitro data from our own laboratory has demonstrated a dose-
dependent inhibition of liver 11B-HSD by ethanol. Thus, although the precise 
causes are unknown, it is not unreasonable to propose that increased foetal 
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glucocorticoid exposure consequent upon attenuated placental 118-HSD may 
represent one possible unifying mechanism whereby environmental factors 
influence foeto-placental growth. Therefore, a series of perfusions were 
undertaken in order to look at the possibility of smoking, nicotine or ethanol 
affecting placental 118-HSD activity in the perfused human placenta. 
First, three pregnant women were enrolled at term delivery according to the same 
criteria as detailed in Section 6.2.1, but this time they all admitted to smoking > 
10 cigarettes daily through pregnancy. The placentas were perfused as before and 
118-HSD efficiency compared with the 16 healthy placentas discussed in the 
previous Section. Second, healthy placentas from 6 non-smokers were perfused as 
previously described, maternal side only with washout/recovery from 0 - 40 min, 
50 nM cortisol from 40 - 80 but then 50 nM cortisol + 0.2 p.M nicotine from 80 -
125 min. This level of nicotine is equivalent to the plasma levels found in chronic 
heavy smokers [Russell et al., 197 5]. Foetal effluent samples were collected over 
the last two 5 min periods of both the cortisol and the cortisol + nicotine phases, 
analysed separately as before and the data averaged for analysis. Third, in 5 
separate perfusions, ethanol replaced nicotine in the concentration of 2 mg/ml, 
enough to intoxicate an average male. Data were processed as for nicotine. 118-
HSD activity was expressed as [(EfF + £) x 100]/g tissue perfused and similarly 
per total placental weight. 
The mean 118-HSD efficiency (% conversion F to E - abbreviated as % in this 
Section) in the 6 placentas perfused in succession without and with nicotine was no 
different when nicotine was co-perfused with cortisol (t-test for dependent samples: 
pre-nicotine 118-HSD efficiency per g tissue perfused was 2.86 ± 0.59 %g-1 and 
with nicotine 2.81 ± 0.55 %g-1). The same applied per total placenta (1424 ± 
283 % vs. 1393 ± 254 % with nicotine). The 3 smokers delivered non-
significant! y lighter babies than the normals (3. 4 ± 0.1 kg vs. 3. 6 ± 0.1 kg 
normals) and significantly heavier placentas (569 ± 61 g vs. 483 ± 13 g normals, 
p < 0.04: t-test). However, the efficiency of cortisol inactivation in the 3 smokers 
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was no different from the 16 controls (t-test for independent samples); 11B-HSD 
efficiency per gram perfused tissue was 2.45 ± 0.26 %g-1 in smokers compared 
with 2.14 ± 0.17 %g-1 in controls. When calculated as total placental 11B-HSD 
efficiency, the figures were 1195 ± 43 % in smokers and 1172 ± 123 % in 
normals. 
Similarly, the dose of ethanol used (2 mg/ml) in perfused healthy placentas (n = 5) 
did not impair 11B-HSD efficiency as estimated by t-test for dependent samples. 
Thus 11B-HSD efficiency per g perfused tissue pre-ethanol was 2.35 ± 0.40 %g-1 
vs. 2.33 ± 0.42 %g-1 with ethanol co-perfused. For total placental 11B-HSD 
efficiency, this was also true, the activities for the 5 placentas being 1077 ± 141 
% pre-ethanol vs. 1067 ± 152 % with ethanol co-perfused. 
6.4. DISCUSSION 
The validation experiments for the ex-vivo, dual circuit, isolated placental 
cotyledon perfusion methodology that was developed here, add confidence to the 
notion that this methodology gives results as close as possible to the in-vivo 
situation at the end of pregnancy, which clearly cannot be investigated in-situ. The 
start of foetal perfusion was within 15 min of delivery and perfusion for an 
extended period did not appear to compromise placental structural integrity, as 
assessed by both light- and electron-microscopy; sections taken from fresh 
placentas and after 3 h of perfusion were remarkably similar, indicating that few, if 
any, structural abnormalities were attributable to the perfusion itself. Several 
tissue samples were looked at, in all of which the morphology was identically well 
preserved. Therefore, the samples are likely to be representative of the whole 
cotyledon. 
Further support for the viability of the preparation was obtained from the pattern of 
foetal effluent lactate release. Previous studies have shown a rapid fall in lactate 
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concentration 1n the foetal effluent of perfused cotyledons under oxygenated 
conditions during the first few minutes, levelling off in the following 15 minutes 
[Young & Schneider 1984]. This closely matches the experiments described here. 
If the preparation suffers hypoxia or anoxia there is no fall, and sometimes a rise 
in lactate concentration in the foetal effluent [Cannell et al., 1988; Illsley et al., 
1984; Bloxam 1985]. The sensitivity of our assay was sufficient to detect the 
effects on lactate production of potential adverse conditions like hypoxia/anoxia. 
Illsley [Illsley et al., 1984] reports lactate production rate of ea. 175 ~-tmollmin/kg 
under oxygenated conditions, rising by a factor of 1.5 - 2 under anoxia 
(recirculating foetal perfusate with the same flow rate as here). The sensitivity of 
our assay is 0.2 mM which approximately translates into minimum production rate 
detectable of 32 ~-tmollmin/kg, (sampling volume 1.5 ml, flow rate 6 ml/min, using 
average cotyledon weight as 38 g, n = 16). 
Not only is the ultrastructure adequately preserved, but so importantly is 11B-HSD 
activity, which is relatively unstable in placental homogenates [Brown et al., 1993; 
Lakshmi et al., 1993], particularly if frozen as was observed here (Section 5). Ex-
vivo 118-HSD activity was thus stable and preserved over an extended 
experimental period (Figure 6. 3). The fact that there was no difference in 11 B-
HSD activity estimated from endogenous steroid levels (Figure 6.3) and the 
activity calculated from data based on artificial perfusion (pre 40 min compared 
with post 40 min), further supports the notion that the data obtained using this 
method parallel closely metabolic capacities in-vivo. It was therefore of interest 
that there seemed to be a certain amount of cortisol leakage (bypassing metabolism) 
in some perfusions during the first 15 min of cortisol perfusion (t = 40 - 55 min, 
Figure 6.6). An "isotope effect" as an explanation for this is not likely as this 
leakage was not apparent in all the perfusions. This supports the use of an 
extended recovery period (up to 55 min; all 11B-HSD activities analysed here are 
from later times) and the use only of data from steady state for analysis. 
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It is noteworthy that there seemed to be a marked materno-foetal gradient across 
the placenta for total corticosteroids, suggesting that 1113-HSD wasn't the only 
mechanism controlling access of glucocorticoids to the foetus. Again, an "isotope" 
effect can be suggested but is not likely as this gradient was also observed while 
perfusing with cold steroids only. This could also be attributable to a poor overlap 
of the maternal and foetal circulations in these experiments (supported by a 
gradient for antipyrine) or due to sequestration of cortisol in placental tissue, the 
latter notion given support by the observation from Figure 6.10, that the fitted line 
does not intercept the maternal axis through zero - thus a certain minimal maternal 
concentration is probably necessary for any transplacental steroid passage to take 
place. If the materno-foetal gradient of steroid was only due to perfusion 
inequalities (poor materno-foetal circulation overlap), this should affect antipyrine 
equally to cortisol and the effect of changing maternal concentrations should not 
affect relative steroid clearance (relative to antipyrine). In fact the relative 
clearance did increase with increasing maternal concentrations, as shown in Figure 
6 .11. Therefore factors like lipid solubility are likely to be contributing to the 
placental glucocorticoid barrier. 
The fact that the total amount of steroids transferred across the placenta from the 
maternal to the foetal side, increased with increasing maternal concentrations is 
important as it means that increasing maternal concentration will result in higher 
absolute foetal concentrations of cortisol, although the same proportion is 
metabolised to cortisone at all maternal concentrations. 
An important fact however is that the activity of 1113-HSD remains constant over a 
wide range of maternal glucocorticoid concentrations, from low to high 
physiological levels. The majority of transplacentally passing corticosteroids are 
inactivated by 1113-HSD (here at 50 nM: 69- 90%), no matter what the absolute 
concentration. Therefore, a defect in 1113-HSD would presumably be of far greater 
consequence than any variations in maternal cortisol concentrations within the 
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physiological range. Thus intact placenta has a high capacity to inactivate maternal 
glucocorticoids, but whether the capacity of the enzyme can be flooded by greatly 
elevated ( > 200 nM) free maternal cortisol levels (in stress or disease) remains 
unknown. Another way of controlling the total transplacental steroid passage 
would be to add proteins to the maternal perfusate. This would lower the absolute 
total corticosteroid transfer but apparently does not affect 118-HSD activity 
[Dancis et al., 1978]. 
Emphasising the role of 118-HSD as the main player in the barrier to maternal 
glucocorticoids are the studies with carbenoxolone and glycyrrhetinic acid. Thus 
by inhibiting 118-HSD there is free transplacental passage of maternal cortisol. 
Previous studies with the synthetic glucocorticoid prednisolone and cortisol 
[Addison et al., 1991; Dodds et al., 1993], which used recirculating maternal and 
foetal perfusates, pharmacological free steroid concentrations (J.LM range), found 
evidence of metabolism by 58-reductase and 20a/B-hydroxysteroid dehydrogenase. 
These studies are likely to be confounded by i) the use of high steroid 
concentrations, resulting in metabolism by normally quiescent or low affinity 
enzymes, and ii) the practice of recirculating perfusates which will subject 
cortisone (or prednisone) to further metabolism, the products thus wrongly 
believed to be the result of primary cortisol metabolism. This was later confirmed 
in studies with prednisolone, where no products were detected if glycyrrhetinic 
acid was included in the perfusate [Addison et al. , 1993]. The studies here found 
no significant contribution of any other enzyme than 11B-HSD to placental cortisol 
metabolism when using physiological concentrations of cortisol and non-
recirculating perfusions - thus 11B-HSD is the major contributor to the human 
placental glucocorticoid barrier. 
The prospective study on birth weight and placental 118-HSD activity ex-vivo, 
shows as in the validation studies, that 118-HSD potently inactivates maternal 
glucocorticoids in intact human placental tissue at term and importantly, that the 
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efficiency of this barrier varies considerably, correlating with birth weight. These 
data in conjunction with studies on the effects of treatment of animals with 
glucocorticoids [Benediktsson et al., 1993] and llB-HSD inhibitors [Lindsay et al., 
1994b] therefore lend support the hypothesis [Edwards et al., 1993a] that excessive 
exposure of the foetus to maternal glucocorticoids due to deficient placental llB-
HSD retards intrauterine growth in humans. 
Using the ex-vivo system it was found that more than two thirds of maternally-
applied cortisol was converted to inert cortisone during placental passage. This 
activity was due to llB-HSD (as discussed above), as cortisone is the only product 
detected and cortisol inactivation was prevented by glycyrrhetinic acid, a potent 
inhibitor of the enzyme, particularly in the liB-dehydrogenase (cortisol 
inactivating) direction [Stewart et al., 1990b]. Previous human studies in-vitro 
[Brown et al., 1993; Blasco et al., 1986], ex-vivo (as here) at term [Dancis et al., 
1978], and in-vivo at mid-gestation [Murphy et al., 1974; Pasqualini et al., 1970] 
and at term [Beitins et al., 1973] have demonstrated that liB-dehydrogenation 
(steroid inactivation) is the predominant activity of placental llB-HSD. This 
presumably reflects the absence of reversible llB-HSD-1 in purified human 
placental preparations [Brown et al., 1993]. Placental llB-HSD showed similar 
fractional cortisol metabolism over a range of maternal steroid concentrations, 
which probably span the broad variation of concentrations of "free" cortisol 
reaching the placenta via the uterine artery, as Blasco had previously calculated 
from in-vitro experiments [Blasco et al., 1986]. 
However, the exclusion of maternal cortisol from the foetus was not complete 
confirming previous estimates of a minor, but detectable, contribution of maternal 
glucocorticoid to foetal plasma cortisol [Murphy et al., 1974; Pasqualini et al., 
1970; Dancis et al., 1978]. Clearly, within a certain tolerance, feedback of 
transplacentally-passed cortisol upon the foetal hypothalamic-pituitary-adrenal axis 
will reduce foetal adrenal secretion and maintain foetal cortisol levels. 
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Nevertheless, given that cortisol levels in the foetus are several fold lower than in 
the maternal circulation [Campbell & Murphy 1977], a relative defect in placental 
1113-HSD is likely to have far greater consequences in terms of the overall foetal 
glucocorticoid load, than any alterations in foetal adrenal cortisol production per 
se. 
The activity of 1113-HSD in intact placenta showed considerable variation, either 
expressed per gram of placental tissue or per whole placenta (presumably a better 
estimate of the total amount of maternal cortisol reaching the foetal circulation). 
The mechanism(s) producing this variation (genetic and/or environmental) remain 
to be determined in humans, but studies in baboons suggest the importance of 
foetal and placental hormones, notably sex steroids [Pepe et al., 1988]. We have 
attempted to exclude some maternal factors (see exclusion criteria), but the role of 
maternal nutrition has not been examined and there is some evidence that this may 
affect placental 1113-HSD in rats [Phillips et al., 1994]. 
From the studies presented here on nicotine and ethanol, it appears that neither 
agent acutely affects the ability of placental 1113-HSD to inactivate glucocorticoids. 
Similarly, the efficiency of placental 1113-HSD does not seem to be altered in 
smokers as compared with non-smokers. There are though a few points that 
deserve to be mentioned: i) the time period of ethanol and nicotine perfusions was 
only 45 min and therefore chronic effects of these agents on placental 1113-HSD 
have not been excluded, and ii) only 3 smokers were included in the study, which 
may therefore not have had the power to detect a small difference in placental 1113-
HSD activity between smokers and non-smokers, and iii) if the growth retarding 
effects of smoking are via interaction with placental 1113-HSD, that is probably via 
other constituents of cigarette smoke than nicotine, and fmally iv) the reported 
smoking habits in smokers and controls were not confirmed objectively. These 
agents therefore deserve further investigation using different experimental models, 
for example cultured trophoblast cells. 
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The close direct correlation of 11B-HSD activity in intact cotyledons with birth 
weight, confirms similar observations with fresh placental homogenates in rats 
[Benediktsson et al. , 1993]. That this relationship with birth weight might be 
causal is suggested by data showing that administration of 11B-HSD inhibitors to 
pregnant rats reduces birth weight [Lindsay et al., 1994b], an action dependent 
upon intact maternal adrenal glands (unpublished observations). Moreover, blood 
pressure in the adult offspring was elevated. Whether placental 11B-HSD 
deficiency correlates with elevated blood pressure in humans in later life remains to 
be determined, but the data presented here lend support to the hypothesis that 
deficiency of placental metabolism of maternal glucocorticoids may provide a 
mechanism to explain the epidemiological link between low birth weight and 
subsequent common disorders of adulthood. 
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7. HUMAN FOETAL 0STEOCALCIN AND 
PLACENTAL 11 B-HSD 
7 .1. INTRODUCTION 
Foetal growth is affected by numerous influences including glucocorticoids 
[Reinisch et al., 1978; Benediktsson et al., 1993] which do not only impair growth 
but also permanently affect differentiation and maturation of specific target organs 
in animals and humans [Slotkin et al., 1992b; Slotkin et al., 1992a; Ballard 1979]. 
A few authors have reviewed the data on outcome of babies exposed transiently 
(for approximately 24 h) to glucocorticoids (as is becoming more and more 
common all over the world as therapy to induce pulmonary surfactant production, 
in cases of threatened premature labour). There is little information available on 
birth weight or other short term parameters, or even longer term effects, and most 
authors have failed to find any detrimental effects of prenatal brief dexamethasone 
exposure in humans [Taeusch, Jr. 1975; Sidhu 1987]. However, some evidence 
exists for altered organ development in animals in this setting [Epstein et al. , 1977; 
Johnson et al., 1981]. We also know that treatment with dexamethasone for a few 
days can alter development of specific target organs in animals, as mentioned 
above, and that chronic low doses are able not only to alter foetal growth, but also 
directly elevate blood pressure in-utero in sheep, possibly via altered vascular 
sensitivity to angiotensin-II [Tangalakis et al., 1992]. Recent data also show that 
in animals, glucocorticoids permanently programme higher blood pressures in later 
life [Benediktsson et al. , 1993]. 
There are two potential sources of glucocorticoids in the foetal circulation; the 
foetal adrenal, which secretes cortisol from first trimester [Murphy 1973; Beitins et 
al., 1973], and transplacental passage of maternal corticosteroids. As the maternal 
plasma levels are 2 - 10 times higher than foetal concentrations [Campbell & 
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Murphy 1977], the integrity of the placental glucocorticoid barrier is critical. The 
previous Section (Section 6) in this thesis has confirmed earlier suggestions 
[Murphy et al., 1974; Dancis et al., 1978; Beitins et al., 1973; Dormer & France 
1973] that this barrier in humans is placental 118-HSD, the efficiency of which 
varies considerably in both humans (see 6.3 .3) and animals [Benediktsson et al., 
1993]. 
Moreover, human placental 118-HSD is the only significant mechanism 
contributing to the placental glucocorticoid barrier (Section 6) protecting the 
human foetus from maternal glucocorticoids throughout pregnancy as documented 
in several previous studies: in-vitro [Brown et al., 1993; Blasco et al., 1986], ex-
vivo (Section 6) at term [Dancis et al., 1978], and in-vivo at mid-gestation [Murphy 
et al., 1974; Pasqualini et al., 1970] and at term [Beitins et al., 1973]. Also, there 
is no change in human placental 118-HSD activity in the short term during labour 
[L6pez Bernal et al., 1982b]. This presumably reflects the absence of reversible 
118-HSD-1 in purified human placental preparations [Brown et al., 1993]. This is 
in marked contrast to what is believed to be the case in some other species, where 
the prevailing direction of enzyme activity changes during pregnancy, favouring 
active steroid (reduction cortisone converted to cortisol) at mid-gestation but at 
term the reverse (dehydrogenation inactivating cortisol) [Pepe & Albrecht 1984b]. 
As is clear from the data presented here previously (Section 6) on human placental 
118-HSD, the activity can readily be determined with ex-vivo placental perfusion 
which probably gives a true estimation of in-vivo efficiency. The method used (ex-
vivo perfusion) is however obviously not suited for mass studies, and as alluded to 
previously, in-vitro experiments are hampered by storage problems. Furthermore, 
no studies exist relating the effectiveness of placental glucocorticoid inactivation in-
vivo with actual foetal glucocorticoid exposure. It would thus aid further research 
considerably if a serum marker of in-vivo placental 118-HSD activity could be 
found, which we knew reflected the effects of glucocorticoids. At first glance, 
cord blood cortisol levels are attractive. 
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Maternal total cortisol levels rise during pregnancy, as does the free biologically 
active fraction [Meulenberg & Hofman 1990; DemeyPonsart et al., 1982; Scott et 
al., 1990]. The levels remain constant after 26 weeks until labour [Carr et al., 
1981], but at term rise markedly in both the mother and the foetus (for a review, 
see Murphy 1983), depending for example on mode of delivery [Leong & Murphy 
197 6]. The intrinsic variation of both term maternal and cord blood cortisol levels 
thus poses a problem and it is clear that term cord cortisol may not be 
representative of "usual" cord levels (the usual level of foetal cortisol exposure). 
One would have to look at surrogate markers to get an idea about long term 
cortisol exposure, reflecting the function of 1113-HSD. 
Glucocorticoids inhibit activity of mature osteoblasts (and bone formation) but 
promote differentiation of marrow osteoprogenitor cells although their proliferation 
is prevented [Cheng et al., 1994]. Osteocalcin (Bone GLA-protein or BGP) is a 
small non-collagenous protein, specific for bone tissue and dentine [Delmas 1990]. 
Osteocalcin is synthesised predominantly by osteoblasts and a small fraction of the 
protein is released into the circulation. Chronic glucocorticoid excess depresses 
circulating osteocalcin levels, the effect becoming apparent after several days 
[Delmas 1990]. Osteocalcin levels are indeed a very sensitive marker of 
corticosteroid exposure, blood levels in adults being reduced after inhaling only 
400 11-g of the synthetic glucocorticoid beclomethasone dipropionate daily for 5 
days [Teelucksingh et al., 1991 b]. The relationship between osteocalcin in cord 
blood and derived indices of 1113-HSD was therefore examined. 
7.2. METHODS 
7.2.1. Subject Selection and Sampling 
Twenty one consecutive women were enrolled on admission for delivery at the 
Simpson Memorial Maternity Pavilion in Edinburgh - Dr. J. Brennand collected 
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the samples. Two were excluded because of coincident disorders (gestational 
diabetes, type I diabetes mellitus) and in two further cases the plasma samples 
obtained were insufficient for assay. The time and mode of delivery varied and the 
subjects were a mixture of primi- and multi-parous women. The umbilical cord 
was kept clamped through the third stage of delivery, at the end of which blood 
was collected separately from the artery and vein into lithium-heparin tubes. 
Following centrifugation, plasma was frozen at -20 oc within 1 h and stored until 
assayed. 
7.2.2. Assays and Data Analysis 
Cortisol, cortisone and osteocalcin were measured by in-house second antibody 
radioimrnunoassays as described in Section 2.3. 
Differences between means of continuous variables were tested using analysis of 
variance (ANOVA). Pearson's product moment correlation was used to seek 
associations between osteocalcin levels and indices of placental 118-HSD activity. 
Several indices were used for determining the effect of placental 118-HSD activity 
on cord blood osteocalcin levels. Firstly, cord venous plasma cortisone (the 
product of the reaction catalysed by 118-HSD). Secondly, overall 118-HSD 
activity, as conventionally assessed, by the percentage cortisone of total 
glucocorticoids (Ef (F +E)) in cord venous blood. However, although most 
cortisone in the cord blood will derive from placental metabolism of maternal 
cortisol [Beitins et al., 1973], some will be derived from the foetus, which has 
endogenous 118-HSD [Murphy 1981; Stew art et al., 1994a]. We therefore also 
determined an 118-HSD Activity Index to account for this foetal (cord arterial) 
component of glucocorticoids, calculated as [cord venous (Ef (F + E))l minus [cord 
arterial (E/ (F +E))]. A high ratio of cortisone to total glucocorticoid (F +E) 
indicates high cortisol inactivating function of placental 118-HSD and the latter 
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half of the 118-HSD Activity Index equation (arterial steroid concentrations) 
corrects for the foetal contribution. 
7.3. RESULTS 
Cortisol levels were significantly higher in the cord artery (241. 6 ± 25.7 nM) than 
the vein (163 .1 ± 13.4 nM; p < 0.0005), but no difference was observed for 
mean cortisone levels (umbilical artery 26.9 ± 4.1 nM; vein 29.5 ± 4.4 nM) or 
osteocalcin levels (artery 25.4 ± 1.8 J-tg/1; vein 29.2 ± 2.8 J-tg/1; mean 27.3 ± 2.1 
~-tgll). Since there was no difference between arterial (blood travelling from foetus) 
and venous osteocalcin levels ( osteocalcin in the foetal circulation does not reflect 
maternal levels but is derived entirely from the foetus [Delmas et al., 1987; Shima 
et al., 1985]), mean cord osteocalcin levels were used for all correlation analyses. 
Venous cord cortisone and mean cord osteocalcin were significantly and positively 
correlated (r = 0.57, p < 0.02). The ratio of cortisone to total steroids in cord 
vein plasma (E/ (F +E)) correlated significantly with mean cord osteocalcin (r = 
0.57; p < 0.02). A significant positive correlation (r = 0.58; p < 0.02) was 
found between the cord 118-HSD Activity Index and mean cord osteocalcin levels 
(Figure 7. 2). Venous cord cortisol did not show a significant correlation with cord 
osteocalcin. 
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Figure 7.1 Term Cord Blood Steroid and Osteocalcin Levels 
The figure shows mean ± SEM for cortisol, cortisone and osteocalcin in cord arterial and venous blood 
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Figure 7.2 Mean Cord Osteocalcin and 118-HSD Activity Index 
The relationship between placental 11 B-HSD Activity Index on the horizontal axis and mean cord 
osteocalcin levels on the Y -axis. The solid line indicates the regression line while the dotted lines 
indicate the 95% confidence interval for the regression (r = 0.58, ~ = 0.33; p < 0.02; n = 17). 
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7.4. DISCUSSION 
Cord steroid values have been the subject of a number of studies reviewed by 
Murphy [Murphy 1983]. In summary, these studies have used variable 
methodologies to arrive at different results, cortisol levels ranging from 90 - 1200 
nM. Murphy [Murphy 1983] considers the probable true mean value to be 
approximately 180 - 250 nM for pooled cord blood, based on rigorous scrutiny of 
the methodology of the studies concerned. The values obtained in this study 
compare favourably with this summary (artery 242 nM and vein 163 nM). As 
regards the difference between arterial and venous values, equal number of studies 
have reported the venous cortisol higher than the arterial and vice versa. It is 
probable that the artery carrying blood from the foetus has higher values as was 
shown in the only study which has employed foetoscopy and thus obtained blood 
from the undisturbed foetus [Partsch et al. , 1991], although the variation in this 
study was also great, possibly reflecting the natural variation in placental 11B-HSD 
effectiveness. As regards cortisone levels, three studies have looked at arterial and 
venous cord levels at mid-gestation [Murphy 1973; Murphy 1977a; Partsch et al., 
1991], arriving at similar values as presented here with no difference between vein 
and artery. Murphy however did look at term cortisone levels with and without 
labour [Murphy 1977a] and found non-significantly higher levels in the umbilical 
vein (blood travelling to the foetus), as here. Murphy however, found the levels 
during labour to be approximately twice the levels when no labour was experienced 
during elective caesarean section. The samples here are a mixture of labour/no 
labour. 
Cord blood osteocalcin levels which have also been the subject of a few studies 
appear, at least in substantial part, to reflect foetal production [Delmas et al., 
1987; Shima et al. , 1985]. This contention is supported by cord levels being at 
least 2 - 3 times higher than those in the maternal blood [Delmas et al., 1987; Seki 
et al., 1993; Shima et al., 1985], although the levels reported in individual studies 
vary considerably. Of these studies, only one looked at venous levels [Delmas et 
- 178-
Human Foetal Osteocalcin and Placental 11 6-HSD: Discussion 
al., 1987], reporting levels half the levels observed here (29 p,g/1). Another [Seki 
et al. , 1993] looked also at arterial levels and found them to be approximately 4 
p,g/1 while venous was reported as ea. 10 p,g/1, again lower than mine (here 25 
p,g/1). Two other studies in contrast reported levels higher than documented here, 
mixed cord blood levels being approximately 40 - 55 p,g/1 (mean here 27 p,g/1). 
The reason for this apparent discordance of different osteocalcin assays is 
unknown, and has recently been the subject of a publication where the differences 
were found to be most marked in certain categories of patients (renal failure where 
different osteocalcin fragments are likely to be found) [Masters et al., 1994]. Thus 
different assays are probably not directly comparable. 
The hypothesis, that human placental 118-HSD activity in-vivo crucially determines 
foetal glucocorticoid exposure over and above any contribution from the foetal 
adrenal, has here been addressed in three different, albeit related ways. Firstly by 
examining cord venous cortisone levels, secondly by looking at the ratio of 
cortisone to total glucocorticoids in cord venous blood and thirdly by looking at 
118-HSD Activity Index, which corrects placental glucocorticoid metabolism for 
the recirculating and/or foetal contribution. All indices correlated significantly and 
positively with cord osteocalcin levels, in keeping with the notion that 
glucocorticoids depress plasma osteocalcin levels even in foetal life [Delmas et al., 
1987; Teelucksingh et al., 1991 b]. A significant correlation of venous cord 
cortisol (blood travelling towards the foetus) and cord osteocalcin was not found, 
which was not unexpected as cortisol concentrations are notoriously variable, 
particularly with the acute stresses of parturition. 
At term, approximately 90% of cord blood cortisone is of maternal origin (via 
placental metabolism of maternal cortisol) [Beitins et al., 1973]. Cord cortisone is 
likely to be a better indicator of overall placental 118-HSD activity than cord 
cortisol, as cortisone shows little acute response to stress or circadian influences 
[Walker et al. , 1992a]. Higher cortisone levels in cord venous blood therefore 
indicate more efficient placental inactivation of maternal cortisol, a notion 
supported by the close relationship between cord venous cortisone levels and the 
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113-HSD Activity Index. Moreover, since the levels of active glucocorticoids in 
the foetal circulation are several fold lower [Campbell & Murphy 1977] than those 
in the maternal circulation, a relative defect in the placental glucocorticoid barrier 
( 11 B-HSD) has far greater potential consequences in terms of the foetal 
glucocorticoid load, than any alterations in foetal adrenal cortisol production. 
The functional importance of cord blood osteocalcin is unknown, but may, by 
analogy with children and adults, reflect foetal osteoblast activity and hence bone 
formation and turnover [Delmas 1990]. Human osteoblasts express glucocorticoid 
receptors [Subramaniam et al., 1992]. Glucocorticoids promote the differentiation 
of human foetal and adult bone, particularly osteoblasts [Cheng et al., 1994; 
Shalhoub et al., 1992], but the apparent paradox is that they inhibit osteoprogenitor 
cell proliferation and also osteocalcin expression from differentiated osteoblasts 
[Cheng et al., 1994]. The latter effect is mediated by glucocorticoid receptor 
interactions with "cis-acting" sequences in the human osteocalcin gene promoter, 
which inhibit transcription, and by interference with vitamin D and/or growth 
factor-mediated stimulation of osteocalcin synthesis [Morrison & Eisman 1993]. 
Although the detailed molecular mechanisms require further study, it is intriguing 
to speculate that glucocorticoid exposure in-utero may programme adult bone 
parameters, perhaps by determining osteoblast numbers [Cheng et al., 1994]. 
Nevertheless, the estimation of cord blood osteocalcin will provide an important 
tool in future studies to determine whether excessive exposure to maternal 
glucocorticoids in-utero increases the risk of the development of hypertension, 




The research presented in this thesis was prompted by a growing body of evidence 
implicating events before or around birth in the pathogenesis of ischaemic heart 
disease. Those data originate mostly from this country, from the MRC 
Epidemiology Unit in Southampton [Barker 1992a], although similar observations 
have also been made in other countries. Not only is death from ischaemic heart 
disease predictable from parameters of early development like birth weight, but so 
is the development of several of the risk factors for this disease, which still is 
responsible for up to 50% of deaths in industrialised countries. In standard 
textbooks of medicine, hypertension is cited as one of 3 major risk factors for 
ischaemic heart disease, the other 2 being smoking and high cholesterol. Low 
birth weight however, has been calculated to be 3 times as strong a predictor for 
the occurrence of ischaemic heart disease as smoking. For hypertension, we are 
still unaware of the precise aetiology in up to 95% of identified adult cases. 
Blood pressure levels track from infancy to adulthood, i.e. those individuals with 
the highest childhood blood pressures continue to have the highest blood pressures 
as adults, the pattern only being temporarily perturbed during the adolescent 
growth spurt [Lever & Harrap 1992]. This tracking of blood pressure levels is a 
strong argument for the notion that hypertension is programmed in early life. 
Indeed, in several discrete populations, low birth weight (sometimes in conjunction 
with increased placental weight) has been shown to potently predict high blood 
pressure levels, independently of adult "life-style" factors such as alcohol intake, 
smoking, obesity and social class. 
Importantly, this correlation is not only observed at the extremes of the birth 
weight distribution, but is continuous throughout the normal range [Barker et al. , 
1990], and is observed already in infancy [Law et al., 1993], the association 
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growing stronger with the age of the population studied. Thus for each kg increase 
in birth weight, systolic blood pressure decreased by 5.2 mmHg in a population 
aged 64 - 71 years [Law et al., 1993], emphasising the strength of this association. 
Many researchers believe that this association can be explained by maternal 
malnutrition leading to disturbed foetal development [Barker et al., 1993a]. We 
have been exploring the alternative hypothesis that glucocorticoid excess in-utero 
might play a role [Edwards et al., 1993a]. The latter hypothesis is supported by 
several lines of evidence: 
1. Prenatal glucocorticoid excess retards foetal growth in both humans and 
animals [Reinisch et al. , 197 8; Benediktsson et al., 1993; Katz et al. , 1990]. 
2. Glucocorticoids, like other steroids, during windows of development 
permanently programme biochemistry, tissue maturation and responses 
[Gustafsson & Stenberg 1974b; Meaney et al., 1993; Bian et al., 1992; Bian 
et al., 1993]. 
3. An example of the above is the foetal growth retardation and programming of 
offspring hypertension by dexamethasone treatment of pregnant rats 
[Benediktsson et al., 1993], dexamethasone largely escaping metabolism by 
the placental glucocorticoid barrier- 11B-HSD. 
4. Treatment of pregnant rats with inhibitors of 11B-HSD also leads to low birth 
weight, offspring insulin resistance and hypertension, effects which are 
prevented by maternal adrenalectomy [Lindsay et al., 1994b; Lindsay et al., 
1994a; Lindsay & Seckl 1994]. 
Therefore, 11B-HSD is likely to be of key importance. This was addressed in the 
experiments presented here, by trying to answer the questions detailed in Section 
1.6. The third Section (Rat Ovarian 11B-HSD, page 88) deals with the possibility 
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of llB-HSD playing a role in controlling glucocorticoid exposure pre-implantation. 
Evidence for the presence of both llB-HSD-1 and llB-HSD-2 in the rat ovary was 
found. Thus ample NAD dependent liB-dehydrogenation activity (llB-HSD-2) 
was found in homogenised ovaries, but in addition, northern blotting and in-situ 
hybridisation detected llB-HSD-1 mRNA expression, and immunohistochemistry 
confirmed the presence of llB-HSD-1 protein. There precise role of ovarian llB-
HSD however still remains open to question. A role for ovarian llB-HSD in 
modulating the effects of cortisol on gonadotrophin induced steroidogenesis 
[Michael et al., 1993b] has been suggested, and also a potential role in determining 
the success of in-vitro fertilisation and embryo transfer [Michael et al., 1993a]. It 
is however by no means clear how the two llB-HSD isoforms interrelate in the 
ovary. Do they exist in the same cells? How are they regulated developmentally -
is follicle maturation important? How does oocyte llB-HSD relate to llB-HSD in 
granulosa-lutein cells? Are glucocorticoids the substrate? These points all remain 
to be answered but a current priority in our laboratory is to examine the pattern of 
expression of llB-HSD-2, since the human cDNA is now available. 
The fourth, fifth and sixth Sections address three principal questions. First, is 
placental llB-HSD the glucocorticoid barrier? Second, is there a relationship 
between the efficiency of glucocorticoid inactivation by placental llB-HSD and 
foetal growth? Third, are there species specific differences in this regard? These 
questions were addressed in-vitro and ex-vivo in humans and in-vitro in an animal 
model, the rat, which has comparable placental anatomy. The presence of 1113-
HSD bioactivity, being dominantly liB-dehydrogenation, was confirmed in-vitro in 
both human and rat placentas. 
In the rat, the presence of llB-HSD-1 mRNA and protein was also confrrmed 
(Section 4, Rat Placental llB-HSD, page 101). A considerable natural variation of 
the activity of llB-HSD was observed and the intra-placental distribution of 
bioactivity was appropriate for the proposed barrier function. The activity of llB-
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HSD per gram of placental homogenate was highly significantly correlated with 
both foetal growth (r = 0.46, p < 0.0005) and placental growth (r = -0.64, p < 
0.00001), such that the smallest foetuses which also had the largest placentas, had 
the lowest placental enzyme activity (were therefore presumably exposed to the 
greatest amounts of maternal glucocorticoids). This pattern is strongly predictive 
of hypertension in some human epidemiological studies [Barker et al., 1990]. No 
reductase activity was found, although tissue manipulation may have destroyed that 
activity [Brown et al., 1993; Lakshmi et al., 1993]. Also, these studies can be 
criticised for being conducted in-vitro, in a non-human model. Further, 
remembering the storage problems with 11B-HSD, one cannot exclude the presence 
of active 11B-HSD-1 (mRNA and protein present), possibly promoting the 
generation of active glucocorticoids. Also in the baboon, 11B-HSD seems to 
furnish the foetus with active glucocorticoids at mid-gestation (reductase), but at 
term functioning as an 11 B-dehydrogenase [Pepe & Albrecht 1985]. These data are 
not necessarily contradictory, as glucocorticoids may be needed to promote 
tissue/cell specific differentiation during windows of development, but detrimental 
at different windows of development. 
In humans, both in-vitro and ex-vivo methodologies were employed. The lack of 
correlation between foetal growth (birth weight) and term placental 11B-HSD 
activity in-vitro was disappointing (Section 5, Human Placental 11B-HSD In-Vitro, 
page 122). However, the human placental enzyme is notoriously unstable in-vitro 
[Brown et al., 1993; Lakshmi et al., 1993]. The result was therefore not entirely 
surprising and further analysis of the data revealed an interesting pattern. Thus the 
oldest group of samples, which had been stored at -70 oc for 15 months, showed 
considerably less variation in activity than younger sample groups. This probably 
means that part of human 11B-HSD is unstable under the storage conditions, 
making it impossible to draw any conclusions regarding placental 11B-HSD and 
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foetal growth from stored samples. Again, any in-vitro result may not represent 
in-vivo physiology. 
It was therefore necessary to resort to a different method, as closely paralleling 
human in-vivo physiology as possible - in-vivo experiments were clearly not 
feasible (Section 6, Human Placental 11B-HSD Ex-Vivo, page 139). The ex-vivo 
dual circuit placental cotyledon perfusion was started on average within 15 minutes 
of delivery. All the parameters employed for assessing integrity and viability of 
the preparation (morphology by light and electron microscopy, metabolic stability 
over an extended time period, lactate production, volume conservation, circuit 
pressure, perfusate p02 and pH), indicated satisfactory function throughout the 
experimental period. The relative corticosteroid clearance was comparable to 
previously reported values, adding to confidence in the results. There was, as in 
the rat, a considerable variation in the efficiency of glucocorticoid inactivation by 
11 B-HSD. However, the majority ( 69 - 90%) of maternally administered cortisol 
was metabolised to inert cortisone on transplacental passage. 
The placental glucocorticoid barrier was abolished by classical 11B-HSD inhibitors 
(glycyrrhetinic acid or carbenoxolone) - maternally administered cortisol passing 
unmetabolised through to the foetal circulation. Finally, and importantly, the 
ability of human placental 11B-HSD to inactivate maternally administered cortisol, 
correlated positively and significantly with birth weight, either calculated per gram 
of perfused placental tissue (r = 0. 67, p < 0. 005), or per total placenta (r = 0. 61, 
p < 0.02). 
These studies can be criticised, i) for not looking at reductase activity ex-vivo, with 
reference to the baboon (see above), ii) only looking at term placentas, again with 
reference to the baboon placenta, iii) not doing parallel studies on other 
"reference" enzymes and iv) the correlations may not represent a cause and effect 
relationship. Regarding the two first points, the available data for human placentas 
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does not support the idea of reductase (11B-HSD-1) being present, as assessed by 
in-vivo studies at mid-gestation [Murphy et al., 1974; Pasqualini et al., 1970], and 
in-vitro and ex-vivo studies at term [Beitins et al., 1973; Dancis et al., 1978; 
Brown et al., 1993; Blasco et al., 1986]. As for the latter two points, the study on 
human placenta in-vitro did include 2 control enzymes (alkaline phosphatase and 
N-y-L glutamyl B-naphthylaminidase), neither of which correlated with birth 
weight. However, although these enzymes are stable on storage, the problems 
with 11B-HSD storage in these samples, makes any interpretation from these 
samples inappropriate. The data on treatment of pregnant rats with glucocorticoids 
or 11B-HSD inhibitors resulting in low birth weight and offspring hypertension (the 
effects of 11B-HSD inhibitors being dependent on intact maternal adrenal glands), 
strongly suggest a cause and effect relationship [Benediktsson et al., 1993; Lindsay 
et al., 1994b; Lindsay et al., 1994a; Lindsay & Seckl 1994]. 
Finally, Section 7 (Human Foetal Osteocalcin and Placental 11B-HSD, page 172) 
deals with the possibility of an in-vivo marker of foetal glucocorticoid exposure. 
Cord blood osteocalcin (a specific indicator of osteoblast function), which is a 
sensitive marker of glucocorticoid exposure in adults, was found to significantly 
correlate with several indices of term placental 11B-HSD efficiency (for 11B-HSD 
Activity Index, r = 0.58, p < 0.02). This may prove to be an important research 
tool in the future, possibly predicting not only hypertension, but also bone disease. 
The studies presented here have clearly shown that placental 11B-HSD plays a 
major role in controlling glucocorticoid access to the foetus, the efficiency of 
placental glucocorticoid inactivation correlating with foetal growth in the two 
species studied. Little is known about the ontogeny of the two 11B-HSD isoforms 
or their regulation in humans or in the rat. These will be priorities in the months 
and years ahead, aided by the recent cloning of human placental 11B-HSD-2 in our 
laboratory. Further important avenues to explore will be: 
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1. The precise mechanism of in-utero programming of hypertension by 
glucocorticoids, including the relevant developmental window (see Section 
1.1.3 for possible mechanisms). 
2. In addition to the acute effects of nicotine and ethanol on human placental 
1113-HSD presented here, further investigations are warranted on whether the 
numerous stimuli known to affect foetal growth (some of which cause 
disproportionate placental enlargement), affect placental 1113-HSD activity. 
Some examples are ethanol, smoking, anaemia, malnutrition and diabetes. 
Indeed, recent evidence indicates a role for placental 1113-HSD in mediating 
the effects of protein malnutrition during pregnancy, which in rats causes 
offspring hypertension [Phillips et al. , 1994]. 
3. The relative contribution of glucocorticoid receptor expression and 
glucocorticoid levels in the foetus. This can be achieved with cross-breeding 
experiments of recently available transgenic mice bearing antisense 
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transfernblc elements that do not resemble conventional plasmids5 
have been isolated from these TriR/MuR S aurew transcipients, 
and Dlll,npts to clone the resistance nre underwny. There is no 
cross-resistance to propamidine, benzalkonium chloride, cctrimide, 
hexachlorophane, chlorhcxidine acetate, chlorhcxidine gluconate, 
or 9-aminoacridine. Our initial experiments indicate that the 
presence ofTriR does not influence tl1c rate of kill nfter 30 s to 2 min 
of exposure to triclosan. Similar cxpcrimt:ntl' have suggested 1.hat 
the same is true for MRSA witJ1 low-level chlorhexidinc resistance.• 
However, the possibility of a rise in MIC to triclosan should be 
considered if eradication of MRSA is dimcull with this agent, and 
we would be grateful if such strains were sent to the division of 
hospital infection for further study. 
Division of Hospital Infection. 
Central Public Health LaboratOf)', 
London NW9 SHT, UK 
Oep11rtment of Microbiology, 
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Liquorice 
Sm,-Dr Baker and Or FanC$til (Feb 16, p 428) point out the 
structural homology between the prostaglandin metabolising 
enzyme, I 5-hydroxyprostaglandin dehydrogenase (PGDH) and 
l 1 ~-hydroxysteroid dehydrogenase (11 ~-OHSD), which converts 
cortisol to its inactive product cortisone. We have previously shown 
that liquorice derivatives arc potent inhibitors of 11 ~-OHSD. Baker 
and Fanl-stil speculate that by inhibiting PGDH, liquorice might, in 
part, exert its biological efTccts through prostaglandins. Their 
suggestion is based on data from Peskar et at' who showed inhibition 
of gastric prostaglandin metabolism by high concentrations of 
carbenoxolone. 
Liquorice and its derivatives possess both mineralocorticoid and 
glucocorticoid properties. The mechanism of these actions was 
poorly understood, although the presence of an intact adrenal gland 
or cortisol replacement in patients with adrenal insufficiency was 
known to be cssentiaJ.l.J We found that glycyrrhetinic acid, the 
active component ofliquorice, is a potent inhibitor of 11 fl-OHSD in 
vitro; in-vivo studies showed that this inhibition could account for 
both the mineralocorticoid and glucocorticoid efTects ofliquorice.•.s 
To assess whether altered prostaglandin metabolism, as suggested 
by Baker and Fanestil, might contribute to these biological actions, 
we examined the effce1s of glycyrrhetinic acid and carbcnoxolone on 
PGDH and 11 P-OHSD activity in vitro. Human placental tissue 
·was chosen because it is a rich source of both I I P-OHSD and 
PGDH. 
01orionic homogenate (protein content 1·5 mg) was incubated 
v.ith 500 ng PGEl and 1 mmol/1 NAD at 37•c for 15 min in a 
phosphate buffer containing 20% glycerol (pH 8·4). PGDH activity 
was mc.'lsured by radioimmunoassay of the quantity of 15-keto-
PGEl produced after transformation to its metl1yl oxime. The 
experiment was completed with glycyrrhetinic acid, carbenoxolone, 
and S-(4-nuorobcnzoyl)2-hydroxybcnzcnc acetic acid (FHBA), a 
known PGDJ t inhibitor. Substances were tested at concentrations 
up to 4{) wnol/1. Tne c:ffl"CtS of similar concentrations of these 
substances on human placental 11 ~-OHSD were evaluated as 
previously dcscribcd.4 Briefly, 0·3 mg protein from fresh placental 
homogenate was incuhated with 12 mmol/1 1H-cortisol and 200 
pmol/1 NAD in Krebs-Ringer butTer at 37"C for 1 h. Steroids were 
extracted with ethyl acetate and separated by thin-layer 
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Effects of iiquorice on enzymes of prostaglandin and steroid 
metabolism. 
Upper, effects of glycyrrhetinic acid, carbcnoxolone, and FHBA on 
15-hydroxyprostaglandin dehydrogenase activity expressed as percentage 
of control; lower. etrects of the same substances on 11 p. hydroxystcroid 
dehydrogenase. e. glycynhetinic acid; 0, carbcnoxolone; 0, FHBA. 
percentage conversion of 3H-cortisol to 'H-cortisone. The TC$ults 
show that glycyrrhetinic acid and c:arbenoxolone had no effect on 
PGDH activity, in contrast to the inhibition produced by FHDA 
(figure, upper). FHBA had no effect on 11 ~-OHSD activity 
whereas c:arbenoxolone and glycyrrhctinic acid were 'inhibitory 
(figure, lower). 
Liquorice ingestion has been shown to produce mineralocorticoid 
efTccts even when plasm~ glycyrrhetinic acid concentr.nions are 
below 2 J.UllOI/1, the lower limit of detection of the: assay.5 This 
evidence, together \vith the current findings, makes it unliY.cJy that 
altered prostaglandin metabolism contributt:s to the salt-retaining or 
anti-inflanunatory actions of liquorice and its derivatives. 
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ABSTRACT 
The enzyme 11 P-hydroxysteroid dehydrogenase ( 11 P-
HSD) catalyses the conversion of physiological gluco-
corticoids to inactive products, thus modifying the 
access of glucocorticoids to glucocorticoid and miner-
alocorticoid receptors. Glucocorticoids may affect 
ovarian function both indirectly and via binding to 
ovarian receptors. We have demonstrated 11 P-HSD 
bioactivity and mRNA expression in rat ovary in 
vitro. The enzyme was localized to oocytes and luteal 
INTRODUCTION 
Glucocorticoid hormones are important regulators of 
cell function in many tissues. Recent evidence suggests 
that glucocorticoids affect ovarian physiology. Thus 
systemic administration of exogenous glucocorticoids 
has been shown to reduce ovarian weight (Inazu, 
Iwata & Satoh, 1990) and to inhibit ovulation 
(Baldwin & Sawyer, 1974). Although the inhibition 
of ovulation is thought to reflect glucocorticoid 
actions at the anterior pituitary, where they inhibit 
the preovulatory luteinizing hormone (LH) surge 
(Baldwin & Sawyer, 1974), the presence of glucocort-
icoid receptors (Schreiber, Nakamura & Erickson, 
1982) and glucocorticoid-responsive gene products 
(Malbon & Hadcock, 1988; Albiston, Lock, Burger 
& Krozowski, 1990) in the ovary suggests that direct 
effects also occur. In support of this, glucocorticoids 
have been shown to inhibit follicle-stimulating hor-
mone (FSH)-stimulated aromatase activity (Hsueh & 
Erickson, 1978) and to augment progesterone accu-
mulation (Adashi, Jones & Hsueh, 1981) in granulosa 
cells in vitro. Similarly, glucocorticoids stimulate the 
production of plasminogen activator by isolated 
bodies immunohistochemically using two antibodies 
raised against purified rat liver 11 P-HSD. These data 
are supported by in-situ hybridization studies, which 
also localized 11 P-HSD mRNA expression to oocytes 
and luteal bodies. The results suggest that 11 P-HSD 
may modulate the effects of glucocorticoid on ovarian 
function. 
Journal of Endocrinology (1992) 135, 53--58 
granulosa cells (Wang & Leung, 1989; Jia & Hsueh, 
1990), an action thought to be important in the 
control of ovulation (Reich, Miskin & Tsafriri, 1985). 
Both protein purification and more recent molecu-
lar cloning studies have demonstrated the existence 
of two types of glucocorticoid receptor, type-I {high-
affinity or mineralocorticoid receptor) and type-11 
(low-affinity or glucocorticoid receptor). Although 
the type-1 and -II receptors show well-described hier-
archies of affinity for the various physiological and 
synthetic glucocorticoids in vitro, ligand access to 
receptors in many tissues in vivo is regulated by 11 P-
hydroxysteroid dehydrogenase (11 P-HSD). This mic-
rosomal enzyme catalyses the reversible conversion of 
physiological glucocorticoids (cortisol in man, 
corticosterone in the rat) to inactive products { corti-
sone or 11-dehydrocorticosterone). The 11-dehydro 
products have very low affinities for either type-I or 
type-II receptors. The activity of 11 P-HSD appears to 
be responsible for the in-vivo aldosterone selectivity 
of the otherwise non-selective renal type-I receptor 
(Edwards, Stewart, Burt et al. 1988; Funder, Pearce, 
Smith & Smith, 1988) and modulates glucocorticoid 
access to type-II receptors in the skin (Teelucksingh, 
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Mackie, Burt et al. 1990) and cerebellum (Moisan, 
Seck!, Brett et al. 1990a). Within reproductive tissues, 
11 P-HSD is present in the placenta where it is thought 
to protect the fetus from the deleterious effects of 
exposure to maternal glucocorticoids (Beitins, 
Bayard, Ances et al. 1973; Lopez Bernal, Anderson 
& TurnbulL 1982) and the enzyme has been demon-
strated in the testis where it may regulate Leydig cell-
glucocorticoid interactions which are critical in the 
control of testosterone production and the onset of 
puberty (Phillips, Lakshmi & Monder, 1989). 
By analogy with the testis, the ovary might be 
expected to contain 11 P-HSD which could regulate 
glucocorticoid access to receptors and thus modulate 
corticosteroid effects in vivo. Although previous stud-
ies have not found 11 P-HSD bioactivity in the rat 
ovary (Ghraf, Vetter, Zandveld & Schriefers, 1975), 
human ovaries have been shown to be able to convert 
cortisol to cortisone (Murphy, 198la), and to contain 
mRNA encoding 11 P-HSD (Tannin, Agarwal, 
Monder et al. 1991 ). Therefore, we have re-examined 
whether 11 P-HSD bioactivity and m RNA expression 
are present in the ovary of the rat, and have deter-
mined their tissue localization. 
MATERIALS AND METHODS 
11 P-HSD bioassay 
Dehydrogenase component 
Ovaries, obtained from adult female Wistar rats 
(240 g; n = 3-4) in pro-oestrus, were homogenized in 
Krebs-Ringer bicarbonate buffer (118 mmol NaCljl, 
3· 8 mmol KCI/1, 1·19 mmol KH2P04jl, 2· 54 mmol 
CaCh·2H20/l, 1·19 mmol MgS04·1H20/l, 25 mmol 
NaHC03/l) using a Dounce tissue grinder. The total 
protein content was estimated colorimetrically (Bio-
Rad protein assay kit, Hemel Hempstead, Herts, 
U.K.), using a sample of the homogenate. The 
incubation was carried out in duplicate with 
0· 0625 g, 0· 25 g and 0· 5 g protein/1 and a final concen-
tration of 200 J..lmol NAD/1 and 12 nmol [1,2,6,7-
3H]corticosterone/l (specific activity: 84 Cijmmol; 
Amersham International plc, Little Chalfont, Bucks, 
U.K.) in Krebs-Ringer buffer ( +0· 2% bovine serum 
albumin and glucose) for 10, 20 and 60 min at 37 °C. 
The total volume was 250 J..ll. Rat kidney, known to 
have very high 11 P-HSD bioactivity, was used as a 
positive control (at0·25 gprotein/1 for 10 min), whilst 
incubation of buffer alone provided an assay blank. 
After incubation, steroids were extracted with ethyl 
acetate and separated by high-pressure liquid chro-
matography (HPLC). The percentage conversion of 
eH] corticosterone to [3H] 11-dehydrocorticosterone 
was calculated from the radioactivity of each fraction. 
Results are expressed as means± S.E.M. 
Journal of Endocrino/ogy ( 1992) 135, 53-58 
Reductase component 
For preparation of (~H] 11-dehydrocorticosterone 
[
3H]corticosterone (Amersham) was incubated with 
rat kidney homogenate for 2 hat 37 oc in the presence 
of 200 J..lmol NAD/1. After incubation, the steroids 
were extracted with ethyl acetate and separated by 
thin-layer chromatography. Extraction yield was 42<X) 
and purity> 93<Yt) as assessed by HPLC. Ovarian 
homogenate was prepared as above ( n = 3), and 0· 25 g 
protein/! incubated with 12 nmol [3H] 11-dehydro-
corticosterone/1 for 10 m in at 37 oc in the presence of 
200 J..lmol NADH/1 in Krebs-Ringer buffer as above. 
Steroids were separated and assayed by HPLC as for 
dehydrogenase activity. 
Northern analysis 
Ovary, hippocampus, kidney and liver were rapidly 
removed from female Wistar rats (240 g) after cervical 
dislocation, snap-frozen and stored at -85 °C. Total 
RNA was extracted from each tissue by the acid guan-
idinium thiocyanate method, as previously described 
(Chomczynski & Sacchi, 1987). Approximately 20 J.lg 
ovary_ 15 J..lg hippocampus and 10 J..lg kidney and liver 
total RNA were fractionated on a 1·2°i<J agarose--
0· 7 mol formaldehyde geljl and blotted on to nitrocel-
lulose (Hybond C extra; Amersham International 
plc) by capillary transfer overnight. Hybridization 
was performed at 42 oc overnight in 50% formamide 
with a randomly primed 32P-labelled 11 P-HSD cON A 
probe cloned from a rat liver cON A library (Agarwal, 
Monder, Eckstein & White, 1989), consisting of the 
excised p 11 D H insert. The m em bra ne was washed to 
a final stringency of 0· 2 x SSC (I x SSC equals 
0·5 mol NaCl and 0·015 mol sodium citrate per litre), 
0·1% sodium dodecyl sulphate at 60 oc and exposed 
to Kodak XAR film for 2 days as previously described 
(Moisan, Seckl & Edwards, 1990b). 
Immunohistochemistry 
Adult Wistar rats (240 g) were deeply anaesthetized 
with pentobarbitone and perfused through the 
ascending aorta with 250 ml ice-cold saline followed 
by 500 ml ice-cold paraformaldehyde (4 moljl) in 
phosphate buffer (0·1 moljl, pH 7·4). Ovaries were 
removed and post-fixed overnight. As previously 
described (Moisan et al. 1990a) sections (4 J..lm) were 
cut and immunostained using two separate polyclonal 
rabbit antisera (5-125 at 1:50 dilution and 5-126 at 
1: 100 dilution) raised against purified rat liver 11 P-
HSD as described elsewhere (Monder & Lakshmi, 
1990). Detection was by the peroxidase-antiperoxid-
ase method (Sternberger, Hardy, Cuculis & Meyer, 
1970) using reagents from Dako Ltd, High Wycombe, 
Bucks, U.K. Control sections were immunostained 
using preimmune rabbit serum. 
In-situ hybridization 
Adult Wistar rats (240 g) were killed by cervical dis-
location, the ovaries rapidly removed and immedi-
ately frozen on dry ice. Cryostat sections ( 10 l-!m) were 
mounted on to gelatin- and poly-L-lysine-coated 
microscope slides and stored at -85 °C. Tissue sec-
tions were post-fixed in 4°;;> paraformaldehyde/phos-
phate (0·1 mol/1) buffer and washed in three changes 
of 2 x SSC containing 0·02°;;> diethylpyrocarbonate. 
T3 RAN polymerase (Promega Ltd, Southampton, 
Hants, U.K.) was used to transcribe a 598 bp anti-
sense cRNA probe containing 35S-Iabelled UTP from 
Sty 1-linearized pBluescript vector containing the 
1265 bp 11 ~-HSD cON A insert (Agarwal et al. 1989). 
The probe was denatured and added at a final concen-
tration of 10 x 106 c.p.m./ml to hybridization buffer 
(50% formamide, 0·6 mol NaCI/1, 10 mmol Tris/1, 
pH 7· 5, 0·02°;;> Ficoll, 0·02% polyvinylpyrrolidone, 
0·1% bovine serum albumin, 1 m mol EDT A/1, 0· 1 g 
salmon sperm DNA/I, 0·1 g yeast tRNA/1, 100 g dex-
tran sulphate/! and 10 m mol dithiothreitol/1) as pre-
viously described (Yau, Van Haarst, Moisan et al. 
1991 ). In brief, 65 l-!1 aliquots of probe were pi petted 
on to sections and covered with a coverslip 
(22 x 50 mm) which was sealed with DPX mounting 
medium. Slides were incubated overnight at 50 °C. 
After hybridization, coverslips were removed by rin-
sing three to four times in 2 x SSC at room tempera-
ture, sections treated with RNAase A (30 g/1, 45 min 
at 37 °C) (Boehringer Mannheim, Lewes, East Sussex, 
U.K.) and washed in reducing salt concentrations to 
a final stringency of 0·1 x SSC/14 mmol 2-mercapto-
ethanol/1 at 60 °C. After dehydration in increasing 
concentrations of ethanol in 0· 3 mol sodium acetate/ 
I, slides were dried in air, dipped in photographic 
emulsion (Ilford Mobberley, Knutsford, Cheshire, 
U.K.) and exposed in light-tight boxes at 4 oc for 21 
days before being developed (019, Ilford) and coun-
terstained with haematoxylin-eosin. Controls were 
hybridized with non-complementary 'sense' probes of 
the same specific activity under identical conditions. 
RESULTS 
11 P-HSD activity 
11 P-HSD activity in the dehydrogenase direction was 
found in all ovarian homogenates and increased lin-
early with protein concentration up to 0· 5 g/1 (data 
not shown). The time curves for the three different 
protein concentrations (Text-fig. 1) indicate linearity 
with respect to time for up to 10 min. At a protein 
concentration of 0· 25 g/1 incubated for 10 m in, ovar-
ian activity was 10% of kidney activity (ovary, 
n = 3: 179· 6 ± 30· 5 fmol product formed; kidney, 
Ovarian 11 {3-HSD · R. BENEDIKTSSON and others 55 
n = 2: 1742·4 ± 44·1 fmol product formed). No 
conversion of [3H] 11-dehydrocorticosterone to 
[
3
H]corticosterone was found. 
Northern blots 
A single band hybridizing to the 11 ~-HSD probe was 
detected in ovarian total RNA which corresponded 
to the major 11 ~-HSD m RNA species demonstrated 
in rat liver and hippocampus. There was no evidence 
of expression of multiple 11 P-H SO m RNA species as 
found in rat kidney (Text-fig. 2). 
Immunohistochemistry 
Using either antiserum to purified rat liver 11 ~-HSD, 
a consistently strong positive immunostaining was 
found in the oocyte (PI. I). Additionally, positive 
immunostaining of moderate or low intensity was 
detected in cells comprising the luteal bodies (not 
shown). This varied between the luteal masses rather 
than within a given luteal body, presumably reflecting 
their varying stages of maturation. No staining was 
observed in the granulosa cells, theca cells, stroma or 
other ovarian components (PI. 1 ). No staining of any 
ovarian subregion was demonstrated with preimmune 
serum. 
In-situ hybridization 
11 ~-HSD m RNA expression was localized to oocytes 
and was also found to a variable extent over the luteal 
bodies, varying between luteal masses rather than 
within individual bodies and parallelling the immu-
nohistochemical findings (PI. 2). 
DISCUSSION 
Previous studies on ovarian 11 ~-HSD are few. Ghraf 
et al. ( 1975) reported no 11 ~-HSD bioactivity in the 
rat ovary but, in contrast, Murphy ( 1981a) found 
considerable bioactivity in human ovaries; both stud-
ies used similar methods. 
We now report high 11 P-HSD bioactivity in homo-
genized whole ovaries, in agreement with the findings 
of Murphy (198la). The reason for the discrepancy 
between our data and those of Ghraf et al. ( 1975) is 
unclear but may relate to the very high pH (9· 5) used 
in the latter study. The presence of 11 P-HSD bioactiv-
ity is supported by the clear expression of mRNA 
encoding the 'liver-type' isoform of the enzyme. Using 
both immunohistochemistry and in-situ hybridization 
we have localized 11 ~-HSD m RNA antigen to 
oocytes and, to a lesser extent, to luteal bodies. The 
Journal of Endocrinology (1992) 135, 53 58 
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TEXT-FTGUR 1. 11 ~-Hydroxysteroid dehydrogena e bioactivity (mea ured as fmol [ H] 11-dehy-
drocorticosterone formed from [3H]cortico terone) in whole ovarian homogenates at protein 
concentration of0·0625 g/ 1 (0; n = 3) 0·25 g/ l (0; n = 4) and 0·5 g/ l ( A ; n = 3). Values are 
means±s .. M . 
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H 
TEXT-FI UR 2. Autoradiogra~h of a orthern blot of 
total mRNA hybridized with 3 P-labelled cDNA probes 
to 11 ~-hydroxysteroid dehydrogena e mR N A. 0 =ovary 
H = hippocampu , K = kidney L =liver. Note the presence 
of a ingle band in ovary corresponding to the one found 
in hippocampu and liver. Kidney how multiple hybrid-
izing mR A species. 
concordance of immunoreactivity and mRNA expres-
ion is in contrast to di tal renal tubule (Edwards 
et al. 1988; Rundle, Funder, Lak hmi & Monder 
1989; Yau et al. 1991), where mRNA expression 
and bioactivity (Naray-Fejes-T6th, Watlington & 
Feje -T6th 1991) are found, but immunoreactivity 
Journal of Endocrinology ( 1992) 135, 53- 58 
(liver-type) is not detected. On the other hand, in 
hippocampus, cerebellum and va culature, 11 P-HSD 
mRNA expression colocalizes with immunoreactivity 
(Moi an et al. 1990a,b; Walker, Yau Brett et al. 
1991 ). It is thus likely that ovarian luteal bodies and 
oocyte express the liver-type mRNA and protein 
which may modulate glucocorticoid access to recep-
tors rather than the distal convoluted tubule isoform 
which is completely protective of the colocalized 
mineralocorticoid receptor. 
The interesting finding of high bioactivity localized 
to the oocyte itself, a indicated by in-situ hybridiza-
tion and immunohistochemistry, implies modification 
of the oocyte glucocorticoid exposure and makes the 
presence of steroid receptors within the oocyte likely 
as is the case in other 11 P-HSD locations. Although 
glucocorticoids are believed to inhibit ovulation by 
inhibiting the preovulatory LH surge, our findings 
point to a po ible 1 cal role of glucoc rticoid in 
ovulation and/ or oocyte differentiation. Intere tingly, 
the pecificity of 11 P-HSD for 11 P-hydroxyproge -
terone and 11 P-hydroxypregnenolone a well a their 
a-counterparts i much higher than for corti ol or 
corticosterone (Murphy, 19 lb ), rai ing the intrigu-
ing po ibility that the sub trate for ovarian I 1 S-HSD 
is not nece sarily a glucocorticoid. 
We were unable to find any indication of the 
presence of 11 P-HSD in the granulo a cells, which 
previously have been shown to contain glucocorticoid 
receptors (Schreiber et al. 1982) and to be metabolic-
ally regulated by glucocorticoids (Hsueh & Erickson, 
!978; Adashi et al. 1981; Wang & Leung, 1989). This 
absence of 11 P-H SO expression in the granulosa cells 
could be the result of aromatase activity generating 
oestrogen, which has been shown to inhibit potently 
activity of the liver-type 11 P-HSD (Monder & Shack-
leton, 1984), as present in the ovary. Similarly, we did 
not demonstrate the presence of 11 P-HSD in theca 
cells, although dexamethasone has been shown to 
alter their metabolism (reducing carbonyl reductase 
content) (lnazu et al. 1990). Our finding of 11 P-H SO 
immunoreactivity and mRNA expression in the luteal 
cells but not the theca cells may be another example 
of cellular ontogeny, as we have shown in the skin 
(Teelucksingh et al. 1990), where 11 P-HSD is not 
detected in the basal cell layer but is located in cells 
of the upper epidermis. 
In summary, we have found 11 P-H SO gene expres-
sion and bioactivity in the rat ovary, localized mainly 
in the oocyte and luteal masses. This suggests that 
glucocorticoids may exert a local modulatory role on 
ovarian function, which can be altered by cell-specific 
metabolism of steroids. The importance of 11 P-HSD 
in ovarian function remains to be determined. 
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DESCRIPTION OF PLATES 
Plate I 
FIGURE I. Immunostaining of rat ovary using antiserum 
to purified rat liver 11 P-hydroxysteroid dehydrogenase, 
displaying marked staining of the oocyte ( x400). 
FIGURE 2. Control using preimmune scrum, showing no 
immunostaining ( x400). 
Plate 2 
FIGURE 3. In-situ hybridization showing a concentration 
of silver grains over the oocyte indicating hybridization 
of the cRNA probe containing 35S-labelled UTP to 11 P-
hydroxysteroid dehydrogenase m RNA ( x600). 
FIGURE 4. In-situ hybridization using 'sense' probe, show-
ing no silver grain concentration ( x600). 
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ed, and serum levels are almost always in the required 
e, making control of these levels less important. 
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I SHORT REPORTS I 
Glucocorticoid exposure in utero: 
new model for adult hypertension 
RAFN BENEDIKTSSON R OBERT S. LINDSAY 
JUNE NOBLE }ONATHAN R . SECKL 
CHRISTOPHER R . W. EDWARDS 
Hypertension is strongly predicted by the 
combinat ion of low birthweight and a large 
placenta. Th is association could be due to 
increased fetal exposure to maternal 
glucocorticoids. Fetal protection is normally 
effected by placental 11 ~ - hydroxysteroid 
dehydrogenase (11 ~ - OHSD) , which converts 
physiological glucocorticoids to inactive 
products. We found that rat placental11 ~ - OHSD 
activ ity correlated positively with term fetal 
weight and negatively with placental weight. 
Offspring of rats treated during pregnancy with 
dexamethasone (which is not metabolised by 
11 ~ - OHSD) had lower birthweights and higher 
blood pressure when adult than did offspring of 
control rats. Increased fetal glucocorticoid 
exposure secondary to attenuated placental11 ~ ­
OHSD activity may link low birthweight and high 
placental weight with hypertension . 
Lancet1 993;341:339-41 . 
The importance of the intrauterine environment in 
relation to cardiovascular disease has been emphasised by 
epidemiological studies showing that low birthweight is a 
marker for ischaemic heart disease mortality1 and 
hypertension.2 Adults who had the unusual combination of 
low birthweight and a large placenta have the highest blood 
pressure. 2 These features have been attributed to maternal 
malnutrition, but they have also been found in rats with 
streptozotocin-induced diabetes mellitus,3 ,4 which have 
high maternal glucocorticoid concentrations. 5 Furthermore, 
exogenous glucocorticoids retard fetal growth in human 
beings and animals.6 
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Correlations of term fetal weight and placental weight with 
placentai11P-OHSD activity. 
11 ~-hydroxysteroid dehydrogenase (I 1 ~-OHSD) 
converts cortisol and corticosterone to inactive products 
(cortisone, 11-dehydrocorticosterone), and placental 11 ~­
OHSD protects the fetus from exposure to the growth-
inhibiting effects of maternal glucocortocoids;7 thus fetal 
cortisol concentrations are much lower than those in the 
maternal circulation.8 Since the effectiveness of this 
placental glucocorticoid barrier could vary, we examined 
11 ~-OHSD activity in rat placentas at term, and 
investigated the effects of treatment of pregnant rats with the 
non-metabolised glucocorticoid dexamethasone on 
offspring birthweight and blood pressure. 
Eight Wistar rats (240 g) were killed at term, and the placentas 
(n =56) were weighed and homogenised in Krebs-Ringer 
bicarbonate buffer. Enzyme assay was carried out in duplicate 
incubations with 0·5 g/L total placental protein, 200 j.U110l/L NAD 
(co-substrate), and 12 runol/L 1,2,6,7,3H-corticosterone in buffer 
(plus 0·2% bovine serum albumin and glucose) for 1 h at 37•c. 
Steroids were separated by thin-layer chromatography and enzyme 
MEAN (SE) BLOOD PRESSURE (BP; mm Hg) IN OFFSPRING OF 
DEXAMETHASONE-TREATED AND CONTROL RATS 
- Treated Control p 
Male offspring 
n 7 11 
SystolicBP 115 (4) 142 (4) <0·05 
DiastolicBP 122 (3) 115 (3) 0·09 
Female offspring 
n 14 16 
SystolicBP 140 (2) 131 (3) <0·05 
DiastolicBP 103 (3) 102 (3) 0·82 
---
activity expressed as percentage conversion of .lH-conicostc : 
.lH 1 d I dr · F th rone to 1 · -1 - e 1y ocorucosterone. ur er groups of rats were tr ; · 
with dexan1ethasone ( 100 ~tg/kg daily subcutaneously· n:::: ~ted ' 
vehicle (4% ethanol-saline, n = 6) throughout pre~ancy ~ 
treatment was st~pped at birth and the pups were reared idcnti~U 
When the offspnng were 140-150 days old carotid cannulae y, 
inserted under halothane anaesthesia and blood pressure:: 
measured on 3 separate days at least 48 h after cannulati 
Comparison was by Student's unpaired t test. on. · 
There was a strong positive correlation between placenta} 
11 ~-OHSD activity and fetal weight at term and an invers 
correlation between placental 11 ~-OHSD and placen~ 
weigh~ (figure). Both correlatio~s remained significant on · 
analysis of mean values for each htter (for mean birth weight ' 
n = 8, r = 0·96, p < 0·00 1; for mean placental weight n ==a' 
r = - 0·66, p < 0·05). Maternal weight gain was significant!; 
lower in dexamethasone-treated than control rats (mean j 
47·3 [SE 2·4] vs 80·0 [3·9]g in controls, p < 0·0001) but there .1 
was no effect on litter size (9·5 [0·5] vs 9·6 [0·6]) or gestation 
length (22·5 [0·2] vs 22·0 [0·3] days). Birthweight was lower 
in dexamethasone-treated than control rats (4·75 [0·08] vs 
5·62 [0·08] g, p < 0·05). Maternal dexamethasone treatment 
significantly increased systolic blood pressure in both male 
and female adult offspring (table) . 
Our hypothesis that relative glucocorticoid excess in utero 
might cause subsequent hypertension is supported by the 
findings that placental 11 ~-OHSD activity correlates ~·· 
directly with birthweight and inversely with placental . 
weight. Fetuses with low birthweight and high placental · 
weight (which in man are at highest risk of subsequent ,jl 
hypertension2) had the lowest 11 ~-OHSD activity and \:1\ 
presumably therefore the greatest exposure to maternal ~ 
glucocortocoids. Excess glucocorticoids inhibit fetal growth .~ 
in rats and human beings. 6 The mechanism of • 
disproportionate placental enlargement remains unclear; '··~ 
rather than being a direct glucocorticoid effect on the "-1 
placenta it could be secondary (or compensatory) to a failure .• : 
of fetal growth as observed in hypoxia and anaemia. 9 
The development of adult hypertension in rats exposed to 
excess glucocorticoid in utero, in doses not affecting fetal i 
viability, also supports our hypothesis. Although our study -~ 
did not address the in-utero mechanisms that brought about ~ 
subsequent hypertension, direct actions of glucocorticoids ·.~ 
?n fetal tissue d~velopment or hormonal imprinting may be ~ 
rmportant. Indrrect effects cannot be excluded, since ;1 
offspring blood pressure is related to maternal blood ' 
pressure during pregnancy2 and dexamethasone may raise 
maternal blood pressure. 
10 
These fmdings lead to a testable 
1 
.. · ... ~ 
hypothesis to explain epidemiological data linking impaired 
human fetal growth and common disorders in later life, 
especially hypertension. 
This study was supported by the Wellcome Trust (C. R. W. E. and J. S.) 
and the Scottish Hospitals Endowment Research Trust (C. R. W. E. 
and R. B.). 11 
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Abnormal growth regulation of 
vascular smooth muscle cells by 
heparin in patients with restenosis 
PHILIP CHAN MAHENDRA PATEL 
LAURA BETIERIDGE EUAN MUNRO 




Proliferation of vascular smooth muscle cells 
1l (VSMC) underlies myointimal hyperplasia, which 
.~can lead to restenosis after angioplasty and vascular 
~surgery. We propose that some individuals have an 
l intrinsic capacity for this exaggerated response to 
I
~ vascular injury, partly through decreased sensitivity 
to the physiological growth inhibitor heparin. We 
investigated the effect of heparin on VSMC from 
restenotic lesions and from apparently normal 
.! vessels of the same patients, and VS MC from control 
! patients undergoing primary bypass procedures. 
~ Cells from patients with restenosis (both restenotic 
11esion and undiseased vein) showed much lower 
I sensitivity to growth inhibition by heparin than the 
i controls (median inhibition 8 [95% Cl -2 to 25] vs 
.· 22 [15-44]%, p < 0·001 ); this finding suggests 
-~ aberrant growth regulation in these cells. 
Lancet 1993; 341: 341-42. 
Myointimal hyperplasia (MIH), a physiological response 
to vascular injury, occurs after every interventional vascular 
procedure. Proliferation of vascular smooth muscle cells 
~l (VSMC) forms the cellular basis of MIH and also underlies 
: atherogenesis and vascular transplant rejection.1 Vascular 
:: bypass surgery and balloon angioplasty are among the 
I commonest procedures in western societies. In about 20% of vein grafts and 30-40% of coronary angioplasties MIH is progressive and associated with significant restenosis. The ~ restenosis usually results in the recurrence of ischaemic 
1 symptoms or in tissue damage and is an important cause of 
treaonent failure. It is not clear why there are differences in 
patient response after vascular procedures. Progressive 
MIH cannot be predicted by technical or haemodynamic 
factors, and systemic risk factors such as diabetes, 
hypertension, continued smoking, and hyperlipidaemia are 
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Fig 1-Representative VSMC growth curves (mean and SO cell 
counts) for 1 restenosis patient and 1 control with (D) and 
without (e) heparin. 
not consistently associated with restenosis. Furthermore, 
some patients suffer repeated restenosis, which suggests 
variations in individual susceptibility to progressive MIH. 
The factors that regulate growth of VSMC remain 
unclear. Mter endothelial injury VSMC are subject to 
paracrine and autocrine regulation by growth factors from 
damaged endothelial cells, platelets, macrophages/ 
monocytes, and VSMC.1 We have tested the hypothesis that 
VSMC from patients who develop restenosis have 
intrinsically abnormal growth regulatory mechanisms. 
We have grown VSMC cultures from 136 samples of vascular 
tissue. 2 The cell cultures used in this study were grown from 43 
vascular tissue samples obtained from 39 unselected patients 
undergoing cardiac and peripheral vascular surgery between 
December, 1990, and April, 1992. Cultures were established by an 
explant method modified from Chamley-CampbelF and grown in 
Dulbecco's modified Eagle's medium supplemented with 15% fetal 
calf serum and antibiotics. VSMC cultures had the characteristic 
hill and valley morphology and stained positively with an antibody 
to ex-actin, a marker for smooth muscle cells, and negatively for 
factor-VIII-related antigen. Cells were plated at the third passage at 
1 0" /mL and allowed to attach for 24 h. The 14 day growth assay was 
preceded by 72 h of growth arrest with 0·4% fetal calf serum. 
Growth was then restarted by addition of medium with 15% fetal 
calf serum, with or without unfractionated heparin 100 llg/mL. 
Cell counts on triplicate wells were done on days 0, 3, 7, 10, and 14 
on a Coulter counter. 
Vascular tissues for this study were classified as follows. 
Rcstenosis cells were derived from patients undergoing rcoperation 
for graft stenosis (from the restenotic lesion in 8 and from 
apparently undiseased saphenous vein in 6). 6 samples of control 
arteries (2 internal mammary artery, 1 common femoral artery, 1 
popliteal artery, and 2 iliac artery) and 29 samples of saphenous vein 
were obtained from organ donors (n = 2) and patients undergoing 
primary cardiovascular surgery. All tissue samples included the full 
thickness of the vessel wall. Ideal control subjects would be patients 
who had undergone vascular surgery and not developed restenosis; 
however, such subjects are not available. We therefore chose to use 
unselected subjects undergoing primary bypass procedures, to 
reflect the patient population requiring vascular intervention. The 
use of vascular tissues discarded at surgery complies with the 
guidelines of our ethics comminee. 
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Fig 2-Summaryofgrowth inhibition (means for individual cell 
strains) of VSMC by heparin. 
1 h"b" . = 1 _ ( cell no day 14 with heparin ) x 100 n 1 ltlon cell no day 14 without heparin · 
There was no significant difference in VSMC growth rate 
between those from restenotic lesions and those from 
control samples (mean increase during 14 days 812 [SE 151] 
vs 986 [102]%; population doubling time 2·84 [0·34] vs 2·47 
[0·31] days). This finding contrasts with a report that 
VSMC from restenotic coronary lesions grow more rapidly 
than those from primary plaques. 3 
There was, however, a clear difference in sensitivity to 
heparin between control cells and cells from patients with 
restenosis, whether from the lesion or from undiseased 
saphenous vein (fig 1). Heparin inhibited the increase in the 
number of control cells at 14 days by a median of28% (95% 
Cl 15-44; n = 29), whereas the proliferation of cells from 
restenotic lesions and normal vessels from the patients with 
restenosis was inhibited by only 8% (-2 to 25; n = 14; 
p <0·001, Mann-Whitney test; fig 2). 
Heparin was the first described inhibitor of VSMC 
growth both in vivo and in vitro.4 Endogenous 
glycosaminoglycans similar to heparin, produced by 
endothelium and VSMC are involved in growth regulation 
of these cells. The heparin concentration used (100 jlg/mL) 
is higher than concentrations normally attained in serum 
after therapeutic doses but similar to concentrations in the 
extracellular matrix around the VSMC of the vessel walLS 
The effect ofheparin on growth inhibition cannot involve its 
antithrombotic action, since these cells are grown in 
preclotted fetal calf serum. 
The mechanism of heparin inhibition is unclear. 
Heparin-like substances may change the extracellular 
matrix, reducing the proliferative capacity of VSMC.6 
Heparin interacts with thrombospondin, a secreted 
glycoprotein involved in VSMC mitogenesis, and may 
reduce the production of tissue plasminogen activator and 
metalloproteinases, which are involved in cell migration and 
proliferation? Furthermore, heparin inhibits protein kinase 
C and the expression of cellular proto-oncogenes that 
depends on this enzyme. 8 
It is unlikely that the reduced heparin sensitivity of 
VSMC from patients with restenosis could be due to 
residual effa:ts of drug treaonents, because the cells had 
been passaged at least twice. Heparin resistance in normal 
vascular tissue may indicate a propensity for the 
development of restenosis. The growth potential ofVSMC 
from these patients may antedate vascular injury and 
therefore represent a risk factor at the cellular level for 
progressive MIH. 
About 3o-40% of patients undergoing primary bypass 
surgery, such as our controls, will develop restenosis; thus 
any differences between restenosis and control VSMc 
would tend to be minimised in this study. The existence of 
persistently significant differences between groups indicates 
the robust nature of the fmdings. There was a wide range of 
heparin sensitivity among controls (fig 2); a prospective 
analysis would be required to correlate the sensitivity with 
the development of restenosis. 
The implications of these findings are important. The 
search for pharmacological treatments to prevent stenosis is 
based on observations in animal models of vascular injury. 
We have defmed an aberration in the growth regulation of 
human VSMC that is associated with restenosis. No 
corresponding fmdings in animals have been reported, 
although Resink et al9 have shown that VSMC from 
spontaneously hypertensive rats have lower sensitivity to 
growth inhibition by heparin than VSMC from Wistar 
Kyoto rats. We propose that animal models are of dubious 
validity unless similarities to human tissue can be 
established. One report has even suggested that heparin 
treatment may promote restenosis. 10 The relative heparin 
resistance of human VSMC may explain why many 
pharmacological agents that inhibit MIH in animal models 
have failed to prevent human vascular restenosis. 
This study was supported by the Institut de RCcherches lntemationalcs 
Servier, the Coronary Flow Trust, and Impra UK. E. M. is a British Hcan 
Foundation junior research fellow and M. S. is a BHF senior research fellow. 
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Dysfunction of placental glucocorticoid barrier: link 
between fetal environment and adult hypertension? 
CHRISTOPHER R. W. EDW ARDS RAFN BENEDIKTSSON 
ROBERT S. LINDSAY ]ONATHAN R. SECKL 
Low birthweight is associated with the 
subsequent development of common disorders of 
adult life, especially hypertension; maternal 
malnutrition has been suggested as the cause. We 
suggest an alternative aetiology-increased fetal 
exposure to maternal glucocorticoids. This 
hypothesis is supported by our findings that in rats 
decreased activity of the enzyme that acts as a 
placental barrier to maternal glucocorticoids (11 P-
hydroxysteroid dehydrogenase) is associated with 
low birthweight. Furthermore, increased exposure of 
the fetus to exogenous glucocorticoids leads to low 
birthweight and subsequent hypertension in the 
offspring. Glucocorticoids acting during critical 
periods of prenatal development may, like other 
steroid hormones, exert organisational effects or 
imprint patterns of response that persist throughout 
life. Thus, the lifetime risk of common disorders may 
be partly determined by the intrauterine environment. 
Lancet1993;341:355-57. 
Birthweight and disease 
Epidemiological srudies have strongly implicated 
intrauterine environmental factors in the risk of common 
disorders in later life. Low birth weight is strongly predictive 
of high blood pressure at all ages;1-5 it is also associated with 
an increased risk of non-insulin-dependent diabetes mellirus 
and hyperinsulinaemia6 and, presumably as a result of these, 
higher mortality from ischaemic heart disease. 7 The 
strongest predictor of adult hypertension is the unusual 
combination of low birth weight and a large placenta. 5 
Factors determining fetal and placental 
growth 
Adult height is closely related to parental height, which 
suggests a strong genetic influence. Are uterine growth and 
birthweight similarly constrained? In crosses between large 
horses and small ponies, the size of the offspring and the 
placenta is directly proportional to maternal size and is not 
intermediate.8 In human beings too, birthweight is strongly 
influenced by maternal height. 9 The correlation between 
birthweight and weight at 12 months is relatively poor, 
whereas weight at 12 months correlates closely with weight 
subsequently. 10 This fmding suggests that in both animals 
and man there are local maternal factors, quite distinct from 
the maternal and paternal genes affecting the infant's 
ultimate size, which limit the growth of the ferus. Physical 
limitation of uterine space is not an important factor in 
rabbits,9 although the evidence in man is less clear.5 
Whatever these maternal factors are, there could be 
catch-up growth after birth. It is interesting that adolescents 
with the highest blood pressures are those who grow fastest 
as children.11 
There are clear geographical differences in the incidence 
of cardiovascular disease in the UK; the correlation between 
these variations and blood pressure, 12 suggests that there are 
important environmental determinants of blood pressure. 
Maternal smoking can affect fetal growth, but not placental 
weight. 14 Moreover, smoking is associated with 
proportional reductions in birthweight and length,15 
whereas in the Preston Srudy, 5 the growth-retardant effects 
in low-birthweight infants who developed hypertension in 
adulthood were not in proportion; for any birth weight, head 
circumference increased with placental weight, but body 
length decreased. The Preston investigators5 suggested that 
there might be diversion of blood away from the trunk in 
favour of the brain, as occurs in animals made hypoxic in 
utero. 16•17 Hypoxia18 and maternal anaemia19 have also been 
associated with retarded fetal growth and disproportionate 
placental enlargement. In both cases the increase in 
placental size was judged to be compensatory. Alcohol 
excess during pregnancy can affect fetal growth and 
development. Chronic alcohol administration to pregnant 
rats leads to low fetal weight and high placental weight. 20 
Unfortunately, smoking habits and alcohol intake were not 
recorded during the Preston srudy. 5 
It is not known whether any of the factors thought to 
cause hypertension, such as salt intake, affect blood pressure 
at an early age. Salt -sensitive rats fed a sodium-enriched diet 
from weaning to 16 weeks develop hypertension earlier than 
animals fed a control diet.13 This effect seems to be 
irreversible-changing from high-salt to control diet after 
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16 weeks has linlc effect on blood prcsure. There arc no data 
on the effects of maternal sodium intake on fetal growth. 
Maternal malnutrition has been suggested as a possible 
cause of impaired fetal growth.5 Birthwcight was reduced in 
the Netherlands during the severe privations of the wartime 
occupation during the 1940s.21 The children subsequently 
showed a high risk of obesity. 22 Body weight and blood 
pressure are significantly related from childhood until 
middle age. 11 However, among sheep with singleton 
pregnancies, animals fed a restricted diet (resulting in only 
0·5 kg weight gain during the last 60 days of pregnancy) and 
fully fed animals (gaining 17·7 kg during the same period) 
had lambs of similar birthweights.8 Findings in canle arc 
similar.23 Furthermore, in London during the war of 
1939-45 (when some of the Preston cohort were in utero5) 
there was no evidence of an effect of the wartime diet on 
birth weight or the frequency of prematurity, 24 and wartime 
maternal supplementation with minerals and vitamins did 
not affect birth weight. 25 Moreover, in the Preston study5 the 
relation between birthweight, placental weight, and adult 
blood pressure was found for each social class (at birth or 50 
years later); thus it seems unlikely that variations in maternal 
nutrition due to social class affect birthweight. With the 
possible exception of extreme malnutrition, there is little 
evidence to link variations in maternal nutrition with 
intrauterine growth. 
Prenatal exposure of the fetus to glucocorticoids retards 
intrauterine growth.2627 In our studies with low-dose 
dexamethasone, rat litter size was not affected but 
birthweight was significantly reduced.28 Hydrocortisone 
can decrease or increase placental size in. rats, perhaps 
depending on dose.27 The association of low birthweight 
with a large placenta has been found in rats with 
streptozotocin-induced diabetes mellitus. 2930 These animals 
have high glucocorticoid concentrations as well as 
hyperglycaemia. 31 
Glucocorticoids and the placenta 
Most maternal cortisol crossing the human placenta is 
converted to biologically inactive cortisoneY Thus, under 
normal circumstances the fetus is protected from the 
growth-retarding effects of maternal glucocorticoids, which 
circulate at concentrations five to ten times higher than those 
in the fetus. Near term, the human fetal adrenal secretes 
75% of circulating fetal cortisol, whereas fetal cortisone is 
mainly of maternal origin. 33 This protection is achieved by a 
placental enzyme, 11 P-hydroxysteroid dehydrogenase 
(11 P-OHSD), which rapidly converts physiological 
glucocorticoids to inactive products. The in-vitro activity of 
11 P-OHSD from the human placenta at term is oxidative 
(cortisol to cortisone), and there is negligible reduction of 
cortisone to cortisol. 34 Our studies in rats show that placental 
11 P-OHSD activity correlates positively with birth weight 
and negatively with placental weight.28 Thus, fetuses with 
low birthweight and high placental weight (which in human 
studies are at highest risk of subsequent hypertension5) have 
the lowest 11 f3-0HSD activity and presumably, therefore, 
the greatest exposure to maternal glucocorticoids. 
What happens if glucocorticoids do cross the placental 
barrier? Administration of low-dose dexamethasone to 
pregnant rats not only reduces birthweight but also leads to 
high blood pressure in young adult offspring. 28 The low, but 
supraphysiological, dose of dexamethasone we used did not 
affect fetal viability and attenuated the normal maternal 
weight gain only moderately, especially after correction for 
the lower fetal weight. Thus, we propose that abnormally 
-
low placental 11 P-OHSD activity, by increasing ·fetal 
exposure to maternal glucocorticoids, leads to intrauterine 
growth retardation and high blood pressure in adulthood. 
Regulators of placental11 P-OHSD 
Low placental11 P-OHSD activity could be congenital or 
acquired. In rats, 11 P-OHSD gene expression and enzyme 
activity are regulated in a tissue-specific manner by, for 
example, various hormones.3536 However, little is known 
about the regulation of placental 11 P-OHSD. Oestrogen 
produced in the placenta from androgen precursors derived 
from the fetal adrenal stimulates enzyme-catalysed 
oxid~tion of cortisol to cortisone in baboons.37 In-vitro 
studies of human placenta showed inhibition of 11 P-OHSD 
by progesterone.34 It is not known whether increased 
transplacental passage of maternal glucocorticoids 
secondary to 11 P-OHSD inactivity (perhaps congenital) 
leads to suppression of fetal adrenal androgen production, 
causing further reduction in placental11 P-OHSD, but such 
excessive transfer could provide a cascade of deleterious 
changes in predisposed individuals. Another possibility is 
that maternal stress or changes in placental production or 
binding of corticotropin-releasing factor could lead to 
inhibition of placental 11 P-OHSD by way of corticotropin, 
since excess endogenous or exogenous corticotropin causes 
inhibition of 11P-OHSD.38 
The effects of attenuation of placental 11 P-OHSD 
activity on fetal growth and offspring blood pressure are not 
yet clear. Conventional pharmacological methods may not 
be applicable, since inhibitors of 11 P-OHSD are not 
completely selective, and we have found placental 11 P-
OHSD difficult to inhibit in vivo (unpublished). This 
finding may reflect the presence of a distinct isoform of 
11 P-OHSD in placenta with different biochemical 
characteristics from the liver enzyme (unpublished). 
Molecular cloning and expression of the placental enzyme 
and its manipulation in transgenic models may shed further 
light on its physological function. 
Possible mechanisms linking in-utero 
glucocorticoid exposure with adult 
hypertension 
Several studies have shown that there is perinatal 
plasticity of hormone receptors and enzymes. Csaba et al 
showed lasting amplification of insulin and vasopressin 
receptor responses after neonatal exposure to a single 
injection of the appropriate ligand,39.40 an effect called 
hormonal imprinting. The permanent effects of steroid 
hormones given during ·the perinatal period are better 
established; brief neonatal exposure to sex steroids leads to 
permanent organisational changes in neuroanatomy, 
neuronal chemistry, and behaviour, which persist 
throughout adult life. Furthermore, there is strong evidence 
that steroids cause irreversible programming at birth of 
microsomal and soluble rat liver enzymes;41~ a single 
neonatal testosterone treatment permanently induces liver 
sp-reductase, whereas Sex-reductase is suppressed 
throughout life. Glucocorticoids could similarly exert 
irreversible effects during a critical stage of development, 
leading to hypertension. How might this be mediated? 
High concentrations of glucocorticoids in the fetus could 
affect the development of the fetal vasculature and its 
responses to pressor agents, since glucocorticoids modulate 
vascular tone by many mechanisms.43 There is much 
evidence that human hypertension persists after removal of 
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the primary cause, possibly because of irreversible changes 
in vascular structure. 11 Glucocorticoids potently affect brain 
development« and another explanation is that 
glucocorticoid overexposure in utero leads to a failure of 
normal central control over cardiovascular growth and 
maturation, possibly by alteration of sympathetic efferents 
and responses to vasoactive stimuli. Furthermore, stressful 
events during the neonatal period change hypothalamic-
pituitary-adrenal axis responses throughout life; these 
effects are mediated, at least partly, by permanent alterations 
of glucocorticoid receptor expression in specific regions of 
the nervous system. 45 We have found abnormal 
corticosteroid receptor gene expression in the brains of adult 
offspring of rats treated with dexamethasone during 
pregnancy (unpublished). 
Indirect effects of changes in maternal metabolism during 
pregnancy or lactation or of high maternal blood pressure 
cannot be excluded. Offspring blood pressure is related to 
maternal blood pressure during pregnancy, and low-dose 
dexamethasone may raise blood pressure in rats.46 
Furthermore, the lasting effect on rats' blood pressure of 
neonatal exposure to excess sodium suggests that maternal 
sodium excess during pregnancy could lead to high blood 
pressure in the offspring. Thus the effect of glucocorticoids 
could be mediated by the mild sodium-retaining properties 
of dexamethasone in the fetus, the mother, or both. 
Physiological glucocorticoids, which have a higher affinity 
for the renal mineralocorticoid receptor than 
dexamethasone, may be more potent sodium retainers and 
this action might be increased by attenuated 11 P-OHSD 
activity in the kidney, where the enzyme normally acts to 
protect the non-selective renal mineralocorticoid receptor 
from circulating cortisol or corticosterone. 47 
This work was supported by the Wellcome Trust (C. R. W. E. and J. S.) 
and by the Scottish Hospitals Endowment Research Trust (C. R. W. E. and 
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CONGENITAL AND ACQUIRED SYNDROMES OF 
APPARENT MINERALOCORTICOID EXCESS 
C. R. W. EDWARDS,* B. R. WALKER, R. BENEDIKTSSON and J. R. SECKL 
Department of Medicine, Western General Hospital, Edinburgh EH4 2XU, Scotland 
Summary-The enzyme 11 fJ -hydroxysteroid dehydrogenase ( 11 fJ -OHSD) interconverts corti-
sol and cortisone. Congenital deficiency of the renal isoform of the enzyme results in 
hypertension, hypokalcmia and suppression of the renin-angiotensin-aldosterone system-the 
apparent mineralocorticoid excess syndrome (AME). In these patients cortisol acts as a potent 
mineralocorticoid. Suppression of plasma cortisol with dexamethasone results in natriuresis, 
potassium retention and reduction in blood pressure. Ingestion of excess liquorice or taking 
carbenoxolone produces an acquired form of AME. The active component of liquorice is 
glycyrrhetinic acid (GE) and carbenoxolone is the hemisuccinate derivative. Both GE and 
carbenoxolone arc potent inhibitors of li{J-OHSD. In vitro studies have shown that 
11 fJ -OHSD is present in aldosterone-selective tissues and acts as an autocrine mechanism 
which prevents cortisol from gaining access to the non-specific mineralocorticoid receptor 
(MR). Congenital or acquired absence of this enzyme allows cortisol to bind to MR resulting 
in AME. II{J -OHSD also appears to be important in controlling cortisol access to glucocor-
ticoid receptors. Variable placental II{J -OHSD may alter foetal exposure to maternal cortisol 
and affect growth as indicated by the correlation between foetal weight and placental 
II{J-OHSD. Thus the tissue-specific distribution, ontogeny and modulation of this enzyme 
allows it to dictate glucocorticoid effects in addition to its key role in ensuring the spccificity 
of the MR. 
INTRODUCTION 
The apparent mineralocorticoid excess syn-
drome (AME) can be classified on the basis of 
whether it is congenital or acquired. The con-
genital syndrome has been further subdivided 
into types I and 2. 
CONGENITAL AME 
This was first described by Maria New and 
Stanley Ulick et al. [l, 2]. The syndrome's rather 
unusual name stemmed from the fact that the 
child described had all the biochemical features 
of gross mineralocorticoid excess with hy-
pokalemia, hypertension and suppression of the 
renin-angiotensin system but no evidence of 
excess mineralocorticoid secretion could be 
found. The patient did not have Liddle's syn-
drome as judged by the failure to respond to 
inhibitors of renal tubular ionic transport. The 
key unexplained finding was the failure of con-
version of cortisol to cortisone, as judged either 
by the very high ratio of cortisol to cortisone 
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metabolites or the failure to metabolize [lla-
3 H]cortisol to cortisone and [3 H]H 2 0. Since 
then over 20 children and I adult with this 
syndrome have been reported [see 3 for review]. 
An even rarer syndrome has been described by 
Ulick et al. [4, 5] in which the clinical and basic 
biochemical features are identical but the ratio 
of urinary cortisol and cortisone metabolites is 
normal. This has been called the type 2 variant. 
There appears to be defective A ring reduction 
in these patients. It is not clear whether there is 
low 11 f3 -hydroxysteroid dehydrogenase ( 11 f3-
OHSD) activity. One possibility is that this is 
the case but it is not apparent in the ratio of 
urinary metabolites because it is masked by 
both the dehydrogenase and the reductase com-
ponents of the enzyme being abnormal. In the 
type I syndrome reductase activity is normal as 
indicated by the normal conversion of cortisone 
to cortisol. 
What was unclear from the initial studies was 
how a deficiency of 11{3-0HSD resulted in the 
clinical picture of mineralocorticoid excess. 
New's group suggested that cortisol was acting 
as a mineralocorticoid in these patients [6]. Oth-
ers demonstrated a beneficial effect of dexa-
methasone. We were able to study this in detail 
in the first adult patient to be described [7, 8]. 
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We showed that giving hydrocortisone 10 mg 
per day for 4 days resulted in marked sodium 
retention and kaliuresis. Conversely, suppres-
sion of cortisol production with dexamethasone 
produced natriuresis and potassium retention. 
Hypertension was improved but not normalized 
by dexamethasone. We suggested that defective 
renal inactivation of cortisol resulted in in-
trarenal cortisol excess which then gained access 
to the mineralocorticoid receptors (MR) in the 
cortical collecting tubule. We coined the term 
Cushing's disease of the kidney to graphically 
describe this [7]. To test this hypothesis we 
needed a model system in which we could 
observe the effects of inhibition of 11 f3 -OHSD 
on the renal handling and effects of cortisol. 
ACQUIRED AME 
The effects of liquorice in producing a clinical 
picture which mimicked primary aldosteronism 
have been known for many years. This was 
thought to be a direct effect of the active 
component of liquorice (glycyrrhetinic acid, 
GE) on renal MR [9 for review]. However, early 
work had indicated that liquorice did not pro-
duce sodium retention in adrenalectomized sub-
jects or patients with Addison's disease unless 
they were on hydrocortisone or cortisone re-
placement therapy. Others had shown that 
dexamethasone produced a natriuresis in 
patients taking GE [10] and that liquorice in-
creased urinary free cortisol without altering 
plasma cortisol [11]. All this suggested to us that 
liquorice might act not directly but by inhibition 
of 11{3-0HSD to produce an acquired form of 
AME. Our subsequent studies both in vivo in 
normal subjects and in vitro confirmed that GE 
is a potent inhibitor of 11/3-0HSD [9, 12]. More 
recently Biglieri et al. [13] have confirmed inhi-
bition of cortisol dehydrogenation in a liquorice 
addict. 
Carbenoxolone, the hemisuccinate derivative 
of GE, also produces a mineralocorticoid excess 
syndrome but does not have the same kaliuretic 
effect as GE. Our studies have shown that it is 
an inhibitor of 11 f3 -OHSD as judged by the 
failure of metabolism of [llcx-3H]cortisol but 
not when assessed by the ratio of urinary corti-
sol and cortisone metabolites [14]. Adminis-
tration of cortisone to normal subjects taking 
carbenoxolone resulted in reduced plasma corti-
sol levels as compared to control indicating that 
carbenoxolone impaired reductase activity in 
addition to its effect on dehydrogenation. This 
raises the possibility that carbenoxolone therapy 
may be a model for the type 2 form of congen-
ital AME. 
ROLE OF llp-OHSD IN PROTECTION OF MR 
Studies by Funder's group [ 15, 16] demon-
strated that the purified MR was non-selective 
and bound aldosterone and cortisol with equal 
affinity. Similar results were obtained by Arriza 
et al. [17] after cloning and expressing the hu-
man MR. Given that the circulating free plasma 
cortisol levels are approx. I 00 times higher than 
those of aldosterone this indicated that there 
had to be some mechanism other than the 
structure of the receptor which defined its 
specificity. We suggested that 11{3-0HSD was 
this mechanism and that in aldosterone-selective 
tissues the enzyme protected the MR from 
seeing cortisol by converting it to inactive corti-
sone [18]. Thus either congenital absence of the 
11{3-dehydrogenase or its inhibition by liquorice 
allowed cortisol to access the receptor and act as 
a mineralocorticoid. These results were 
confirmed by Funder et al. [19]. An essential 
part of this mechanism is that aldosterone is not 
a substrate for the enzyme. This would suggest 
that aldosterone is not present in the free 11/3-
hydroxyl form but as either the 11-18 hemiac-
etal or the 11-18-20 species. Studies using 
NMR have confirmed this with the 11-18 bridge 
form being the major one at physiological 
pH [20]. 
Further studies using either isolated tubules 
or cortical collecting duct cells in vitro have 
shown that 11{3-0HSD is present in the same 
cells as the MR indicating that this is an au-
tocrine system [21, 22]. Immunohistochemistry 
using an antiserum raised against purified hep-
atic 11/3-0HSD, however, failed to show that 
the enzyme was in the distal nephron but was in 
the proximal tubule [18, 23]. It is now clear that 
the kidney contains at least two isoforms of the 
11 f3 -dehydrogenase and that the distal enzyme 
is NAD rather than NADP dependent [24, 25]. 
RELATIONSHIP OF ltp-OHSD TO 
GLUCOCORTICOID RECEPTORS (GR) 
The distribution of 11 f3 -OHSD in tissues not 
normally regarded as mineralocorticoid target 
tissues suggests that it may be important in 
controlling access of cortisol to GR in addition 
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to its MR protective role. Thus high concen-
trations of ll {J -OHSD are found in the testis, 
the liver, cerebellum and lung. To demonstrate 
this possible role for the enzyme we used a 
classic assay of glucocerticoid activity, the cu-
taneous vasoconstrictor test [26]. Topical hydro-
cortisone applied to the forearm had very low 
vasoconstrictor activity as judged by the lack of 
blanching after overnight application. However, 
when both hydrocortisone and GE were applied 
together the glucocorticoid effect was signifi-
cantly enhanced. 
OTHER CONDITIONS IN WHICH DEFECTIVE 
llp-OHSD MAY PLAY A ROLE 
Congenital 11 fJ -OHSD deficiency is very rare 
and liquorice abuse uncommon. However, there 
is evidence that there is a failure of conversion 
of cortisol to cortisone in other more common 
situations. These include chronic renal fail-
ure [27, 28], hypothyroidism [29], essential hy-
pertension [30] and the ectopic ACTH 
syndrome [31, 32]. In a study of patients with 
essential hypertension we found that about one-
third had impaired 11 fJ -OHSD activity assessed 
by the prolonged half-life of [llcx-3 H]cortisol 
[30]. However, despite this there was no evi-
dence of activation of renal MR (no significant 
difference in plasma potassium, plasma renin 
activity, plasma aldosterone or urinary free 
cortisol). This raised the possibility that the site 
of abnormal metabolism might be in tissues 
such as the vasculature rather than the kid-
ney [33]. 
Recent epidemiological studies by Barker et 
al. [34] in Southampton have demonstrated that 
low birth weight is associated with an increased 
risk for developing adult cardiovascular disease. 
They have shown a correlation of birth weight 
or length with ischaemic heart disease mor-
tality [34], non-insulin dependent diabetes 
mellitus and hyperinsulinaemia [35], and hyper-
tension [36, 37]. All these data pointed to the 
importance of the in utero environment in deter-
mining long-term cardiovascular risk. In the 
Preston study in which adults aged 50 were 
studied it was shown that those with the highest 
blood pressures were those who had been small 
babies with large placentas [37]. 
The mechanisms underlying these relation-
ships have been obscure. It has been suggested 
that they might relate to maternal malnutrition 
but little evidence for this has been produced. It 
is also unclear how this could relate to the 
well-known genetic predisposition to the associ-
ated cardiovascular and metabolic conditions. 
Using an animal model we tested the hypothesis 
that variations in the in utero exposure to gluco-
corticoid might be the explanation. 
ll{J -OHSD is present in high concentrations 
in the placenta [38] and has been thought to play 
a key role in the protection of the foetus from 
exposure to maternal glucocorticoids [39, 40]. 
We thought that this protection might not be 
absolute and that a relative deficiency of the 
placental inactivation mechanism might result 
in increased foetal glucocorticoid exposure with 
consequent reduction in growth. To test this we 
looked at the relationship between placental 
11 fJ -OHSD activity, birth weight and placental 
weight. In term rat placenta we found that 
enzyme activity was strongly positively corre-
lated (r = 0.46, P < 0.0005) with foetal weight 
and negatively correlated with placental weight 
(r = 0.63, P < 0.0000 I) [41 ]. These results sup-
port our hypothesis. Further studies are re-
quired to show how in utero glucocorticoid 
excess might lead to hypertension in the adult. 
One attractive possibility is that there is hor-
monal imprinting. This has been demonstrated 
for several hormones such as vasopressin and 
insulin, and for the metabolism of steroids [42]. 
Hypokalemic alkalosis is a key feature of the 
ectopic ACTH syndrome in contrast to other 
forms of Cushing's syndrome. Ulick et al. [31] 
have suggested on the basis of studies in 2 
patients that this might be due to overload of 
the cortisol inactivation mechanism. Our own 
results in a series of 26 patients with Cushing's 
syndrome (9 with ectopic ACTH secretion) indi-
cate that the hypokalemic alkalosis results from 
a combination of mechanisms including cortisol 
overload, deoxycorticosterone and cortico-
sterone excess and decreased inactivation of 
cortisol and corticosterone by the kidney [32]. 
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Summary: 
In 1979, Ulick and New first coined the term Apparent 
Mineralocorticoid Excess (AME) for a syndrome of 
hypertension, hypokalaemia, suppressed renin-
angiotensin-aldosterone axis and raised urinary ratio 
of 11 beta-hydroxy to 11-oxo metabolites of cortisol 
(suggesting a failure of conversion of cortisol to corti-
sone). In retrospect, the first case was described in 
1974 and since then over 20 children have been re-
ported worldwide but only one adult patient. The en-
zyme 11 beta-hydroxysteroid dehydrogenase (11 beta-
OH SO) confers aldosterone specificity on intrinsically 
nonspecific kidney mineralocorticoid receptors by con-
verting the active glucocorticoid cortisol to its inactive 
11-oxo form (cortisone). Patients with AME have a defi-
ciency of this enzyme which allows physiological levels 
of cortisol to flood mineralocorticoid receptors. Dexa-
methasone, by suppressing adrenal cortisol production, 
reverts the biochemistry but not usually the BP to 
Introduction 
When presented with a patient suffering from 
hypertension in conjunction with hypokalaemia, 
aldosterone excess immediately springs to mind. 
Over the past two decades, however, a rare syn-
drome of hypertension with hypokalaemia and, in-
tringuingly, suppressed plasma renin activity and 
aldosterone has emerged. More than 20 children 
with this disorder have now been diagnosed, dis-
tinguished from Liddle's syndrome by failure of the 
latter to respond to spironolactone. Other disorders 
like congenital adrenal hyperplasia and primary 
glucocorticoid resistance are distinguished from 
AME by virtue of raised 11-deoxycorticosterone 
(DOC) in these conditions. Clinical features in addi-
tion to hypertension in children with AME are short 
stature, failure to thrive, polyuria and polydipsia. 
Although in retrospect the first case 1 was des-
cribed in 1974 it was not until New and colleagues 
described similar cases2 .:1 that the term Apparent 
Mineralocorticoid Excess (AME) was coined for this 
disorder. The term 'apparent' was appropriate, as 
intensive search for a hitherto unknovn1 mineralo-
corticoid steroid was fruitless and DOC levels were 
not raised. The salient abnormality in this syn-
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normal. Liquorice inhibits 11 beta-OHSD by virtue of its 
active ingredient glycyrrhetinic acid, resulting in an 
identical clinical picture. Renal 11 beta-OHSD is the pro-
tagonist in AME but this enzyme is found in many other 
tissues including liver, placenta and vasculature, and 
one-third of essential hypertensives have deficient 
11 beta-OHSD. The placental isoform is thought to be 
the main barrier to maternal glucocorticoids reaching 
the fetus. The lowest rat placental 11 beta-OHSD activity 
is found in the largest placentas corresponding to the 
smallest fetuses (presumably exposed to the highest 
glucocorticoid levels). This is the group which in hu-
mans are most at risk of developing hypertension. In 
support of the hypothesis that glucocorticoid excess in 
utero imprints patterns leading to hypertension in 
adults is our observation that treatment of pregnant rats 
with dexamethasone leads to the development of hyper-
tension in adult offspring. 
drome is a defect in the peripheral metabolism of 
the physiological glucocorticoid cortisol. Thus urin-
ary 11beta-hydroxy metabolites of cortisol were 
raised in comparison with the 11-oxo metabolites 
(cortisone metabolites) indicating impaired conver-
sion of the active glucocorticoid cortisol to its inact-
ive counterpart cortisone. The half-life of cortisol 
was thus prolonged, estimated by conversion of 
11alpha3H-cortisol to unlabelled cortisone and triti-
ated water indicating impaired oxidation of the 
11-hydroxyl group. Cortisol levels in peripheral 
blood were normal, however, accmnplished by re-
duced adrenal secretion rate via hypothalamic/ 
pituitary feedback. 
These children responded to pituitary-adrenal 
suppression by administration of the pure gluco-
corticoid dexamethasone. Treatment with hydro-
cortisone aggravated the condition leading to the 
suggestion that cortisol was the mineralocorticoid 
involved,4 but the exact mechanism was not ex-
plained until the first adult case was described in 
Edinburgh. 
11 beta-Hydroxysteroid dehydrogenase 
The enzyme 11 beta-hydroxysteroid dehydrogenase 
(11beta-OHSD) was first described in the placenta5 
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in 1960 but has since been found in many tissues. 
This enzyme is an oxidoreductase complex catalys-
ing the interconversion of active cortisol and inact-
ive cortisone. 
Ulick and New2·3 had described an abnormality of 
the dehydrogenase component of 11 beta-OHSD in 
the children with AME but the pivotal role in the 
pathogenesis of the syndrome remained obscure 
until a 20 year old male presented with severe 
hypertension, hypokalaemia and suppression of the 
renin-angiotensin-aldosterone axis.b The diagnosis 
of AME was made, based on metabolic balance 
studies and the urinary steroid metabolite profile 
along with a prolonged half-life of 11alpha3H-corti-
sol confirming the impaired inactivation of cortisol. 
These studies showed that the hypertension and 
biochemical abnormalities responded to pituitary-
adrenal suppression with dexamethasone and on 
oral hydrocortisone supplementation (or dexa-
methasone withdrawal) the syndrome could be re-
produced with kaliuresis, sodium retention with 
corresponding changes in the plasma electrolytes 
and suppression of the renin-angiotensin-aldo-
sterone axis. Concomitantly the patient's weight 
rose and there was an increase in his BP. 
The liquorice connection 
Key to understanding the pathogenesis of this 
syndrome was the recognition of the similarities 
between the type of hypertension induced by 
liquorice and the syndrome of AME. It had been 
known for many years that abuse of liquorice 
caused classical mineralocorticoid hypertension. 7 
Suggested explanations included binding of glycyr-
rhetinic acid (the active component of liquorice) to 
the kidney mineralocorticoid receptor8 but two facts 
contradicted this. First, the affinity of the mineralo-
corticoid receptor for glycyrrhetinic acid was far 
lower than that for aldosterone and second, some 
elegant studies in both humans9 and animals 10 had 
shown that an intact adrenal gland was necessary 
for liquorice to exert its action. In fact, oral corti-
sone was able to restore the effect of glycyrrhetinic 
acid in patients with Addison's disease9 and dexa-
methasone produced natriuresis in subjects taking 
glycyrrhetinic acid. 11 
Further studies reproduced AME in subjects tak-
ing liquorice, confirmed by raised urinary excretion 
of 11beta-hydroxy metabolite of cortisol in compari-
son to 11-oxo metabolites (cortisone metabolites), 
sodium retention, kaliuresis and a prolonged half-
life of 11alpha3H-cortisol with suppression of the 
renin-angiotensin-aldosterone axis. 12 It therefore 
seemed that liquorice abuse resulted in an acquired 
form of AME. 
To clinch the site of the defect Edwards and 
Steware2 looked at the effect of glycyrrhetinic acid 
on binding of glucocorticoids to renal receptors. 13 
This was carried out in the rat where the physio-
logical glucocorticoid is corticosterone but not cor-
tisol. It was shown by autoradiography that inhibi-
tion of 11beta-OHSD in rat kidney with glycyrrhizic 
acid allowed 3H-corticosterone to bind to aldo-
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sterone binding sites whereas none bound in the 
absence of the 11 beta-OHSD inhibitor. 
In vitro work with purified type 1 mineralocorti-
coid receptor14 as well as cloning and expression of 
the human type 1 receptor15 has since shown it to 
have similar affinities for cortisol and aldosterone 
lending plausibility to the hypothesis that in vivo 
an additional factor was necessary to ensure tissue 
mineralocorticoid specificity, namely 11beta-OHSD. 
This hypothesis is obviously of paramount impor-
tance in a biological sense, challenging the sim-
plistic view that receptor activation depended 
solely on ligand-receptor interaction. 
Variants of the AME syndrome 
The above description relates to what is now known 
as type 1 AME, being a defect in the dehydrogenase 
component of 11beta-OHSD but not the oxidase 
component. This is supported by finding a normal 
increase in plasma cortisol following oral admini-
stration of cortisone in addition to the characteristic 
urinary steroid metabolite profile and a prolonged 
half-life of 11alpha3H-cortisol. 
Recently Ulick and colleagues described three 
cases of what has become known as type 2 
AME. 16·17 These patients have an identical picture 
of low renin hypertension with hypokalaemic alka-
losis and suppressed aldosterone and DOC but a 
normal ratio of urinary metabolites of cortisol/corti-
sone. There is evidence for abnormal steroid meta-
bolism beyond 11beta-OHSD and until further stud-
ies have been carried out in these individuals the 
precise defect underlying this particular syndrome 
has to be considered unknown. However, admini-
stration of carbenoxolone, the hemisuccinate deri-
vative of glycyrrhetinic acid which inhibits both the 
dehydrogenase and reductase component of 11 beta-
OHSD, produces a similar state in humans. 18 
Variants of 11 beta-hydroxysteroid 
dehydrogenase 
Knowledge about 11beta-OHSD is currently ac-
cumulating with amazing speed, new discoveries 
calling for a wider appraisal of its role. In the liver 
the enzyme's prevailing direction appears to be 
opposite to that in the kidney. Similarly. different 
tissues exhibit different activities, show different 
cofactor preferences and a body of knowledge is 
accumulating about regulation of the enzyme by 
various influences in different tissues. Tissue spe-
cific differences in 11 beta-OHSD may not only be 
the result of variations in the intracellular 
environment or post-translational modifications but 
probably represents different species of the enzyme. 
The initial idea that the enzyme protected the 
renal mineralocorticoid receptor in a paracrine fash-
ion stemmed from the observation of positive im-
munostaining for the enzyme in the proximal 
tubules, upstream from the classical mineralocorti-
coid receptor sites. 13 Later studies however, 19·20 con-
firmed bioactivity in the distal tubules supporting 
the more plausible autocrine hypothesis (i.e. 
11beta-OHSD regulates access to receptors within 
the same cell) and recently multiple mRNA species 
have been identified in the kidney. 21 Recent studies 
have identified at least two renal isoforms of 
11beta-OHSD.22- 24 
Finally, there is not only evidence now for mul-
tiple isoforms of 11 beta-OHSD but work from our 
laboratory25 has shown the human placenta to con-
tain 11beta-OHSD of a different size to the liver 
isoform having different cofactor preferences and 
kinetic parameters. The differences indicate that it 
is possible that the 'liver-type' 11beta-OHSD and 
'placental-type' 11 beta-OHSD are the products of 
two separate genes. 
Role for extrarenal11 beta-OHSD 
Although the bulk of plasma cortisone derives from 
the kidney as we have shown26·27 and another pa-
thogenic role for the renal enzyme has been 
demonstrated in the ectopic ACTH syndrome/7 the 
wide distribution of 11 beta-OHSD in mammalian 
tissue indicates the probability of a more wide-
spread role. In the ectopic ACTH syndrome, ACTH 
is thought to directly inhibit the kidney enzyme as 
assessed by plasma cortisol/cortisone ratios in indi-
viduals with Cushing's syndrome and in healthy 
volunteers infused with cortisol or ACTH resulting 
in a similar elevation of plasma cortisol. 
Outside the kidney, one of the earlier observa-
tions from our laboratory was the potentiation of 
action of topically applied glucocorticoids by eo-
application of glycyrrhetinic acid. 28 The skin vaso-
constrictor assay used to compare glucocorticoid 
potency is simply an estimate of dermal blood flow 
and this, along with the observation in AME that 
although sodium retention occurs in the acute 
phase BP increase occurs only after a lag period, 6 
prompted us to look for other sites of 11 beta-OHSD 
expression which might play part in BP regulation. 
Another stimulating observation was also at hand, 
namely that dexamethasone suppresses hyper-
tension in a proportion of what otherwise would be 
considered patients with essential hypertension. 29·30 
We looked at rat vasculature31 and found positive 
immunostaining and mRNA expression for 11beta-
OHSD in vascular smooth muscle. The density of 
11 beta-OHSD was found to be higher in the appro-
priate locations, i.e. resistance vessels. It was also 
well known from animal experiments (for review 
see ref. 32) that glucocorticoids affect vascular re-
sponses to a variety of agents. When these observa-
tions were followed-up in humans in vivo, healthy 
volunteers consuming liquorice had increased der~ 
mal vasoconstriction to cortisol, the dermal vaso-
constriction being still more intense in a subject 
with AME type 1. 33 Individuals with essential 
hypertension similarly had more intense dermal 
vasoconstriction in response to topically applied 
glucocorticoid than controls and about 30% of 
hypertensive individuals have prolonged half-life of 
11alpha3H-cortisol. 34 
Recent epidemiological data has implicated early 
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development in the pathogenesis of ischaemic heart 
disease. 35 These data are especially striking for BP 
where the stron~est correlate for elevated child-
hood:w and adult 7 BP was the combination of low 
birthweight and a large placenta. Of particular im-
portance is the fact that this is not only observed at 
the extremes of weights but a continuous spectrum 
exists. On analysing all the currently available data 
it was concluded that the fetal environment (rather 
than infant development) was the most important 
determinant. 38 
How this might come about is by no means clear 
although suggestions of malnutrition being the most 
important factor have been put forward. This hypo-
thesis is still surrounded with controversv and we 
have looked for an alternative. It maY' be that 
11beta-OHSD again plays a decisive role~ The pla-
cental enzvme was the first isoform to be dis-
covered5 ai1d has been believed to be the main 
protecting mechanism against the \veil-known 
grm.vth inhibiting effects of glucocorticoids on the 
fetus. 3!1 Ontogeny and regulation by sex steroids of 
the placental enzyme has then been thought to 
ensure correct timing of development of the fetal 
hypothalamic-pituitary-adrenal axis in baboons40 
and perhaps other fetal developmental aspects in 
other species. 41 
For our hypothesis of a deficiency in placental 
11 beta-OHSD allowing increased access of physio-
logical maternal glucocorticoids to the fetus causing 
fetal growth impairment, it was crucial to discover 
that the unusual pattern of a low birthweight with 
high placental weight had been observed in rats 
with streptozotocin-induced diabetes mellitus42·43 
which have markedly increased glucocorticoid 
levels.44 
We tested this hypothesis45 by examining rat pla-
cental 11beta-OHSD activity in vitro, correlating it 
with birth- and placental weights. We found a posi-
tive correlation of enzyn1e activity with birthweight 
and a negative correlation with placental weight. 
Both were highly significant and indeed the largest 
placentas which had the lowest enzyme activity 
corresponded to the smallest fetuses, which is the 
group in humans most at risk for hypertension. 
Several explanations can be thought of to explain 
how glucocorticoid excess in utero might lead to 
adult disease. One of then1 is the phenomenon of 
imprinting (or programmin~) which is well recog-
nised for steroid hormones4 as well as for vasoact-
ive substances like vasopressin. 47 Effects on the 
brain leading to deranged control of development of 
other systems is also a possibility supported by 
observations on neonatal handling (stress) of rats 
which modifies hippocampal glucocorticoid recep-
tor mRNA expression.48 
To look at whether programming of hypertension 
by glucocorticoid excess in utero did take place, we 
measured BP in adult offspring of rats receiving 
dexamethasone while pregnant.45 This synthetic 
glucocorticoid escapes metabolism by 11beta-OHSD 
by virtue of 9alpha-fluoro substitution ensuring 
fetal exposure. No effects were observed on litter 
size, resorption rate or frequency of offspring mal-
formation when compared with a control group 
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receiving vehicle only. vVhen the BP was measured 
in earlv adulthood we observed a significantly 
raised SBP in both males and females when com-
pared with controls. 
We have now obtained further evidence indicat-
ing a wider role for 11 beta-OHSD in protecting the 
developing individual frmn an earlier stage as the 
enzyme is found in the rat ovarr where it seems to 
concentrate in the oocyte itself.'H 
Conclusion 
The discovery of the role of 11 beta-OHSD in the 
pathogenesis of the very rare syndrome of AME has 
led to further investigations on this widely dis-
tributed enzyme. We now have indications for the 
existence of more than one type of this enzyme 
which dictates the effects of glucocorticoids in a 
tissue-specific manner. A potential for a role in 
more common disorders like essential hypertension 
and ischaemic heart disease is emerging. 
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